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ABSTRACT
TRIPLE FUNCTIONALIZATION OF TITANIUM ALUMINUM VANDIUM FOR
ORTHOPEDIC IMPLANT APPLICATIONS

By
Ashley Marie Blystone
August 2019
Dissertation supervised by Dr. Ellen S. Gawalt
Orthopedic implant surgeries are on the rise in the United States, with well over a million
surgeries performed annually. Common materials used for these applications include titanium and
its alloy, titanium aluminum vanadium (Ti-6Al-4V). Ti-6Al-4V is chosen for this application due
to its mechanical strength and corrosion resistance. However, Ti-6Al-4V does not support
osseointegration and is susceptible to bacterial colonization. Therefore, these implants suffer from
aseptic loosening and infection, necessitating removal and replacement. Revision surgery and
treatment is financially burdensome and taxing on the patient. Current approaches focus on
modifying the surface of Ti-6Al-4V through a variety of means to allow for improved
osseointegration and limited bacterial adhesion.
In this work, self-assembled monolayers (SAMs) were used as linkers to immobilize
bioactive molecules to the Ti-6Al-4V surface that would help encourage osteoblast attachment
while limiting bacterial adhesion. This was accomplished by forming phosphonic acid head group
SAMs on the surface of Ti-6Al-4V with different tail groups. These tail groups were then used to
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perform chemical reactions at the interface, using orthogonal chemistry, to covalently link the
bioactive molecules. Bioactive molecules were chosen that would address both osteoblast
attachment as well as bacterial adhesion. Vancomycin, an antibiotic effective against Gram
positive bacteria as well as spermine NONOate, a nitric oxide releasing molecule, were chosen to
address bacterial adhesion and colonization of Ti-6Al-4V. A cell adhesion peptide, KRSR was
selected to encourage osteoblast anchoring and viability on the Ti-6Al-4V surface.
The single, dual, and triple immobilization of these molecules was confirmed through
diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy. The covalent attachment of
these molecules resulted in hydrophilic surfaces with contact angle values less than 90°. Nitric
oxide release from functionalized Ti-6Al-4V was assessed through the Griess assay, with single
and triple functionalized surfaces releasing comparable amounts of nitric oxide, 77.0 ± 1.8 and
74.7 ± 1.6 nanomoles respectively. Dual functionalized substrates with co-immobilized spermine
NONOate exhibited higher nitric oxide release of 107.6 ± 1.5 nanomoles for spermine NONOate
with KRSR(C) and 117.6 ±1.4 nanomoles for spermine NONOate with vancomycin.
The activity of the antimicrobial molecules immobilized alone and in conjunction with the
other bioactive molecules was determined via challenges with Staphylococcus epidermidis (S.
epidermidis), a Gram positive species and Escherichia coli (E. coli), a Gram negative species
through fluorescence staining and imaging of the bacteria. Vancomycin immobilized alone was
able to reduce the viability of S. epidermidis by 64 ± 27%. Spermine NONOate was able to reduce
viability of E. coli by 27 ± 20% but not that of S. epidermidis. The selectivity observed was
attributed to Gram positive species’ ability to generate their own nitric oxide, leading to tolerance
of nitric oxide’s effects. Spermine NONOate was able to prevent the adhesion of both species to
single functionalized surfaces which has previously been observed in the literature.27-29
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Antimicrobial effectiveness was only maintained for one of the dual functionalizations,
when KRSR(C) was co-immobilized with vancomycin. This dual functionalized surface showed
a reduction in S. epidermidis viability of 36 ± 28%. This was approximately half the reduction in
viability observed for vancomycin immobilized alone. The loss in effectiveness may be due to
interactions between vancomycin and KRSR(C) or lower surface loading. Surfaces possessing all
three bioactive molecules were not able to limit viability of either bacterial species. Local
concentrations were either not sufficient or interactions between molecules negatively impacted
their effectiveness.
Finally, osteoblast adhesion and viability on functionalized Ti-6Al-4V was characterized
through fluorescence staining and microscopy. Covalent attachment of these bioactive molecules
should not elicit cytotoxic effects within osteoblast cells. Furthermore, attachment of the KRSR(C)
cell adhesion peptide to Ti-6Al-4V was expected to encourage osteoblast adhesion to Ti-6Al-4V
and improve cell viability. While individual immobilization of bioactive molecules did not
negatively affect adhesion or viability, KRSR(C) functionalized substrates showed no statistically
significant increase in live osteoblast adhesion or viability. Surface loading and distribution of the
cell adhesion peptide dictate its effectiveness at recruiting osteoblast adhesion. These factors may
contribute to the lack of a positive, observed effect.
Co-immobilization of spermine NONOate with either vancomycin or KRSR(C) negatively
impacted osteoblast viability. Dual functionalized substrates exhibited higher concentrations of
nitric oxide release than single or triple functionalized. The larger, local concentrations are thought
to be the source of observed cytotoxicity. The lack of observed cytotoxicity on triple functionalized
substrates supports this, as these substrates showed nitric oxide release consistent with single
functionalized Ti-6Al-4V.
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In this work, SAMs were utilized as a platform to chemically immobilize bioactive
molecules to the Ti-6Al-4V surface aimed at addressing osteoblast adhesion and bacterial
colonization. This flexible platform allows for the immobilization of a variety of molecules
including antibiotics, peptides, and nitric oxide releasing compounds. Although in this work
immobilized molecules did not retain their bioactivity, alternative immobilization strategies can
be employed. The functional groups within these molecules used in the formation of covalent
bonds are prevalent in other classes of bioactive molecules. This permits control of the interfacial
properties of Ti-6Al-4V with bioactive molecules specific to the metal’s application. Furthermore,
as SAMs form on other metal oxide surfaces, this transferable platform can be used to alter their
interfacial properties as well.
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Chapter 1. Orthopedic Implants
1.1 Introduction
Orthopedic implants are currently on the rise in the United States, with over 700,000 knee
and 300,000 hip replacement surgeries performed annually. 1 These numbers are only expected to
increase in the coming decades, with predicted occurrences for 2030 of 572,000 hip replacements
and 3.48 million knee replacements.2 This is due in part to degenerative diseases such as arthritis
which can lead to pain or loss in joint function.2 These ailments contribute to alteration of the
mechanical properties of the bone due to excessive loading or the absence of normal biological
self-healing mechanisms. These issues are addressed by surgically replacing the joints with
artificial biomaterials to help restore function of these compromised structures.
In the hip replacement process, the patient’s damaged femoral head is removed and then
replaced with a metal head and stem that is placed into the hollow center of the femur, either with
or without cement.3 The damaged cartilage surface of the socket is removed and then replaced with
a metal socket. This socket is held in place by either screws or cement.4 A plastic, ceramic, or
metal spacer is inserted between the new ball and the socket to allow for gliding motion. When a
total knee replacement occurs, the femur is resurfaced to remove any damaged bone or cartilage.
Then the femoral component is secured to the femur with bone cement. The tibia is prepared for
the placement of the tibial component. After the tibial component is attached, the implant will be
checked for issues with alignment, sizing, and positioning. Once implanted, hip and knee
replacements are expected to last for 10-15 years, and unfortunately, many patients are outliving
their implants.2, 5-6
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1.2 Orthopedic Implant Materials
There are multiple materials that are used in orthopedic applications, including polymers,
ceramics, and metals.7 Polymers are commonly used in hip replacements as articulating surfaces
and as an interposition cementing material between the implant surface and bone. Ceramics are
employed as articulating surfaces as well. Total hip replacements are commonly comprised of a
titanium,

titanium

alloy,

or

cobalt-chromium

alloy femoral

stem

(cemented

with

polymethylacrylate, (PMMA), or press fit into place), and then connected to a “modular” cobaltchromium alloy or ceramic head that articulates on an ultra-high molecular
weight polyethylene or ceramic acetabular cup fitted into a titanium or cobaltchromium cup liner, which is then cemented, screwed or press fitted into place.
(Figure 1.1).7 Stainless steel has also been used in this application.8 Titanium,
and its alloy, titanium aluminum vanadium (Ti-6Al-4V) are the primary
implant materials used in these types of joint replacements.9-12
1.2.1 Desirable Implant Properties

Figure 1.1: Total
hip replacement.

The mechanical properties of orthopedic implants are critical to their
function. Mechanical properties of particular importance include hardness, tensile strength, elastic
modulus, and elongation.8 The material’s response to repeated cyclic loads or strains is based on
the fatigue strength of the material, which, in part, determines the long-term success of the implant.
The implant material being used to replace the natural bone is expected to have mechanical
properties similar to that of natural bone. 2 For example, the materials used to replace bone should
have elastic moduli characteristic of that of natural bone, which ranges from 4 to 30 gigapascals
(GPa), depending on the type of bone being characterized as well as the characterization method.13
Stainless steel and cobalt-chromium alloys both exhibit significantly higher elastic moduli than
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bone; this leads to insufficient stress transfer to the bone, which can cause bone resorption and
loosening of the implant, contributing to implant failure.2 This is known as the “stress shielding
effect”.14 Therefore, a material that exhibits a proper combination of high strength and low elastic
modulus comparable to that of natural bone is desired. Ti-6Al-4V, a titanium alloy, exhibits an
elastic modulus closer to that of natural bone when compared to the cobalt-chromium alloys
(Table 1.1).15 Furthermore, the torsional and axial stiffness of titanium alloys are also closer to
those of natural bone, and therefore theoretically provide less stress shielding than the
cobalt/chromium alloys and stainless steel.7, 16 In addition, the strength of titanium alloys is on par
with that of stainless steel, but it weighs about half of that of stainless steel.8, 17 Ti-6Al-4V is used
preferentially in orthopedic replacements due to these more desirable mechanical properties, with
its mechanical strength taking precedence.9-10, 18
Table 1.1: Elastic moduli of orthopedic implant alloys and natural bone.7
Material
Cast cobalt chromium (CoCr)
Stainless steel (SS) AISI 316
Titanium Aluminum Vanadium (Ti-6Al-4V)
Bone

Elastic Modulus (GPa)
240
210
112
30

Although titanium alloys exhibit some desirable mechanical properties, other mechanical
characteristics are not comparable to the cobalt/chromium alloys. For example, titanium and its
alloys tend to be softer materials, and they also have poor wear, frictional, and fatigue properties
(Table 1.2).7, 19 The cyclic loading experienced by the implant may lead to alternating plastic
deformation of stress induced superelevations produced by grooves or microstructural
inconsistencies. These areas of heterogeneity are where cracks in the implant material initiate,
propagate, and finally fracture due to the repeated cyclic loading causing mechanical implant
failure.19 These undesirable mechanical properties also contribute to the generation of wear debris
at the implant site, which in itself contributes to implant failure.
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Table 1.2: Mechanical properties of dominant orthopedic biomaterials.7 ASTM = American
Society for Testing and Materials (ASTM International), t = tension, RC = Rockwell
Hardness scale, MPa = megapascals, HVN = hardness Vickers number.
Material
Co Cr ASTM
F75
CoCr ASTM
F90
CoCr ASTM
F562
CoCr ASTM
1537
SS ASTM
F138
Ti-6Al-4V
ASTM 136

Elastic
Modulus
(GPa)
210-253
210
200-230
200-300
190
116

Yield Strength
(MPa)

Fatigue
Strength
(MPa)
207-950

Hardness
(HVN)

448-841

Ultimate
Strength
(MPa)
655-1277t

300-400

Elongation
at Fracture
(%)
4-14

448-1606

1896t

586-1220

300-400

10-22

300-2000

800-2068t

340-520

8-50 (RC)

10-40

960

1300t

200-300

41 (RC)

20

792

930t

241-820

130-180

43-45

897-1034

965-1103t

620-689

310

8

Implants should exhibit not only specific mechanical properties, but also appropriate
chemical and biological compatibility characteristics as well.19-20 The biomaterial’s ability to meet
these needs strongly influences its success as an implant material. The implanted material should
be robust enough to resist degradation in vivo.5, 7 This material should not corrode, be susceptible
to chemical attack, or release toxic species into the human body. Furthermore, the implant material
should allow for bony in-growth to secure the prosthesis, encourage new bone deposition on its
surface (osteoinduction) to accelerate the stabilization process, and provide limiting distinctions
between the bone and implant interface.1-2, 21 It is desired that osteoblasts, the bone cells that form
new bone, will proliferate and then differentiate on the surface, leading to osseointegration.11, 22
This process is vital for the successful integration of the implant material into the host tissue.23
Not only should these materials be attractive to osteoblasts and encourage natural bone modeling,
they should limit bacterial adhesion. Bacterial adhesion and subsequent proliferation of these
bacteria on the surface lead to implant infection, further destabilizing the implant, causing implant
failure.
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The materials currently used in orthopedic applications do not meet the totality of necessary
mechanical, biological, and chemical characteristics for long-term orthopedic implant success.
Certain implant materials meet or exceed specific demands but falter in other areas. Therefore,
implants comprised of these materials will often fail prematurely. This failure necessitates revision
surgery, which is taxing on the patient. Subsequent revision surgeries have even higher rates of
implant failure. Therefore, there is a need for improved materials that can meet the requirements
of their orthopedic applications.
1.3 Implant Failure and Concerns
Roughly 10% of implants fail prematurely.7 Implant failure necessitates revision surgery,
which is often very taxing on the patient due to the presence of co-morbidities. Failure of the
implant presents itself in a variety of ways. The primary manner of failure is aseptic
osteolysis/loosening (75%), followed by infection (7%), recurrent dislocation (6%), periprosthetic
fracture (5%), and surgical error (3%).7, 23-28 These sources of implant failure are often intertwined
with each other, with specific pathways contributing to multiple modes of failure.
1.3.1 Aseptic Loosening
Aseptic loosening is traditionally defined as the failure of the bond between an implant and
bone in the absence of infection.29 This is a major source of implant failure, and can be difficult to
diagnose clinically, as signs/symptoms may not appear until the end-stage of the implant’s life.30
There are many contributing factors for aseptic loosening including biomaterial wear and
corrosion.31
The generation of wear debris and the body’s response to this debris, is critical to the
longevity/success of the orthopedic implant.7, 32-33 Consequences due to wear are the primary
factors in the long-term performance of orthopedic implants. There are multiple mechanisms and
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consequences due to wear such as the generation of particulate debris and inflammation. Each of
these contribute to aseptic loosening and implant failure.
The formation of wear debris is caused by the loss of material in particulate form, a direct
consequence of the relative motion between two surfaces of the implant.7 In orthopedic implants,
wear is caused by three different processes: 1) abrasion, by which a harder surface plows grooves
into the softer material; 2) adhesion, when a softer material is smeared onto a harder surface
forming a transfer film, and 3) fatigue, alternative episodes of loading and unloading resulting in
the formation of subsurface cracks which propagate to form particles that are shed from the
surface.7
The micromotion that is experienced at the interface of implant and natural bone is
enhanced due to the presence of gaps between the implant material and the patient’s bone.1 These
large gaps are a concern because they are slow to be filled by bony in-growth during osteogenesis,
hence these large spaces will persist for an extended period of time, destabilizing the implant.
Increasing the contact between the bone and implant material reduces the size and quantity of
spaces around the implant, which in turn helps stabilize the joint replacement and limits
micromotion.1 Micromotion is particularly concerning, due to the generation of wear debris in this
process which contributes to aseptic loosening and implant failure.
Another contributing factor to aseptic loosening and destabilization of the implant is
corrosion. Corrosion leads to degradation of the implant, which reduces its structural integrity,
weakening its mechanical properties. Furthermore, the release of degradation products is
potentially detrimental to the patient.7 Corrosion of the implant material is dictated by two
processes, the thermodynamic driving forces for corrosion and the kinetic barrier to corrosion
(surface oxide layer).5, 7 In the first process, the chemical driving force or the change in Gibb’s
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free energy and charge separation control if corrosion will occur. Corrosion in the body is
exacerbated due to the hostile electrolytic environment in vivo.5 The biological molecules present
upset the equilibrium of the corrosion reactions of the implant by consuming the products due to
anodic or cathodic reactions.5 Adsorbed proteins on the biomaterial surface can also contribute to
corrosion, as adsorbed proteins have been shown to reduce the diffusion of oxygen at specific areas
on the implant surface, facilitating corrosion in these areas (Figure 1.2).
The main impediment to corrosion is the formation of a native oxide layer on the surface
of metal orthopedic implants.5 These passive oxide layers prevent further transport of metallic ions
as well as electrons across the oxide layer.7 For oxide layers to be effective at preventing corrosion,
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Figure 1.2: Interface of a passivating alloy surface in contact with a biological environment.
Figure adapted from Ratner et al.
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they must present with uniform coverage across the metal, possess a structure that limits ion and
electron transfer, and they must be robust enough to withstand the mechanical stress and abrasion
experienced by orthopedic devices.
If the oxide layer becomes corrupted, then corrosion of the implant material is possible.7
Dissolved oxygen, inorganic ions, proteins, and the presence of cells can all compromise the oxide
layer, resulting in corrosion and ion release.5 The integrity of the oxide layer can also be corrupted
through mechanical means. Therefore, the machining and shaping of the alloy plays a role in
preserving oxide layer integrity, and preventing subsequent corrosion.7 The unique shaping of
orthopedic implants causes different areas to experience mechanical stress and abrasion in unique
ways which can damage the oxide layer. This renders these tapered areas vulnerable to corrosion,
especially crevice corrosion.7, 34 Furthermore, these oxide layers must also be able to withstand the
mechanical demands post-implantation. For example, both wear and fretting have been shown to
result in the rupture of the protective oxide layer, initiating cracks and causing the formation of
reactive metal atoms on the surface, accelerating corrosion.
Corrosion, wear, micromotion, and other forms of degradation at the implant site lead to
the generation of particles in vivo.31, 35-36 These particles are unique depending on the material used
in the implant. In stainless steel implants, the wear debris is usually encapsulated by a fibrous
membrane, with little or no inflammation.7 The particles themselves are primarily composed of
iron oxide and hydroxide species. In cobalt-chromium systems, the products are chromium
phosphate. Finally, in the case of titanium-based alloys, despite their high corrosion resistance due
to the stable titanium oxide layer, particles with the same elemental composition as the parent alloy
are observed. The larger insoluble species are a concern given that the body will attempt to clear
them, which causes inflammation at the implant site, discussed in more detail later.
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As the presence of wear and corrosion degrades the implant, there is concern over the
leaching of chemically and biologically active metal ions which can travel to surrounding tissues
and organs, with potential negative health consequences to the patient.
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Patients who have

orthopedic implants have potentially higher blood serum levels of common implant metals, when
compared to those without an implant.37 The presence of elevated serum levels is of concern due
to the toxic nature of the elements present in implants. Elevated levels of ions can cause a host of
ailments including carcinogenicity, anemia, and neuroglial dysfunction. These ailments are
generally due to soluble forms of these wear debris, and therefore more needs to be known about
the cytotoxic effects of these elements in the forms released from implants.38
The generation of wear particles at the implant site due to micromotion elicits particular
responses from the body.1, 39 Macrophages, a type of immune cell, attempt to ingest these wear
particles.40 If macrophages ingest these particles, a host of biochemical processes occur. These
include the activation of T-cells, the release of pro-inflammatory mediators, cytotoxicity, DNA
damage, and oxidative stress.7 Macrophages contribute to local inflammation by secreting proinflammatory cytokines (Figure 1.3).30 These cytokines lead to the recruitment of osteoclasts,
bone cells that break down bone, and contribute to the local resorption of bone tissue.1 Other
factors in bone resorption include the enzymes responsible for catabolism of the organic
components of bone such as collagen.7 These include metalloproteinases collagenase and
stromelysin. Prostaglandins are also important messengers in the osteolytic cascade produced by
implant debris.7 Other mediators involved in stimulation or inhibition of osteoclast differentiation
and maturation and osteoprotegerin have been suggested as key players in the development and
progression of bone loss due to implant debris.
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Normal bone maintenance requires the balance of both bone formation and bone resorption,
which involves the function of both osteoblasts and osteoclasts.7 Therefore a decrease in
osteoblastic bone formation or an increase in osteoclastic bone resorption can result in net bone
loss and osteolysis, the destruction of bone tissue. Bone loss around an implant is a concern for
implant stability given that it is a major cause of aseptic loosening.41

Wear particles
Osteoclast

Pro-inflammatory cytokine
Macrophage

Figure 1.3: Pathways that contribute to aseptic loosening of orthopedic implants, a main
cause of implant failure.
1.3.2 Infection
The presence of inflammation at the implant-bone interface is a concern not only for aseptic
loosening, but for infection as well. The presence of inflammation at the implant site can
potentially make the implant more susceptible to microbial colonization.42-43 If the host’s cells can
reach and occupy the implant surface first, this will limit the potential for aseptic loosening, and
provide a defensive barrier against microbial attachment and colonization.23 There are multiple
species of bacteria that will colonize an implant, with Staphylococcus bacteria, particularly
Staphylococcus aureus and Staphylococcus epidermidis accounting for a majority (70%) of
implant infections.26, 44-47 Pseudomonas aeruginosa accounts for another 8% of infections.7, 48-50
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These sessile bacteria will adhere to the implant surface as it provides a preferential place for
attachment.51
Attachment and subsequent colonization occur via multiple factors. Frist, initial
interactions between the bacteria and the implant surface occur. These include hydrophobic,
electrostatic, and Lifshitz-Van der Waals forces, among others.44, 52 It is thought that the degree of
hydrophobicity of the staphylococcal bacterial cell surface and that of the biomaterial play a critical
role in initial attachment.52 There are also specific proteins, the autolysins, which help mediate
attachment. This type of protein has dual roles: enzymatic and adhesive. The second step in
bacterial colonization is growth-dependent cell accumulation resulting in multiple cell layers in
microcolonies.7,

44

In S. epidermidis this aggregation is linked with a β-1,6-linked

glycosaminoglycan polysaccharide complex, known as polysaccharide intercellular adhesion
(PIA) which is regulated by the Ica gene locus.7 Although this complex is conserved in related
staphylococci, PIA and Ica are not required for biofilm formation, as bacteria lacking these are
able to form biofilms. Once adhered after the second step, bacteria will produce a protective,
polymeric, extracellular matrix known as a biofilm.53 This extracellular matrix contains a variety
of materials including expolysaccharides, proteins, teichoic acids, and extracellular DNA.44, 54 This
protective matrix renders the bacteria less susceptible to antibiotics, disinfectants, phagocytosis,
and other mechanisms of infection response from the host.44, 48 In the last step of the cycle, the
bacteria previously encased and protected in the biofilm disperse, returning to their initial
planktonic form, ready to invade a new area (Figure 1.4).26, 44, 54 These biofilms are very difficult
to treat with traditional antibiotics, not only because of the biofilm matrix, but also because many
of these bacteria are resistant to clinically used antibiotics. High systemic doses of antibiotics are
often needed to achieve effective local concentrations. Furthermore, microbial growth on the
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implant hinders osteoblast adhesion and proliferation on the surface, negatively affecting implant
integration. If treatment of these infections is unsuccessful, the implant must be removed.

4) Detachment
of bacterial cells
Bacteria
Polymeric extracellular matrix
1) Initial
attachment
of bacteria

3) Maturation of
bacterial biofilm

2) Accumulation
of multiple
bacterial layers

Figure 1.4: Formation of bacterial biofilms on orthopedic devices.
1.4 Current Directions
1.4.1 Alternative Implant Alloys
When using various alloys, there is often a tradeoff with different properties of the material.
For instance, one may use titanium for its inertness, over stainless steel and cobalt-chromium, but
then may lose some of the beneficial mechanical properties. In order to impart desirable properties
into metallic implant materials, various metals will be alloyed with previously existing alloys.7
These “new” alloys are often variations on the alloys already used clinically in orthopedic
implants, including the stainless steels, cobalt-chromium alloys, and titanium alloys. Outside of
these groups zirconium and tantalum alloys are also used. These materials form stable oxide layers,
which help prevent corrosion. These materials are also hard and have high wear resistance. The
drawback being that these materials are expensive. In addition, one must still consider the potential
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for corruption of the oxide layer, which would render the alloy vulnerable to corrosion, as is
observed with currently utilized materials.
Alteration of other implant alloys includes substitution of toxic elements with less toxic
ones: i.e. vanadium for the less toxic metals niobium and iron in Ti-6Al-4V.7 These alternative
alloys have similar properties to traditional Ti-6Al-4V, but with supposedly higher fatigue strength
and a lower elastic modulus. This enhances bone to implant transfer and limits stress shielding.
Modification of stainless steel alloys is also an area of interest. In these alloys, a high nitrogen
content is incorporated to maintain its fatigue strength and improve resistance to pitting corrosion
and crevice corrosion, as compared to nickel-containing alloys.
1.4.2 Surface Modification
Since the interface between the surface and the host tissue is critical to implant success,
the modification of the implant surface is of extreme interest in current research.11, 15, 17, 55-60 Many
of the previously described chemical and biological phenomena: corrosion, osteoblast attachment,
and bacterial adhesion, occur at the implant-tissue interface. The surface of the metallic implant
can be modified by a variety of methods. These methods address either aseptic loosening or
infection, with few examples addressing both.
As the gaps that occur between the implant material and natural bone contribute to aseptic
loosening and subsequent failure, research has tried to address this issue with gap-bridging
coatings.1 These coatings are designed to swell to fill the gap between the implant and host tissue,
ideally reducing micromotion and wear-particle induced osteolysis. The selection of the coating
materials needs to be thoroughly considered, as the coating should not be susceptible to mechanical
wear and negatively impact the implant’s utility. It should be composed of a material that does not
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degrade or lead to the accumulation of toxic byproducts in vivo. Materials used for these coatings
include hydrogels, foams, or deformable elastic metallic structures. Several of the current coatings
contain Nitinol, a nickel-titanium alloy.61 There is some concern over the use of Nitinol, given its
high nickel content. If the oxide layer of the Nitinol becomes damaged, nickel ions can release
from this material. This is of concern as there are potential toxic and allergenic worries for nickel.62
The most common type of coatings, porous coatings, are either metallic or ceramic foams
on the surface that have been utilized for decades to facilitate bony in growth (osteoconduction) to
help stabilize the implant.1 Many different types of porous structures have been developed, with
beads commonly sintered together to form either open, interconnected pores or closed, individual
pores. Other examples include trabecular metals and wire meshes.63 These types of modifications
have had poor clinical success, with revision rates around 10%, which is on par with unmodified
implants.64-65 Researchers are currently examining methods to optimize the pore structure to
facilitate osteointegration, while also combating infection, another major contributor to implant
failure.
Hydroxyapatite coatings are also of interest for surface modification to improve
osteointegration, given hydroxyapatite’s presence in natural bone.66-71 These coatings have been
functionalized with antimicrobial agents to help prevent infection of the implant material. The
concern with these functionalized materials is their mechanical stability as well as controlling the
release of the antimicrobial agents to be most beneficial at preventing infection.1 Therefore,
different methods of incorporation of the antimicrobial molecule either onto or into the surface
coating have been examined in an attempt to adjust the timeframe of which these antimicrobials
are viable, to provide longer-term protection from bacterial infection.72
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Directly modifying the topography of the implant surface is another area of interest to
improve the interactions between the implant and host.1 Modifying the surface topography to
increase the surface area and porosity of the implant can improve osteoblast adhesion and ingrowth which help prevent aseptic loosening.73 Furthermore, the surface can be etched to create
pits which serve as points of attachment for osteoblasts. Altered surface energy could prevent the
adhesion of bacteria via passive means. In tailoring these surface properties, the chemical and
mechanical stability of the implant should not be compromised.
One of the long-standing clinical approaches to improving the implant-host interaction is
bioactive glass coatings.1,

74-78

These coatings contain elements and molecules to encourage

osteogenesis such as calcium and growth factors.79 These coatings deliver a surface apatite layer
during dissolution, promoting osteogenesis. Unless modified with other substances, these coatings
have limited antimicrobial properties. Although there are those that combine these bioactive glass
coatings with antimicrobial agents to prevent infection.42,

80

In these functionalized coatings,

design is critical. The antimicrobial agents must remain active through the manufacturing process
and need to prevent infection on an appropriate time-frame. These coatings must also be strongly
adhered to the implant material, to avoid delamination and cracking.
1.5 Summary
A variety of materials are utilized in orthopedic implants. Unfortunately, no single material
meets the totality of demands for these applications. Therefore, implants are susceptible to failure
due to aseptic loosening and bacterial colonization. These issues are currently addressed through
surface modification. However, these modifications are rarely multifunctional, focusing on only
one cause of implant failure. Therefore, as the rates of knee and hip implants are expected to arise,
future endeavors should address both aseptic loosening and infection of the implant.

15

1.6. References
1.Raphel, J.; Holodniy, M.; Goodman, S. B.; Heilshorn, S. C., Multifunctional coatings to
simultaneously promote osseointegration and prevent infection of orthopaedic implants.
Biomaterials, 2016, 84, 301-314.
2.Geetha, M.; Singh, A. K.; Asokamani, R.; Gogia, A. K., Ti based biomaterials, the ultimate
choice for orthopaedic implants – A review. Prog. Mater Sci., 2009, 54 (3), 397-425.
3.Foran, J. Total Hip Replacement. https://orthoinfo.aaos.org/en/treatment/total-hip-replacement/
(accessed 04/45/18).
4.Ducheyne, P.; De Meester, P.; Aernoudt, E.; Martens, M.; Mulier, J., Influence of a functional
dynamic loading on bone ingrowth into surface pores of orthopedic implants. J. Biomed. Mater.
Res., 1977, 11 (6), 811-838.
5.Manivasagam, G.; Dhinasekaran, D.; Rajamanickam, A., Biomedical Implants: Corrosion and
its Prevention-A Review. Recent Pat. Corros. Sci., 2010.
6.Campbell, A. A., Bioceramics for implant coatings. Mater. Today, 2003, 6 (11), 26-30.
7.Ratner, B. D.; Hoffman, A. S.; Schoen, F. J.; Lemons, J. E., Biomaterials science: an
introduction to materials in medicine. Academic press: 2004.
8.Geetha, M.; Singh, A. K.; Asokamani, R.; Gogia, A. K., Ti based biomaterials, the ultimate
choice for orthopaedic implants - A review. Prog. Mater Sci., 2009, 54 (3), 397-425.
9.MacDonald, D. E.; Rapuano, B. E.; Deo, N.; Stranick, M.; Somasundaran, P.; Boskey, A. L.,
Thermal and chemical modification of titanium–aluminum–vanadium implant materials: effects
on surface properties, glycoprotein adsorption, and MG63 cell attachment. Biomaterials, 2004,
25 (16), 3135-3146.
10.Johansson, C. B.; Han, C. H.; Wennerberg, A.; Albrektsson, T., A quantitative comparison of
machined commercially pure titanium and titanium-aluminum-vanadium implants in rabbit bone.
Int. J. Oral Maxillofac. Implants, 1998, 13 (3), 315-321.
11.Gittens, R. A.; Olivares-Navarrete, R.; McLachlan, T.; Cai, Y.; Hyzy, S. L.; Schneider, J. M.;
Schwartz, Z.; Sandhage, K. H.; Boyan, B. D., Differential responses of osteoblast lineage cells to
nanotopographically-modified, microroughened titanium–aluminum–vanadium alloy surfaces.
Biomaterials, 2012, 33 (35), 8986-8994.

16

12.Taddei, E.; Henriques, V.; Silva, C.; Cairo, C., Production of new titanium alloy for
orthopedic implants. Mater. Sci. Eng., C, 2004, 24 (5), 683-687.
13.Gkomoza, P.; Lampropoulos, G.; Vardavoulias, M.; Pantelis, D.; Karakizis, P.; Sarafoglou,
C., Microstructural investigation of porous titanium coatings, produced by thermal spraying
techniques, using plasma atomization and hydride-dehydride powders, for orthopedic implants.
Surf. Coat.Technol., 2019, 357, 947-956.
14.Thelen, S.; Barthelat, F.; Brinson, L. C., Mechanics considerations for microporous titanium
as an orthopedic implant material. J. Biomed. Mater. Res., Part A, 2004, 69 (4), 601-610.
15.Kirmanidou, Y.; Sidira, M.; Drosou, M.-E.; Bennani, V.; Bakopoulou, A.; Tsouknidas, A.;
Michailidis, N.; Michalakis, K., New Ti-Alloys and Surface Modifications to Improve the
Mechanical Properties and the Biological Response to Orthopedic and Dental Implants: A
Review. Biomed Res Int, 2016, 2016, 21.
16.Metsemakers, W. J.; Moriarty, T. F.; Nijs, S.; Pape, H. C.; Richards, R. G., Influence of
implant properties and local delivery systems on the outcome in operative fracture care. Injury,
2016, 47 (3), 595-604.
17.Kulkarni, M.; Mazare, A.; Schmuki, P.; Iglič, A., Biomaterial surface modification of
titanium and titanium alloys for medical applications. Nanomedicine, 2014, 111, 111.
18.Anselme, K.; Linez, P.; Bigerelle, M.; Le Maguer, D.; Le Maguer, A.; Hardouin, P.;
Hildebrand, H.; Iost, A.; Leroy, J., The relative influence of the topography and chemistry of
TiAl6V4 surfaces on osteoblastic cell behaviour. Biomaterials, 2000, 21 (15), 1567-1577.
19.Bauer, S.; Schmuki, P.; von der Mark, K.; Park, J., Engineering biocompatible implant
surfaces: Part I: Materials and surfaces. Prog. Mater Sci., 2013, 58 (3), 261-326.
20.Kang, S. M.; Kong, B.; Oh, E.; Choi, J. S.; Choi, I. S., Osteoconductive conjugation of bone
morphogenetic protein-2 onto titanium/titanium oxide surfaces coated with non-biofouling
poly(poly(ethylene glycol) methacrylate). Colloids Surf. B. Biointerfaces, 2010, 75 (1), 385-389.
21.Guglielmotti, M. B.; Olmedo, D. G.; Cabrini, R. L., Research on implants and
osseointegration. Periodontology 2000, 2019, 79 (1), 178-189.
22.Anselme, K., Osteoblast adhesion on biomaterials. Biomaterials, 2000, 21 (7), 667-681.

17

23.Shi, Z.; Neoh, K. G.; Kang, E. T.; Poh, C.; Wang, W., Bacterial adhesion and osteoblast
function on titanium with surface-grafted chitosan and immobilized RGD peptide. J. Biomed.
Mater. Res., Part A, 2008, 86A (4), 865-872.
24.Kruszewski, K. M.; Gawalt, E. S., Perfluorocarbon Thin Films and Polymer Brushes on
Stainless Steel 316 L for the Control of Interfacial Properties. Langmuir, 2011, 27 (13), 81208125.
25.Stinson, Z.; Rosenfeld, S.; McNeil, J. C., Infections Complicating Orthopedic Surgery and
Implants. In Healthcare-Associated Infections in Children, Springer: 2019; pp 133-151.
26.Belt, H. v. d.; Neut, D.; Schenk, W.; Horn, J. R. v.; Mei, H. C. v. d.; Busscher, H. J., Infection
of orthopedic implants and the use of antibiotic-loaded bone cements: a review. Acta Orthop.
Scand., 2001, 72 (6), 557-571.
27.Kutzner, I.; Hallan, G.; Høl, P. J.; Furnes, O.; Gøthesen, Ø.; Figved, W.; Ellison, P., Early
aseptic loosening of a mobile-bearing total knee replacement. Acta Orthop, 2018, 89 (1), 77-83.
28.Ulrich, S. D.; Seyler, T. M.; Bennett, D.; Delanois, R. E.; Saleh, K. J.; Thongtrangan, I.;
Kuskowski, M.; Cheng, E. Y.; Sharkey, P. F.; Parvizi, J., Total hip arthroplasties: what are the
reasons for revision? Int, Orthop., 2008, 32 (5), 597-604.
29.Price, J.; Tencer, A.; Arm, D.; Bohach, G., Controlled release of antibiotics from coated
orthopedic implants. J. Biomed. Mater. Res., Part A, 1996, 30 (3), 281-286.
30.Abu-Amer, Y.; Darwech, I.; Clohisy, J. C., Aseptic loosening of total joint replacements:
mechanisms underlying osteolysis and potential therapies. Arthritis Res. Ther., 2007, 9 (Suppl 1),
S6-S6.
31.Sundfeldt, M.; V Carlsson, L.; B Johansson, C.; Thomsen, P.; Gretzer, C., Aseptic loosening,
not only a question of wear: a review of different theories. Acta Orthop, 2006, 77 (2), 177-197.
32.Brunette, D. M.; Tengvall, P.; Textor, M.; Thomsen, P., Titanium Med., Springer Science &
Business Media: 2012.
33.Greenfields, E. M.; Bi, Y.; Ragab, A. A.; Goldberg, V. M.; Van De Motter, R. R., The role of
osteoclast differentiation in aseptic loosening. J. Orth. Res., 2002, 20 (1), 1-8.
34.Levine, D.; Staehle, R., Crevice corrosion in orthopedic implant metals. J. Biomed. Mater.
Res., 1977, 11 (4), 553-561.

18

35.Agins, H. J.; Alcock, N.; Bansal, M.; Salvati, E.; Wilson, P.; Pellicci, P.; Bullough, P.,
Metallic wear in failed titanium-alloy total hip replacements. J Bone Joint Surg, 1988, 70 (3),
347-356.
36.Amanov, A.; Cho, I.-S.; Kim, D.-E.; Pyun, Y.-S., Fretting wear and friction reduction of CP
titanium and Ti–6Al–4V alloy by ultrasonic nanocrystalline surface modification. Surf.
Coat.Technol., 2012, 207, 135-142.
37.Kiran, M.; Armstrong, C.; Shivarathre, D.; Peter, V. K., Blood metal ion levels have limited
utility in the surveillance of asymptomatic large-head metal-on-metal total hip arthroplasties. J.
Arthroplasty, 2017, 32 (12), 3685-3688.
38.Campbell, P.; Ebramzadeh, E., ARMD and Presumed Dangerous!: Commentary on an article
by Gulraj S. Matharu, BSc (Hons), MRCS, MRes, et al.:“Blood Metal Ion Thresholds to Identify
Patients with Metal-on-Metal Hip Implants at Risk of Adverse Reactions to Metal Debris. An
External Multicenter Validation Study of Birmingham Hip Resurfacing and Corail-Pinnacle
Implants”. JBJS, 2017, 99 (18), e100.
39.Wooley, P. H.; Schwarz, E. M., Aseptic loosening. Gene Ther., 2004, 11 (4), 402-407.
40.Brown, B. N.; Badylak, S. F., Expanded applications, shifting paradigms and an improved
understanding of host–biomaterial interactions. Acta Biomater., 2013, 9 (2), 4948-4955.
41.Albrektsson, T.; Jemt, T.; Mölne, J.; Tengvall, P.; Wennerberg, A., On inflammation‐
immunological balance theory—A critical apprehension of disease concepts around implants:
Mucositis and marginal bone loss may represent normal conditions and not necessarily a state of
disease. Clin. Implant Dent. Relat. Res., 2019, 21 (1), 183-189.
42.Rahaman, M. N.; Bal, B. S.; Huang, W., Review: Emerging developments in the use of
bioactive glasses for treating infected prosthetic joints. Mater. Sci. Eng., C, 2014, 41, 224-231.
43.Zhao, B.; van der Mei, H. C.; Subbiahdoss, G.; de Vries, J.; Rustema-Abbing, M.; Kuijer, R.;
Busscher, H. J.; Ren, Y., Soft tissue integration versus early biofilm formation on different dental
implant materials. Dent. Mater., 2014, 30 (7), 716-727.
44.Arciola, C. R.; Campoccia, D.; Speziale, P.; Montanaro, L.; Costerton, J. W., Biofilm
formation in Staphylococcus implant infections. A review of molecular mechanisms and
implications for biofilm-resistant materials. Biomaterials, 2012, 33 (26), 5967-5982.

19

45.Trampuz, A.; Widmer, A. F., Infections associated with orthopedic implants. Curr. Opin.
Infect. Dis., 2006, 19 (4), 349-356.
46.Widmer, A. F., New developments in diagnosis and treatment of infection in orthopedic
implants. The University of Chicago Press: 2001.
47.Soriano, A.; Gomez, J.; Gomez, L.; Azanza, J.; Pérez, R.; Romero, F.; Pons, M.; Bella, F.;
Velasco, M.; Mensa, J., Efficacy and tolerability of prolonged linezolid therapy in the treatment
of orthopedic implant infections. Eur. J. Clin. Microbiol. Infect. Dis., 2007, 26 (5), 353-356.
48.Høiby, N.; Bjarnsholt, T.; Moser, C.; Bassi, G. L.; Coenye, T.; Donelli, G.; Hall-Stoodley, L.;
Holá, V.; Imbert, C.; Kirketerp-Møller, K.; Lebeaux, D.; Oliver, A.; Ullmann, A. J.; Williams,
C., ESCMID∗ guideline for the diagnosis and treatment of biofilm infections 2014. Clin.
Microbiol. Infect., 2015, 21, Supplement 1, S1-S25.
49.Nablo, B. J.; Rothrock, A. R.; Schoenfisch, M. H., Nitric oxide-releasing sol–gels as
antibacterial coatings for orthopedic implants. Biomaterials, 2005, 26 (8), 917-924.
50.Campoccia, D.; Montanaro, L.; Arciola, C. R., The significance of infection related to
orthopedic devices and issues of antibiotic resistance. Biomaterials, 2006, 27 (11), 2331-2339.
51.Costerton, J.; Montanaro, L.; Arciola, C. R., Biofilm in implant infections: its production and
regulation. Int. J. Artif. Organs, 2005, 28 (11), 1062-1068.
52.An, Y. H.; Friedman, R. J., Concise review of mechanisms of bacterial adhesion to
biomaterial surfaces. J. Biomed. Mater. Res., Part A, 1998, 43 (3), 338-348.
53.Niska, J. A.; Shahbazian, J. H.; Ramos, R. I.; Pribaz, J. R.; Billi, F.; Francis, K. P.; Miller, L.
S., Daptomycin and tigecycline have broader effective dose ranges than vancomycin as
prophylaxis against a Staphylococcus aureus surgical implant infection in mice. Antimicrob.
Agents Chemother., 2012, 56 (5), 2590-2597.
54.Kruszewski, K. M.; Nistico, L.; Longwell, M. J.; Hynes, M. J.; Maurer, J. A.; Hall-Stoodley,
L.; Gawalt, E. S., Reducing Staphylococcus aureus biofilm formation on stainless steel 316L
using functionalized self-assembled monolayers. Mater. Sci. Eng. C Mater. Biol. Appl., 2013, 33
(4), 2059-2069.
55.Guleryuz, H.; Cimenoglu, H., Surface modification of a Ti–6Al–4V alloy by thermal
oxidation. Surf. Coat.Technol., 2005, 192 (2), 164-170.

20

56.Heinl, P.; Müller, L.; Körner, C.; Singer, R. F.; Müller, F. A., Cellular Ti–6Al–4V structures
with interconnected macro porosity for bone implants fabricated by selective electron beam
melting. Acta Biomater., 2008, 4 (5), 1536-1544.
57.Larsson Wexell, C.; Thomsen, P.; Aronsson, B.-O.; Tengvall, P.; Rodahl, M.; Lausmaa, J.;
Kasemo, B.; Ericson, L., Bone response to surface-modified titanium implants: studies on the
early tissue response to implants with different surface characteristics. Int. J. Biomater., 2013,
2013.
58.Liu, Q.; Ding, J.; Mante, F. K.; Wunder, S. L.; Baran, G. R., The role of surface functional
groups in calcium phosphate nucleation on titanium foil: a self-assembled monolayer technique.
Biomaterials, 2002, 23 (15), 3103-3111.
59.Liu, X.; Chu, P. K.; Ding, C., Surface modification of titanium, titanium alloys, and related
materials for biomedical applications. Mater. Sci. Eng., R, 2004, 47 (3), 49-121.
60.Simchi, A.; Tamjid, E.; Pishbin, F.; Boccaccini, A., Recent progress in inorganic and
composite coatings with bactericidal capability for orthopaedic applications. Nanomed.
Nanotechnol. Biol. Med., 2011, 7 (1), 22-39.
61.Friend, W. Z., Nickel and High-Nickel Alloys. Ind. Eng. Chem., 1949, 41 (10), 2126-2132.
62.Rocher, P.; El Medawar, L.; Hornez, J. C.; Traisnel, M.; Breme, J.; Hildebrand, H. F.,
Biocorrosion and cytocompatibility assessment of NiTi shape memory alloys. Scripta Mater.,
2004, 50 (2), 255-260.
63.Ryan, G.; Pandit, A.; Apatsidis, D. P., Fabrication methods of porous metals for use in
orthopaedic applications. Biomaterials, 2006, 27 (13), 2651-2670.
64.Kawamura, H.; Dunbar, M. J.; Murray, P.; Bourne, R. B.; Rorabeck, C. H., The porous coated
anatomic total hip replacement: a ten to fourteen-year follow-up study of a cementless total hip
arthroplasty. JBJS, 2001, 83 (9), 1333-1338.
65.Hailer, N. P.; Lazarinis, S.; Mäkelä, K. T.; Eskelinen, A.; Fenstad, A. M.; Hallan, G.; Havelin,
L.; Overgaard, S.; Pedersen, A. B.; Mehnert, F., Hydroxyapatite coating does not improve
uncemented stem survival after total hip arthroplasty! An analysis of 116,069 THAs in the
Nordic Arthroplasty Register Association (NARA) database. Acta Orthop, 2015, 86 (1), 18-25.
66.Buckholtz, G. A.; Reger, N. A.; Anderton, W. D.; Schimoler, P. J.; Roudebush, S. L.; Meng,
W. S.; Miller, M. C.; Gawalt, E. S., Reducing Escherichia coli growth on a composite

21

biomaterial by a surface immobilized antimicrobial peptide. Mater. Sci. Eng., C, 2016, 65, 126134.
67.Cook, S. D.; Thomas, K. A.; Kay, J. F.; Jarcho, M., Hydroxyapatite-coated titanium for
orthopedic implant applications. Clin Orthop, 1988, 232 (225), 43.
68.Qiu, H.; Yang, J.; Kodali, P.; Koh, J.; Ameer, G. A., A citric acid-based hydroxyapatite
composite for orthopedic implants. Biomaterials, 2006, 27 (34), 5845-5854.
69.Bakar, M. A.; Cheng, M.; Tang, S.; Yu, S.; Liao, K.; Tan, C.; Khor, K.; Cheang, P., Tensile
properties, tension–tension fatigue and biological response of polyetheretherketone–
hydroxyapatite composites for load-bearing orthopedic implants. Biomaterials, 2003, 24 (13),
2245-2250.
70.Soballe, K.; Hansen, E.; Brockstedt-Rasmussen, H.; Bunger, C., Hydroxyapatite coating
converts fibrous tissue to bone around loaded implants. J. Bone Surg. Brit., 1993, 75 (2), 270278.
71.Clemens, J.; Klein, C.; Vriesde, R.; Rozing, P.; De Groot, K., Healing of large (2 mm) gaps
around calcium phosphate‐coated bone implants: A study in goats with a follow‐up of 6 months.
J. Biomed. Mater. Res., 1998, 40 (3), 341-349.
72.Stigter, M.; Bezemer, J.; De Groot, K.; Layrolle, P., Incorporation of different antibiotics into
carbonated hydroxyapatite coatings on titanium implants, release and antibiotic efficacy. J.
Controlled Release, 2004, 99 (1), 127-137.
73.von der Mark, K.; Park, J., Engineering biocompatible implant surfaces. Part II: cellular
recognition of biomaterial surfaces: lessons from cell–matrix interactions. Prog. Mater Sci.,
2013, 58, 327-381.
74.Lopez-Esteban, S.; Saiz, E.; Fujino, S.; Oku, T.; Suganuma, K.; Tomsia, A. P., Bioactive
glass coatings for orthopedic metallic implants. J. Eur. Ceram. Soc., 2003, 23 (15), 2921-2930.
75.Fathi, M.; Doostmohammadi, A., Bioactive glass nanopowder and bioglass coating for
biocompatibility improvement of metallic implant. J. Mater. Process. Technol., 2009, 209 (3),
1385-1391.
76.Gonzalez, P.; Serra, J.; Liste, S.; Chiussi, S.; Leon, B.; Perez-Amor, M.; Martınez-Fernández,
J.; de Arellano-Lopez, A.; Varela-Feria, F., New biomorphic SiC ceramics coated with bioactive
glass for biomedical applications. Biomaterials, 2003, 24 (26), 4827-4832.

22

77.Tomsia, A. P.; Saiz, E.; Song, J.; Bertozzi, C. R., Biomimetic bonelike composites and novel
bioactive glass coatings. Adv. Eng. Mater., 2005, 7 (11), 999-1004.
78.Boccaccini, A. R.; Erol, M.; Stark, W. J.; Mohn, D.; Hong, Z.; Mano, J. F., Polymer/bioactive
glass nanocomposites for biomedical applications: a review. Compos. Sci. Technol., 2010, 70
(13), 1764-1776.
79.Peter, B.; Gauthier, O.; Laïb, S.; Bujoli, B.; Guicheux, J.; Janvier, P.; van Lenthe, G. H.;
Müller, R.; Zambelli, P. Y.; Bouler, J. M., Local delivery of bisphosphonate from coated
orthopedic implants increases implants mechanical stability in osteoporotic rats. J. Biomed.
Mater. Res., Part A, 2006, 76 (1), 133-143.
80.Pishbin, F.; Mouriño, V.; Flor, S.; Kreppel, S.; Salih, V.; Ryan, M. P.; Boccaccini, A. R.,
Electrophoretic deposition of gentamicin-loaded bioactive glass/chitosan composite coatings for
orthopaedic implants. ACS Appl. Mater. Interfaces, 2014, 6 (11), 8796-8806.

23

Chapter 2: Formation and Characterization of Multi-tailed Self-assembled Monolayers on
Titanium Aluminum Vanadium
2.1 Introduction
Although no one material meets the totality of desirable characteristics for load-bearing
orthopedic implants, titanium aluminum vanadium (Ti-6Al-4V), a titanium alloy, is frequently
used as the femoral stem in hip replacement and as the femoral and tibial components in total knee
replacements.1-3 The ubiquity of Ti-6Al-4V in these applications is due to its high strength to
weight ratio, moderate moduli, corrosion resistance, and biocompatiblity.4-7 The material’s bulk
mechanical properties are owed to the presence of both aluminum and vanadium in the alloy, with
Ti-6Al-4V consisting of 90% titanium, 6% aluminum, and 4% vanadium by weight.8-10 Aluminum
stabilizes the α phase, whereas vanadium stabilizes the β phase and does not form chemical
compounds with titanium. Therefore, Ti-6Al-4V exhibits higher tensile and yield strengths due to
the presence of both of these phases at room temperature when compared to titanium alone.2, 11
The chemical properties of Ti-6Al-4V, are dictated by the material’s surface content. Once
exposed to water or oxygen, a thin (4-6 nm thick), strongly adhered oxide layer is formed on the
surface of Ti-6Al-4V.2, 12 This layer consists of titanium dioxide followed by aluminum oxide
(9%), and vanadium oxide (2%).10, 13 This oxide layer contributes to the inertness and corrosion
resistance of the alloy and dictates its interfacial properties.2
Ti-6Al-4V is chosen for orthopedic implant applications due to its high strength to weight
ratio and corrosion resistance.4 However, Ti-6Al-4V suffers from poor osseointegration. It does
not allow for the recruitment of immature cells onto the surface to then differentiate into
preosteoclasts (osteoinduction) or for the growth of mature osteoblasts on the surface
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(osteoconduction).14-15 Osteoblasts at the implant surface are necessary for the deposition of new
bone, allowing for osseointegration. The alloy is also susceptible to bacterial colonization and
biofilm formation, which can lead to implant infection.16-19 Poor osseointegration and/or infection
contribute to implant failure.18, 20-26
2.1.1 Surface Modification with Self-Assembled Monolayers
Modification of the alloy surface is difficult due to the presence of the stable, relatively
chemically inert oxide layer.27 However, the surface of Ti-6Al-4V can be modified using selfassembled monolayers (SAMs).28 SAMs are molecular assemblies that form spontaneously on
metal oxides and other surfaces.29-35 Monolayers are formed when organic molecules in the
solution phase adsorb onto the substrate surface (Figure 2.1).31 These films are designed to be
non-toxic and strongly adhered to the metal oxide surface. SAM molecules are comprised of three
parts, an organic acid head group, an alkyl chain, and tail group (Figure 2.1b). The organic acid
head group chemically binds to the oxide layer of the metal. SAM head groups include carboxylic,
sulfonic, hydroxamic, and phosphonic acid.4, 30 The alkyl chain provides stability to the SAM
through van der Waals interactions, with longer alkyl chains leading to increased stability.

36-37

These SAMs can be described as either ordered or disordered (Figure 2.2).38 In ordered SAMs,
the alkyl chains exist in a trans configuration. In disordered or loosely-packed monolayers, the
alkyl chains possess cis orientations. The tail group aids stability through interactions such as
hydrogen bonding or electrostatic forces.39 Since SAMs can form defined structures on the surface,
these tail groups are presented at the interface in a consistent, active manner. The tail group allows
for chemical reactions at the surface.35, 40-43
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a)

Metal Oxide

Metal Oxide
b)
Tail Group

Alkyl Chain

Head Group
Metal Oxide
Figure 2.1: a) SAM molecule interacting with the metal oxide surface. b) SAM components
and growth via island formation and aggregation.
a)

b)

Metal Oxide

Metal Oxide

Figure 2.2: a) SAMs can form in an ordered, crystalline all ordered all trans configuration. b)
SAMs in a disordered, liquid-like monolayer with gauche interactions.
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SAMs formed on orthopedic implant materials can be used as a flexible platform for
altering the interfacial properties, allowing for the formation of a multifunctional surface.33 In this
work, SAMs comprised of a phosphonic acid head group were chosen. Phosphonic acid was
chosen as the head group due to its increased stability over SAMs possessing a carboxylic acid
head group when formed on titanium dioxide, a primary component of the Ti-6Al-4V surface.30
Commercially, phosphonic acid SAM molecules of various tail groups are available. These
functional tail groups allow for specific, organic reactions at the surface. A selection of these SAM
molecules with similar alkyl chain lengths was chosen to modify the surface of Ti-6Al-4V.
In order to generate a flexible SAM platform, multifunctionality was incorporated via the
presentation of different tail groups at the interface. Here, a systematic approach was undertaken
to form SAMs of one or multiple tail groups on Ti-6Al-4V (Figure 2.3). This was performed to
determine SAM combinations that were easily formed, chemically stable to solvent, possessing
tail groups with unique reactivities.
a)

c)

b)

Metal Oxide

Metal Oxide

Metal Oxide

Figure 2.3: a) Single modification of Ti-6Al-4V with SAMs possessing on type of tail group.
b) Dual modification of Ti-6Al-4V with SAMs possessing two different tail groups. c) Triple
modification of Ti-6Al-4V with SAMs possessing three different types of tail groups.
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2.2 Materials
11-phosphonoundecanoic acid (96% purity), 11-hydroxyundecylphosphonic acid (≥95%
purity), 11-phosphonoundecylacrylate, 12-aminododecylphosphonic acid hydrochloride salt
(≥95% purity), 12-mercaptododecylphosphonic acid (95% purity), and retinoic acid (≥98% purity)
were obtained from Sigma Aldrich and used as received. Tetrahydrofuran, Optima grade, obtained
from Fisher Scientific was distilled over sodium and benzophenone prior to use. Methanol was
obtained from Duquesne University and dried over 4A molecular sieves. Ethanol and 18 MΩ water
were also obtained from Duquesne University. Ti-6Al-4V, 0.52 mm thickness was purchased from
Goodfellow Inc. (Coraopolis, PA US) and prepared as described below.
2.3 Methods
2.3.1 Preparation of Titanium Aluminum Vanadium
Ti-6Al-4V was prepared by sanding with 150, 320, 400, and 600 grit sand paper. Substrates
were then cut into 1 cm by 1 cm coupons. These coupons were sonicated in acetone for 15 minutes
and then placed in boiling methanol for 15 minutes to remove any residue from the surface. Then,
substrates were removed and placed sanded-side-up on a petri dish in a 120°C oven overnight to
dry. After drying, substrates were stored in a glass vial until use.
2.3.2 Formation of Self-assembled Monolayers on Titanium Aluminum Vanadium
2.3.2.1 Single Modification with Self-assembled Monolayers
SAMs were formed using a thin layer chromatography (TLC) aerosol sprayer with nitrogen
as the propellant, where the phosphonic acid solutions (Table 2.1), were sprayed onto the Ti-6Al4V coupons. Deposition conditions including substrate temperature, solution temperature, number
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of spray cycles, drying time/temperature were altered to facilitate SAM formation (Table 2.2,
Table 2.3).
Table 2.1: Formation of phosphonic acid solutions.
Phosphonic Acid
11-phosphonoundecanoic acid
11-hydroxyundecylphosphonic acid
11-phosphonoundecylacrylate
12-aminododecylphosphonic acid
12-mercaptododecylphosphonic acid
12-bromododecylphosphonic acid

Concentration (mM)
1.0
1.0
2.0
0.5
1.0
1.0

Solvent
Methanol
Tetrahydrofuran
Tetrahydrofuran
Ethanol
Tetrahydrofuran
Tetrahydrofuran

Table 2.2: Formation conditions for single modified Ti-6Al-4V.
SAM
Carboxylic
Hydroxyl
Acrylate
Amine
Thiol

Number of
Spray
Cycles
3
3
3
2
3

Substrate
Temperature
(°C)
4
4
4
4
4

Solution
Temperature
(°C)
55
55
55
55
55

Drying
Temperature (°C)
60
60
60
60
60

Drying
Time
(Hours)
18
18
18
18
18

Table 2.3: Formation methods attempted to form ordered and stable SAMs of bromine
terminated phosphonic acid.
Deposition Method
Aerosol
Solution
Aerosol

Number of
Spray
Cycles
5
NA
5

Substrate
Temperature
(°C)
4
55
55

Solution
Temperature
(°C)
55
55
4

Drying
Temperature (°C)
60
60
60

Drying
Time
(Hours)
18
18
18

SAMs were then rinsed in the solvent used to dissolve the acid for 15 minutes to remove
any loosely bound material and allowed to dry overnight in a 60°C oven. Substrates were sonicated
in solvent for 15 minutes to test the stability of formed SAMs and then placed in a 60°C oven to
dry prior to analysis. The formation of ordered and stable SAMs in this part of the project was

29

crucial, since these deposition conditions were used as the initial parameters for the formation of
dual modified Ti-6Al-4V.
2.3.2.2 Dual Modification with Self-assembled Monolayers
The phosphonic acid molecules were used in combination to generate surfaces with two
different SAM tails at the interface. Bromine was excluded from the combinations as it did not
successfully form SAMs. Reaction conditions determined in the above section were used as
starting points for the formation of dual modified Ti-6Al-4V (Table 2.1, Table 2.2). The different
phosphonic acid solutions were sprayed separately during each spray cycle. The order of spraying
as well as other reaction conditions were altered to form stable and ordered SAMs on the Ti-6Al4V surface (Table 2.4).
Table 2.4: Formation conditions for dual modified Ti-6Al-4V.

SAM
Carboxylic (1) & acrylate (2)
Carboxylic (1) & thiol (3)
Carboxylic (1) & amine (4)
Carboxylic (1) & hydroxyl (5)
Acrylate (2) & thiol (3)
Acrylate (2) & amine (4)
Acrylate (2) & hydroxyl (5)
Thiol (3) & amine (4)
Thiol (3) & hydroxyl (5)
Amine (4) & hydroxyl (5)

Number
of Spray
Cycles
2
2
3
3
3
2
3
3
3
2

Substrate
Temperature
(°C)
4
4
4
4
4
4
4
4
4
4

Solution
Temperatures
(°C)
55
55
55
55
55
55
55
55
55
55

Spray
Order
1,2
3,1
4,1
5,1
3,2
4,2
5,2
4,3
5,3
5,4

Drying
Temperature
(°C)
60
60
60
60
60
60
60
60
60
60

Drying
Time
(Hours)
18
18
18
18
18
18
18
18
18
18

After deposition, SAMs were rinsed in the solvents used to dissolve the acids for 15
minutes and allowed to dry overnight in a 60°C oven. Substrates were sonicated in solvent for 15
minutes to test the stability of formed SAMs and then placed in a 60°C oven to dry prior to analysis.
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2.3.2.3 Triple Modification with Self-assembled Monolayers
Combinations of three different phosphonic acids were used to form SAMs on the Ti-6Al4V surface. Reaction conditions including substrate temperature, number of spray cycles, and
order of SAM deposition were modified from those used to form single and dual SAMs on Ti-6Al4V (Table 2.5). Phosphonic acid solvent and concentration remained constant (Table 2.1). After
deposition, SAMs were rinsed in the solvents used to dissolve the acids for 15 minutes and allowed
to dry overnight in a 60°C oven. Substrates were sonicated in solvent for 15 minutes to test the
stability of formed SAMs and then placed in a 60°C oven to dry prior to analysis.
Table 2.5: Formation conditions for triple modified Ti-6Al-4V.

SAM
Thiol (3), acrylate (2),
& carboxylic (1)
Thiol (3), acrylate (2),
& amine (4)
Thiol (3), acrylate (2),
& hydroxyl (5)
Thiol (3), carboxylic
(1), & hydroxyl (5)
Thiol (3), amine (4), &
hydroxyl (5)
Acrylate (2), carboxylic
(1), & amine (4)
Acrylate (2), carboxylic
(1), & hydroxyl (5)
Acrylate (2), amine (4),
& hydroxyl (5)
Carboxylic (1), amine
(4), & hydroxyl (5)

Number
of Spray
Cycles

Substrate
Temperature
(°C)

Solution
Temperatures
(°C)

Spray
Order

Drying
Temperature
(°C)

Drying
Time
(Hours)

2

4

55

1,3,2

60

18

2

4

55

4,3,2

60

18

2

4

55

5,3,2

60

18

2

4

55

3,5,1

60

18

2

4

55

3,5,4

60

18

2

4

55

2,1,4

60

18

3

4

55

1,2,5

60

18

2

4

55

2,5,4

60

18

2

4

55

5,1,4

60

18
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2.3.3 Characterization of Self-assembled Monolayers
2.3.3.1 Diffuse Reflectance Infrared Spectroscopy
SAM formation was confirmed through diffuse reflectance infrared Fourier transform
(DRIFT) spectroscopy using a Thermo Nicolet-Nexus FT-IR with a diffuse reflectance attachment.
The spectra were collected under N2 to suppress stretches associated with CO2 and H2O. A total
of 256 scans were collected per sample with a resolution of 4 cm-1. Unmodified Ti-6Al-4V
substrates were used as the backgrounds for analysis; they did not possess stretches in the spectral
regions of interest.
2.3.3.2 Contact Angle
The wettability of unmodified and modified Ti-6Al-4V substrates was examined using
static contact angle analysis. This was performed after the substrates were sonicated in solvent for
15 minutes and allowed to dry overnight. Millipore water (4 µL) was brought into contact with the
coupon surface using a 10 µL syringe. A total of three drops were placed on each surface, on a
total of three different substrates of each modification type were examined (n=9). The droplets
were then analyzed using Image J software to obtain contact angle values. Contact angle values of
the modified substrates were then compared to unmodified substrates and standard deviations (SD)
were calculated.
2.3.3.3 Matrix-assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) Mass
Spectrometry
MALDI-TOF was used to distinguish between the formation of monolayers and
multilayers on the triple modified Ti-6Al-4V. In addition, this technique was used to confirm the
presence of each phosphonic acid SAM on a triple modified surface. An Agilent Technologies
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(G3250AA) LC/MSD-TOF mass spectrometry system with model G1969A AP MALDI source
was used. The SAM modified coupons were fixed to the MALDI target using double-sided tape.
Substrates were then spotted with a 10 mg/mL solution of retinoic acid in tetrahydrofuran
repeatedly, until the substrates were covered. Spectra were collected on three different areas on
each substrate in negative mode with the capillary voltage at 3500 V, a fragmentor voltage of 350
V, and a skimmer voltage of 65 V. Nitrogen drying gas at 325 °C, was used to purge the instrument.
2.4 Results
2.4.1 Characterization of Self-Assembled Monolayer Ordering and Binding
The formation of ordered and stable SAMs on Ti-6Al-4V was confirmed through DRIFT
spectroscopy. Peaks attributed to the CH2 asym and sym stretching of the alkyl chain were used to
indicate if an ordered SAM with aligned, all trans, alkyl chains was formed. A SAM was
considered ordered if the CH2 asym was <2918 cm-1 and the CH2 sym was <2850 cm-1.30 These
SAMs are considered crystalline with close packing of their alkyl chains. Conversely, CH2 asym
stretching of >2918 cm-1 and CH2 sym >2850cm-1 within the IR spectrum indicates cis
confirmations of the alkyl chains with gauche interactions. These SAMs are characterized as more
liquid-like.44
DRIFT was used to determine the binding mode of the molecules in the SAM to the surface
of Ti-6Al-4V by examining the absence or presence of peaks indicative of the phosphonic acid
head group. The position of the stretches in the spectrum of the phosphonic acid solid were
compared to their position in the deposited SAM. The stretches of the phosphonic acid head group
included the P=O stretch at 1211 cm-1, P-O asym and sym at 1075 and 1003 cm-1, as well as P-OH
stretching at 947 and 931 cm-1. The presence of the P=O, P-O, and P-OH stretch within the
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spectrum indicates monodentate binding, whereas the presence of P=O and P-O stretching
represent bidentate finding, and the presence of a single stretch for P-O indicates tridentate binding
(Figure 2.4). The ordering of the alkyl chain and binding of the head group were determined after
rinse (15 min) and sonication (15 min) in deposition solvent.
a)

b)

c)

d)

Figure 2.4: Potential binding modes of phosphonic acid SAMs to oxide surface: a)
monodentate, b) bidentate, c) tridentate, d) mixed with covalent bonding in conjunction with
hydrogen bonding to surface hydroxyls.
2.4.1.1 Single Modification of Titanium Aluminum Vanadium with SAMs
The formation of SAMs possessing one type of functional tail on the surface of Ti-6Al-4V
was achieved through alteration of the deposition conditions. These conditions were tailored
specifically to each SAM molecule. SAMs were ordered and stable after sonication with the CH2
asym stretch at <2918 cm-1 and the CH2 sym stretch at <2850 cm-1 (Figure 2.5, Table 2.6). In the
case of the bromine terminated phosphonic acid, ordered and stable SAMs were not formed despite
rigorous attempts to optimize reaction conditions.
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100.0

Percent Reflectance

99.5

2848

99.0

2912
98.5

Sonicated carboxylic terminated SAM
98.0
3000

2900

2800
-1

Wavenumbers (cm )

Figure 2.5: DRIFT spectrum of the methylene stretching region of the carboxylic terminated
SAM indicating the presence of ordered alkyl chains with all trans confirmations attributed to
the position of the CH2 asym at 2912 cm-1 and the CH2 sym at 2848 cm-1.

Table 2.6: Ordering of phosphonic acid SAMs on Ti-6Al-4V.
SAM
12-mercaptododecylphosphonic acid
12-aminododecylphosphonic acid
11-phosphonoundecanoic acid
11-phosphonoundecylacrylate
11-hydroxyundecylphosphonic acid
12-bromododecylphosphonic acid

CH2 asym Stretch Position (cm-1)
2914
2915
2912
2915
2915
-

CH2 sym Stretch Position (cm-1)
2847
2847
2848
2847
2847
-

These phosphonic acid headgroups of the SAMs exhibited various binding modes to the
Ti-6Al-4V surface. All but one type of the SAMs formed presented stretches corresponding to
mixed binding to the surface, in which hydrogen bonding in conjunction with covalent bonding
was occurring between the surface and the SAM headgroup (Figure 2.6, Table 2.7).
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Figure 2.6: DRIFT spectrum of the binding region, where the peak at 1207 cm-1 corresponds
to P=O stretching and the peak at 1003 cm-1 represents a combination of P-O and P-OH
stretching.
Table 2.7: Binding of phosphonic acid SAMs to Ti-6Al-4V.
SAM

Peak (cm-1)

12-mercaptododecylphosphonic acid
12-aminododecylphosphonic acid
11-phosphonoundecanoic acid
11-phosphonoundecylacrylate
11-hydroxyundecylphosphonic acid
12-bromododecylphosphonic acid

1203, 1018, 941
1123, 915
1207, 1003
976
1188, 996
-

Corresponding
Stretch
P=O, P-O, P-OH
P-O, P-OH
P=O, P-O
P-O/P-OH
P-O, P-OH
-

Binding Mode
Monodentate
Mixed
Bidentate
Mixed
Mixed
-

Stretches corresponding to the functional tail group of the SAM molecules were observed
within the IR spectra; their presence indicated the presentation of the functional tail at the interface
(Figure 2.7, Table 2.8). The spectra of hydroxyl and carboxylic terminated SAMs both contained
OH stretching at 3110 cm-1 and 3154 cm-1 respectively. Additionally, the IR spectrum of a SAM
with a carboxylic acid tail group contained a C=O stretch due to the presence of the carbonyl at
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1719 cm-1. N-H stretching and bending of the amine tail group was observed within the spectrum
of the amine terminated phosphonic acid SAM at 3171 cm-1 and 2941 cm-1. The IR spectrum of
the acrylate terminated SAM possessed C=O stretching due to the carbonyl observed at 1722 cm1

, as well as stretches representative of the C=C of the alkene at 1632 cm-1. The IR spectrum of the

thiol terminated SAM did not possess stretches representative of the functional tail group. This is
attributed to the weak nature of the C-S and S-H stretches, which renders them of little diagnostic
value.45
Table 2.8: Stretches of SAM functional tail groups observed within the IR spectra.
Peak (cm-1)
3171, 2941
3154,1719, 1650
1722, 1632, 1426
3110
-

SAM
12-mercaptododecylphosphonic acid
12-aminododecylphosphonic acid
11-phosphonoundecanoic acid
11-phosphonoundecylacrylate
11-hydroxyundecylphosphonic acid
12-bromododecylphosphonic acid

Corresponding Stretch
N-H, salt
OH, C=O, C-O
C=O, C=C, C-H
OH
-

100.0

Percent Reflectance

3154
99.5

2848

99.0

2912
98.5

1719
Sonicated carboxylic terminated SAM
98.0
3250

3125

3000

2875

1875

1750

1625

1500

-1

Wavenumbers (cm )

Figure 2.7: DRIFT spectrum of the regions possessing stretches attributable to the functional
tail group of the carboxylic terminated SAM including OH stretching at 3154 cm-1 and C=O
stretching at 1719 cm-1.
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2.4.1.2 Dual Modification of Titanium Aluminum Vanadium with SAMs
The reaction conditions utilized for the formation of ordered and stable SAMs possessing
one tail group were used as the foundation for the generation of SAMs with two different tail
groups. Each phosphonic acid molecule used in the formation of single modified surfaces was used
to form unique combinations of dual modified surfaces, with the exception of the bromine
terminated molecule, since this did not form stable SAMs on its own. The presence of more than
one tail group required alteration of these initial methods. With adjustment, SAMs possessing more
than one tail group were formed on the Ti-6Al-4V surface. All SAMs were ordered and stable
through sonication (Figure 2.8, Table 2.9). The binding of these SAMs to the oxide surface was
similar to that observed for the single-tail SAMs (Figure 2.9, Table 2.10).

Percent Reflectance

100.0

2846
2914
99.5

Sonicated acrylate and carboxylic terminated SAMs
99.0
3000

2900

2800
-1

Wavenumbers (cm )

Figure 2.8: DRIFT spectrum of the methylene stretching region of the carboxylic and acrylate
terminated SAMs indicating the presence of ordered alkyl chains with all trans confirmations
attributed to the position of the CH2 asym at 2914 cm-1 and the CH2 sym at 2846 cm-1.
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Table 2.9: Ordering of dual phosphonic acid SAMs on Ti-6Al-4V.
SAM Combination
Carboxylic & Acrylate
Carboxylic & Thiol
Carboxylic & Amine
Carboxylic & Hydroxyl
Acrylate & Thiol
Acrylate & Amine
Acrylate & Hydroxyl
Thiol & Amine
Thiol & Hydroxyl
Amine & Hydroxyl

CH2 asym Stretch Position (cm-1)
2914
2916
2914
2912
2914
2914
2914
2914
2914
2914

CH2 sym Stretch Position (cm-1)
2846
2848
2847
2845
2847
2846
2847
2847
2847
2846

100

100

Percent Reflectance

871
75
98

50
96

1400

1111
Sonicated acrylate and carboxylic terminated SAMs
11-phosphonoundecanoic acid solid
11-phosphonoundecylacrylate solid
1200

1000

25
800

Wavenumbers (cm-1)

Figure 2.9: DRIFT spectrum of the binding region, where the peak at 1111 cm-1 corresponds
to P-O stretching and the peak at 871 cm-1 represents a P-OH stretch with hydrogen bonding to
the surface.
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Table 2.10: Binding of dual phosphonic acid SAMs to Ti-6Al-4V.
SAM Combination

Peak (cm-1)

Carboxylic & Acrylate
Carboxylic & Thiol
Carboxylic & Amine
Carboxylic & Hydroxyl
Acrylate & Thiol
Acrylate & Amine
Acrylate & Hydroxyl
Thiol & Amine
Thiol & Hydroxyl
Amine & Hydroxyl

1111, 871
1145
1125, 913
1082,913
1166, 1079, 908
1206, 1145, 980
1069, 969
1125, 1051, 916
1064, 914
1049, 922

Corresponding
Stretch
P-O, P-OH
P-O
P-O, P-OH
P-O, P-OH
P-O, P-OH
P=O, P-O, P-OH
P-O, P-OH
P-O, P-OH
P-O, P-OH
P-O, P-OH

Binding Mode
Mixed
Tridentate
Mixed
Mixed
Mixed
Monodentate
Mixed
Mixed
Mixed
Mixed

2.4.1.3 Triple Modification of Titanium Aluminum Vanadium with SAMs
Finally, SAMs of three different tail groups were formed on the surface of Ti-6Al-4V. This
resulted in ten unique combinations of tail groups. The conditions used for the duals were used as
the foundation for the reaction conditions, and these conditions were then altered to facilitate
stabled and ordered SAM formation (Table 2.11, Figure 2.10). The binding of these mixed SAMs
was again representative of that observed for single and dual modified surfaces with a mixed
binding mode illustrating covalent bonding in conjunction with hydrogen bonding to the surface
(Figure 2.11, Table 2.12).
Table 2.11: Ordering of triple phosphonic acid SAMs to Ti-6Al-4V.
SAM Combination
Thiol, Acrylate, & Carboxylic
Thiol, Acrylate, & Amine
Thiol, Acrylate & Hydroxyl
Thiol, Carboxylic & Amine
Thiol, Carboxylic, & Hydroxyl
Thiol, Amine, & Hydroxyl
Acrylate, Carboxylic, & Amine
Acrylate, Carboxylic, & Hydroxyl
Carboxylic, Amine, & Hydroxyl
Acrylate, Amine, & Hydroxyl

CH2 asym Stretch Position (cm-1)
2916
2914
2914
2914
2918
2913
2914
2914
2913
2914
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CH2 sym Stretch Position (cm-1)
2848
2846
2847
2847
2849
2847
2847
2847
2847
2846

Percent Reflectance

100.0

2848
2916
99.5

Sonicated acrylate, carboxylic, and thiol terminated SAMs
99.0
3000

2900

2800
-1

Wavenumbers (cm )

Figure 2.10: DRIFT spectrum of the methylene stretching region of the carboxylic, thiol, and
acrylate terminated SAMs indicating the presence of ordered alkyl chains with all trans
confirmations attributed to the position of the CH2 asym at 2916 cm-1 and the CH2 sym at 2848
cm-1.

Table 2.12: Binding of mixed phosphonic acid SAMs to Ti-6Al-4V.
SAM Combination

Peak (cm-1)

Thiol, Acrylate, & Carboxylic
Thiol, Acrylate, & Amine
Thiol, Acrylate & Hydroxyl
Thiol, Carboxylic & Amine
Thiol, Carboxylic, & Hydroxyl
Thiol, Amine, & Hydroxyl
Acrylate, Carboxylic, & Amine
Acrylate, Carboxylic, & Hydroxyl
Carboxylic, Amine, & Hydroxyl
Acrylate, Amine, & Hydroxyl

1092, 909
1145, 991
1049, 987
1126,918
1088, 902
1101, 905
1076, 922
1142, 1003
1090, 919
1087,918
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Corresponding
Stretch
P-O, P-OH
P-O, P-OH
P-O, P-OH
P-O, P-OH
P-O, P-OH
P-O, P-OH
P-O, P-OH
P-O
P-O, P-OH
P-O, P-OH

Binding Mode
Mixed
Mixed
Mixed
Mixed
Mixed
Mixed
Mixed
Tridentate
Mixed
Mixed

Percent Reflectance

100.0

909

97.5

1092

Sonicated acrylate, carboxylic, and thiol terminated SAMs
95.0
1400

1200

1000

Wavenumbers (cm-1)

Figure 2.11: DRIFT spectrum of the binding region, where the peak at 1092 cm-1 corresponds
to P-O stretching and the peak at 909 cm-1 represents a P-OH stretch with hydrogen bonding to
the surface.

2.4.2 Wettability of Unmodified and SAM Modified Titanium Aluminum Vanadium
The hydrophobicity of SAM modified and unmodified Ti-6Al-4V substrates was examined
using static contact angle analysis to determine what effect SAM tail groups had on this property.
Surfaces were considered hydrophilic if they exhibited a contact angle value <90˚, in which the
water droplet preferentially interacted with the surface, and hydrophobic if the value was >90˚.
2.4.2.1 Wettability of Single Modified Titanium Aluminum Vanadium
The unmodified Ti-6Al-4V exhibited a hydrophilic contact angle value (<90°) at 77 ± 4°
(Table 2.13). This was expected given the presence of hydroxyls and oxygens on the Ti-6Al-4V
surface.27 Modification of the Ti-6Al-4V surface with a single type of phosphonic acid SAM also
resulted in hydrophilic contact angle values (Table 2.13, Figure 2.12). The hydrophilic nature of
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the values observed for the thiol, carboxylic, hydroxyl, and amine terminated SAMs were expected
given the ability of these tail groups to hydrogen bond.46 The contact angle value observed for the
acrylate terminated was not expected; the presence of an alkene at the end of the alkyl chain would
likely result in an unfavorable interaction with water. However, this SAM resulted in a hydrophilic
surface (52 ± 8°). This is attributed to the presentation of the ester,
and not the alkene tail of the acrylate at the interface. The standard
deviations also indicate that there was variability in SAM
formation for single modified surfaces.

Figure 2.12: Contact angle
image of amine terminated
SAMs on Ti-6Al-4V.

Table 2.13: Contact angle results for single SAMs on Ti-6Al-4V.
Phosphonic Acid SAM
12-mercaptododecylphosphonic acid
12-aminododecylphosphonic acid
11-phosphonoundecanoic acid
11-phosphonoundecylacrylate
11-hydroxyundecylphosphonic acid
Unmodified Ti-6Al-4V

Value (deg)
33
59
47
52
54
77

±Stdev
5
5
7
8
8
4

2.4.2.2 Wettability of Dual Modified Titanium Aluminum Vanadium
When examining SAMs of dual tail groups formed on Ti-6Al4V, hydrophilic contact angle values were also observed (Table 2.14,
Figure 2.13). This was anticipated as several of the phosphonic
acid SAMs exhibited hydrophilic contact angle values when

Figure 2.13: Contact angle
image of carboxylic and
hydroxyl terminated SAMs
on Ti-6Al-4V.

formed individually. The tail groups of these acids are capable
of hydrogen bonding, which contributes to the hydrophilic values observed when SAMs comprised
of these acids were formed in combination. The carboxylic and acrylate dual modified Ti-6Al-4V
and carboxylic and thiol dual modified Ti-6Al-4V presented hydrophilic contact angle values with
large standard deviations (42 ± 11°, 23 ±11°). These large standard deviations indicate variability
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in the presentation of the tail groups at the interface. The orientation of the molecules at the
interface as well as their distribution both influence the contact angle.

Table 2.14: Contact angle results for dual SAMs on Ti-6Al-4V.
SAM Combination
Carboxylic & Acrylate
Carboxylic & Thiol
Carboxylic & Amine
Carboxylic & Hydroxyl
Acrylate & Thiol
Acrylate & Amine
Acrylate & Hydroxyl
Thiol & Amine
Thiol & Hydroxyl
Amine & Hydroxyl

Value (deg)
42
23
49
36
33
59
47
59
61
63

±Stdev
11
11
3
7
5
6
3
4
3
6

2.4.2.3 Wettability of Triple Modified Titanium Aluminum Vanadium
Triple modification of Ti-6Al-4V with three different tail
groups simultaneously resulted in hydrophilic contact angle values as
well (Table 2.15, Figure 2.14). This was anticipated as several
of the phosphonic acid SAMs exhibited hydrophilic contact
angle values when formed individually and in combination. One

Figure 2.14: Contact angle
image
of
carboxylic,
acrylate,
and
thiol
terminated SAMs on Ti-6Al4V.

exception to this trend was the mixed SAM comprised of thiol, acrylate, and carboxylic terminated
phosphonic acids. This combination resulted in surface with a higher contact angle (75 ± 4°) value,
indicating less hydrophilicity. This was not observed when the acrylate was used to form SAMs
alone or in combination with the other phosphonic acids. The inclusion of acrylate with the
carboxylic and thiol terminated phosphonic acids may have resulted in multilayers in which the
alkyl chain was exposed at the interface. This alkyl chain would increase the hydrophobicity of
the surface.
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Table 2.15: Contact angle results for triple SAMs on Ti-6Al-4V.
SAM Combination
Thiol, Acrylate, & Carboxylic
Thiol, Acrylate, & Amine
Thiol, Acrylate & Hydroxyl
Thiol, Carboxylic & Amine
Thiol, Carboxylic, & Hydroxyl
Thiol, Amine, & Hydroxyl
Acrylate, Carboxylic, & Amine
Acrylate, Carboxylic, & Hydroxyl
Carboxylic, Amine, & Hydroxyl
Acrylate, Amine, & Hydroxyl

Value (deg)
75
52
51
56
36
54
52
61
58
64

±Stdev
4
7
6
6
4
3
6
4
6
4

2.4.3 MALDI Analysis of SAMs Formed on Titanium Aluminum Vanadium
Substrates were subjected to MALDI analysis to confirm the formation of monolayers or
multilayers on the surface. This technique was also used to determine the presence of the three
individual phosphonic acids on the same modified substrate. Desorption of the bound molecules
either resulted in observation of the monomer (monolayer) or dimer m/z (multilayer) of the
phosphonic acid within the mass spectrum. MALDI-TOF analysis of an acrylate, carboxylic, and
thiol triple modified surface revealed the presence of both monomer and dimer peaks of each
phosphonic acid (Table 2.16, Figure 2.15). In the case of the monomers, the values observed for
each phosphonic acid corresponded to the loss of a hydrogen. This indicated that on this triple
modified surface, multilayers were formed with monolayer coverage on parts of the substrate. This
supports the hydrophobic contact angle values observed for this combination of SAMs. The
stacking of the multilayers contributed to the hydrophobic nature of these substrates as the alkyl
chains are potentially presented at the interface.
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Table 2.16: MALDI results for acrylate, carboxylic, and thiol SAMs on Ti-6Al-4V.
Molecule
11-phosphonoundecyl acrylate
11-phosphonoundecanoic acid
12-mercaptododecylphosphonic acid

a)

Actual Mass
305.1523
265.1210
281.1346

b)

Observed (m/z)
305.1507
265.1193
281.1334

Error (ppm)
5.2433
6.4122
4.2684

c)

Figure 2.15: MALDI results for a) carboxylic terminated SAM, b) acrylate terminated SAM,
and c) thiol terminated SAM on triple modified Ti-6Al-4V.
2.5 Discussion
The formation of ordered and stable SAMs on metal oxide surfaces is dependent on
properties of both the organic acids used and the surface chemistry of the metal.30, 47-50 In this
study, SAMs were formed on the same alloy, Ti-6Al-4V. Therefore, differences observed in SAM
formation are characteristic of the organic acids used. SAMs are formed due to the acid-base
chemistry that occurs between the organic acid head group and the metal oxide substrate.30, 36-37, 51
In one proposed mechanism, the µ-oxo and hydroxyl groups present on the surface act as Lewis
bases and thus react with the organic acids.30 This generates a strong, covalent bond. In an
alternative proposed method, proton transfer from the organic to the surface hydroxyls followed
by dehydration leads to an ionic interaction between the deprotonated organic and dehydrated
surface.30
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Traits of the organic acid that can affect SAM formation include the acidity of the head
group, length of the alkyl chain, and the potential for tail group interactions.30, 52-55 The acidity of
the head group is considered a potential factor given its role in the binding mechanism. The SAMs
formed here all contained the same phosphonic acid head group with the same immediate
neighboring atoms. The head groups of these SAMs bound to the surface in similar manners with
evidence of covalent bonding as illustrated by the presence of the P-O stretch in conjunction with
weaker, intermolecular hydrogen bonding between the phosphonic acid head group and a surface
hydroxyl as evidenced by the shifted P-OH stretch. Although attachment occurred through both
strong and weak mechanisms, the SAMs formed were stable through sonication, indicating the
SAMs were tightly bound to the surface.
Another parameter affecting SAM formation is the length of the alkyl chain.4 The length
of the alkyl chain affects stability through the potential for van der Waals interactions. A longer
alkyl chain enhances these interactions, which aids in SAM stability. The phosphonic acid
molecules used in this study contained uninterrupted alkyl chains of similar length, 11-12 carbons.
Therefore, alkyl chain length does not explain observed differences in SAM formation. Finally,
the tail group of the SAM molecule can affect stability through hydrogen bonding and electrostatic
interactions.54, 56 The variability in SAM formation is most likely due to the different tail groups
of each molecule and their interactions with each other when used in combination to form SAMs
on Ti-6Al-4V.
After alteration of reaction conditions, ordered SAMs of each phosphonic acid were formed
on Ti-6Al-4V (Table 2.6). This was with the exception of the bromine terminated phosphonic acid
molecule. SAMs of this molecule were not successfully formed on the surface, despite rigorous
optimization of reaction conditions. This is potentially due to the large, atomic radius of bromine,
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which could interfere with alignment of the alkyl chains, minimizing the van der Waals
interactions, destabilizing the SAM. Additionally, unlike the majority of the other phosphonic
acids studied, the bromine terminated molecule is incapable of hydrogen bonding in a traditional
manner which would help stabilize the SAM.57
The other phosphonic acids were able to form SAMs on the surface of Ti-6Al-4V in a facile
manner. The molecules terminated in thiol, amine, carboxylic acid, or hydroxyl were capable of
hydrogen bonding with neighboring molecules. These interactions aided in film stability. The
acrylate terminated phosphonic acid also formed ordered and stable SAMs without the influence
of hydrogen bonding. For the acrylate terminated SAMs, the van der Waals interactions were
sufficient to stabilize the film.
Contact angle analysis of the SAMs formed indicated hydrophilic surfaces (Table 2.13).
This was expected given these molecules’ ability to hydrogen bond.32, 58 Of note, is the low value
observed for thiol terminated SAMs. This indicates a favorable interaction between the water
droplet and modified surface. This value was lower than that observed for the other molecules
capable of hydrogen bonding. These molecules may form a hydrogen bonding network with
themselves, which limits their ability to hydrogen bond with the water molecule.59 This would
increase the hydrophobicity of the surface. Hydrogen bonding of the carboxylic and hydroxyl
terminated SAMs was evidenced by the position and broad appearance of these peaks in the IR
spectrum (Table 2.8).
The acrylate terminated SAM also resulted in a hydrophilic contact angle value. Alkene
terminated SAMs typically exhibit hydrophobic contact angle values due the presentation of the
C=C bond at the surface.60 Therefore, the hydrophilic behavior observed here was unexpected. It
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is possible that the orientation of the SAM on the substrate prevented the presentation of the alkene
at the interface. The presence of the ester of the tail group may explain the hydrophilic value.
When the phosphonic acids molecules were used in combination to form SAMs on Ti-6Al4V, these SAMs were also ordered and stable through sonication (Table 2.9). The incorporation
of more than one tail group did not interfere substantially with the close packing of the alkyl chain.
Stability of these SAMs was also aided through hydrogen bonding between the different
phosphonic acid molecules. These SAMs presented hydrophilic contact angle values (Table 2.14).
Hydrophilic values were anticipated as the phosphonic acids exhibited hydrophilic contact angle
values when used individually in the formation of SAMs. Variability in surface coverage of the
SAMs was noted in the carboxylic and acrylate as well as carboxylic and thiol combinations. These
samples possessed larger standard deviations in contact angle values compared to the other
combinations. Isolation of hydrophilic molecules by more hydrophobic molecules on the surface
limits the wettability of the hydrophilic molecules.61 Therefore, it is possible that distribution of
these molecules on the surface is not presented in an even manner; phase segregation of the
molecules may be occurring which would account for the larger, observed standard deviation.61-65
This should be examined further through atomic force microscopy and mass spectrometry to
understand the distribution of the molecules on the surface.
Finally, all three phosphonic acids were utilized in the formation of SAMs to generate triple
modified Ti-6Al-4V. These SAMs were ordered through stability testing (Table 2.11) In the
formation of these SAMs, the deposition conditions were altered to reduce the number of spray
cycles (Table 2.5). This was done to limit the opportunity for multilayering within the SAM.
Despite this modification, multilayer was observed in one of the samples where thiol, acrylate, and
carboxylic acid terminated SAMs were formed simultaneously.
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Evidence of multilayering within this sample was observed in the contact angle and
MALDI-TOF analyses. These samples exhibited a higher contact angle value (75 ± 4°) than
observed for the other mixed SAMs (Table 2.15). The individual phosphonic acid molecules used
in this mixed SAM all exhibited hydrophilic contact angle values when formed alone and in
combination with each other (Table 2.13, Table 2.14). If the SAMs were forming multilayers on
the surface, the alkyl chain of these SAMs may be presented at the interface to some extent, which
would account for the larger contact angle value. Evidence of multilayering in this mixture was
also observed through MALDI-TOF analysis via the presence of both monomer and dimer peaks
of each phosphonic acid molecule in the mass spectrum (Table 2.16). The presence of the dimer
within the mass spectrum for each phosphonic acid indicates that these molecules were involved
in multilayer formation.66 The presence of the monomer implies that some portions of the substrate
possessed only monolayer coverage. Therefore, heterogeneity of the substrate occurred in which
some portions demonstrated monolayer coverage and others multilayer coverage. This can be
addressed through decreasing the number of spray cycles.
2.6 Conclusions
SAMs with phosphonic acid head groups of various tail groups were formed alone and in
combination on the surface of Ti-6Al-4V. These SAMs were ordered and stable through sonication
with covalent and hydrogen bonding to the surface observed. The tail groups at the interface
resulted in hydrophilic surfaces with evidence of hydrogen bonding where applicable. The
systematic study of these SAMs allowed for insight into which phosphonic acid molecules are
suitable for the formation of SAMs alone and in combination with each other. SAMs that are
ordered present the functional tail in a consistent, predictable manner at the interface.
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Understanding which SAMs were ordered and stable allowed for the determination of
which functional tails were optimal for the second portion of this project. In the second portion,
these SAMs were used as chemical anchors to immobilize bioactive molecules to the Ti-6Al-4V
surface. The thiol, acrylate, and carboxylic phosphonic acids were chosen for this part as they were
ordered and stable through rinse and sonication alone and in combination. Although these SAMs
did exhibit multilayering, their tail groups’ unique reactivities allowed for orthogonal
immobilization of the chosen bioactive molecules.
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Chapter 3: Functionalization of Titanium Aluminum Vanadium with Bioactive Molecules
3.1 Introduction
The two main causes of orthopedic implant failure are infection and aseptic loosening.1-7
Addressing these concerns with surface modification is desired, as these processes occur at the
interface between the implant and host tissue. Current approaches focus on modifying the surface
with bioactive molecules to encourage the deposition of new bone, while preventing the
attachment and proliferation of bacteria.2, 8-9 Therefore, the molecules chosen in this work for the
functionalization of Ti-6Al-4V via self-assembled monolayers (SAMs) addressed both bacterial
adhesion and osseointegration.
3.1.1 Vancomycin
Orthopedic implants are susceptible to colonization by several types of bacteria, including
both Gram positive and Gram negative species.3, 10-12 However, Gram positive species, such as
Stapylococcus bacteria account for a majority of infections (70%).4 Infection is addressed
clinically through intravenous administration of antibiotics.13 Often, vancomycin, a glycopeptide
antibiotic that targets Gram positive bacteria, with very limited efficacy against Gram negative
species, is used to treat orthopedic implant infection.13-17 Vancomycin forms hydrogen bonds with
the peptidoglycan terminal residues through four hydrogens and one oxygen from five secondary
amides within its structure (Figure 3.1).18-21 This interaction causes vancomycin to prevent the
crosslinking of peptides within the peptidoglycan layer (Figure 3.2).22-24 This compromises the
integrity of the cell walls, rendering the cells incapable of responding to changes in osmotic
pressure; therefore the cells lyse.
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Figure 3.1: Interactions between vancomycin and the D-ala-D-ala residues in the bacterial
peptidoglycan wall which are crucial to its mechanism of action.
Immobilization of vancomycin to the implant surface is preferred over systemic
administration for several reasons. This approach allows for direct delivery of the antibiotic to the
site of infection, where it is more likely to be effective, compared to a high concentration of
circulating systemic antibiotic which results in insufficient drug concentrations at the site of
infection.4 Direct surface delivery reduces potentially harmful side effects as local concentrations
are sufficient to combat the infection without the side effects and toxicity associated with high
systemic doses.17, 22, 25-26 In previous studies, immobilized vancomycin on ceramic materials was
as successful as soluble vancomycin in culture against bacteria.18 When immobilized to SS 316L
using SAMs as linkers, vancomycin reduced biofilm formation by 99% for 48 hours.27 Therefore,
chemically linking vancomycin to the surface of Ti-6Al-4V using the previously developed
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tunable SAM platform would help prevent the growth of Gram positive bacteria. Immobilization
of vancomycin to Ti-6Al-4V in conjunction with other bioactive molecules in a multifunctional
coating using SAMs as the linker system has not been reported in the literature.

D-alanine bound through van der Waals interactions and hydrogen bonding

Enzyme unable to recognize
site; no cross-linking occurs

Cell wall is compromised

Cross-linking enzyme
Vancomycin
N-acetylmuramic acid

N-acetylglucosamine
D-alanine

Pentaglycine chain

D-glutamate

L-lysine

Figure 3.2: Mechanism of action for vancomycin against bacteria species in which
vancomycin interacts with D-alanine residues of peptides of the peptidoglycan layer. This
interaction prevents a crosslinking enzyme from recognizing the residues and therefore
crosslinking does not occur, which compromises the integrity of the cell wall.
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3.1.2 Nitric Oxide Donor Spermine NONOate
Nitric oxide (NO) is a cell-signaling molecule that plays a role in several biological
processes including vasodilation, cancer, host infection, and wound repair.28-35 It is produced in
the body by the nitric oxide synthase (NOS) enzyme.29, 36 The formation of NO through NOS in
macrophages and monocytes allows these cells to be cytostatic and cytotoxic to various viruses,
bacteria, fungi, and tumor cells.37 The antibacterial effect of NO is attributed to the nitrosative and
oxidative stress it causes in a virus or bacterial cell.38 NO reacts with oxygen, water, and
superoxides within the body to form highly reactive nitrogen and oxygen intermediates (Figure
3.3). These reactive species overwhelm the cell’s ability to eliminate these species, which leads to
damage of the bacterial deoxyribonucleic acid, lipids, and proteins.39 The modes of action for these
occurrences include deamination of the deoxynucleotides in DNA, disruption of the reaction sites
of proteins, and damage to cellular membranes through lipid peroxidation (Figure 3.3).40

NO· + O2

NO2 + NO·

N2O3 + Met, Trp, or Cys

RSNO

.

.

.

Bacterial Membrane
NO· + O2-

OONO- + H+ ⇋ HOONO ⇋ ·NO2 + ·OH
Lipid Peroxidation

Protein Damage

DNA Cleavage

Figure 3.3: Intracellular and extracellular targets of endogenously and exogenously delivered
NO (Image adapted from Carpenter et al.)39.
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Furthermore, evidence suggests that NO can trigger a dispersal event in biofilms (Figure
3.4).41 The release of planktonic bacterial cells from the biofilm renders them susceptible to
treatment with traditional antibiotics. The mechanism of dispersal is not entirely understood, but
it is attributed to nutrient availability, cell lysis within the biofilm, and release of quorum sensing
molecules.38, 41 Nanomolar concentrations of NO are capable of decreasing biomass and increasing
planktonic biomass of single and mixed biofilms containing E.coli, S. epidermidis, Vibrio cholera,
C.albicans,
aeruginosa.38,

and
42

P.

It has also

Biofilm
NO molecule
Planktonic bacteria

been observed that coupling
NO with an antibiotic increases the

Figure 3.4: Biofilm dispersal due to nitric oxide.

effectiveness of the antibiotic through
synergistic effects.38, 43-45
NO’s antibacterial capability is limited by its delivery method.34, 46 Several donors have
been synthesized to allow for the controlled release of NO. These include NO-metal complexes,
nitroamines, N-diazeniumdiolates (NONOates), and S-nitrosothiols (RSNOs).33, 37 NONOates are
the most widely used donors in NO releasing biomaterials.47 These donors release two moles of
NO per parent compound under physiological conditions. They are formed via the reaction of a
secondary amine with high pressure NO gas.48-49 A second basic residue, such as a metal alkoxide
base, is necessary to deprotonate the secondary amine within the diazeniumdiolate backbone.50
The diazeniumdiolate can then perform a nucleophilic attack of the NO. The cation from the
alkoxide base stabilizes the resulting anionic NONOate.48-49 Upon protonation of the NO moiety
of the NONOate donor, the NO is released. The structure of the amine precursor affects the release
kinetics of the NO. Diethylenetriamine NONOate (DETA/NONOate) has a half-life of 20 hours,
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whereas diethylamine NONOate (DEA/NONOate) has a half-life of 2-4 minutes.51-52 This
difference is due to hydrogen bond stabilization due to the presence of additional amines.50
These NO releasing molecules are incorporated into polymeric coatings in order to achieve
local release on metals.53 For example, Nablo and coworkers developed a stainless steel implant
material coated with a silica sol-gel containing a NONOate donor. Release of NO from these
materials were in the picomole per cubic centimeter per second range (pmol cm-3 s-1; with sustained
release for over 24 hours. These modified surfaces also reduced Staphylococcal bacterial adhesion.
Holt et al. coated the surface of commercially pure titanium fixation pins with a silica xerogel
possessing a NONOate functionality.54 Here, pmol cm-2 s-1 amounts of NO were released which
reduced bacterial adhesion at 48 days post implantation in a mouse model. Previous work using
SAMs to immobilize NO releasing molecules to the surface of Ti-6Al-4V demonstrated a 41.5 ±
1.5% reduction in E. coli growth and a 25.3 ± 0.6% reduction in S. epidermidis growth when
compared to controls.43 Also, a synergistic effect between the NO and an antibiotic, tetracycline,
was observed. Furthermore, NO modified Ti-6Al-4V did not demonstrate any cytotoxic effects
against mouse fibroblasts for 24 hours.43-44
In this work, spermine NONOate, which has a half-life of approximately 39 minutes, was
chosen as the NO releasing compound for the functionalization of Ti-6Al-4V.55 Preliminary work
by Autumn Schultz suggested enhanced antimicrobial effectiveness over other NONOates. The
immobilization of both vancomycin and spermine NONOate to the surface of Ti-6Al-4V via SAMs
would mitigate bacterial adhesion and proliferation allowing for a synergistic antimicrobial effect.
3.1.3 Cell Adhesion Peptide Lys-Arg-Ser-Arg (KRSR)
Ti-6Al-4V orthopedic implants suffer from poor osseointegration, as the alloy is neither
osteoinductive or osteoconductive.2,

56-57

A common approach to engineering cell and tissue
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behavior at device surfaces is to modify the material to selectively interact with a specific cell type
through biomolecular recognition events.58 Often, peptides containing cell-binding domains found
in the extracellular matrix (ECM) proteins are immobilized on the material to promote cell
adhesion via ligand-receptor interactions.58-60 These peptides are specifically chosen to target
osteoblasts, allowing for osteoblast adhesion and proliferation onto the implant surface.61 The use
of cell adhesion peptides in orthopedic applications is attractive for several reasons. Peptides can
be produced synthetically allowing for precise control of their chemical composition allowing for
a broad range of synthetic applications.60, 62
One such group of peptides are those possessing the Arg-Gly-Asp (RGD) sequence.60, 63
This sequence is present in fibronectin, an ECM protein, and serves as an attachment cue. Peptides
containing the RGD sequence serve as ligands for integrins.59, 64 Peptides possessing the RGD
sequence not only promote cell attachment, but they also enhance other fundamental cell functions
such as mineralization in osteoblasts. Another class of cell adhesion peptides includes those that
bind proteoglycans via electrostatic interactions.58 An example of this type is Lys-Arg-Ser-Arg
(KRSR).65 Research has suggested improved osteoblast adhesion with KRSR compared to RGD
modified surfaces.63, 65-67 KRSR peptides have also been shown to promote the selective adhesion
of osteoblasts while, simultaneously, inhibiting the adhesion of soft-tissue forming cells like
fibroblasts (scar tissue).68
There are various methods to adhere these bioactive molecules to the surface. Molecules
can be adsorbed to the surface by simple dipping methods.62-63 While this is a facile approach, it
provides little control over the kinetics and delivery. A different strategy for controlled release
from surfaces is the physical entrapment of biomolecules, where the molecules are retained by a
barrier but not chemically bound to it. These often involve polymer-based matrices, ceramic
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coatings, or reservoir systems.69 There are several concerns with this approach. These include
cracking or degradation of the coating, local inflammation, lack of controlled release, and toxicity
of degradation products.
Covalent binding of bioactive molecules to the surface is an alternative method of delivery.
Functionalization of Ti-6Al-4V using SAMs as chemical linkers allows for coatings that are
strongly adhered with consistent presentation of bioactive molecules. In this work KRSR modified
with a sacrificial cysteine was immobilized to the Ti-Al-4V surface using a SAM as a chemical
linker. KRSR was chosen over a RGD containing peptide due to its specificity for osteoblasts over
fibroblasts and enhanced cell adhesion properties.65-66, 68, 70-72
3.1.4 Triple Functionalization through Orthogonal Chemistry
Immobilization of bioactive molecules to the surface of Ti-6Al-4V using SAMs as
chemical linkers must consider both the appropriate SAM, as well as the target functional group
within the bioactive molecule. In the formation of a triple functionalized surface, a SAM linker
system, in which three unique tail groups were presented at the interface was desired. The unique
chemistries of these tails allowed for specific, predictable reactions between the SAM and the
target moiety of the bioactive molecule. Functional groups within the bioactive molecules that did
not participate in their mechanism of action were selected. Therefore, these molecules would
theoretically maintain their bioactivity once immobilized. Finally, orthogonal chemistries were
used to covalently link the bioactive molecules to the surface. This approach avoids non-specific
reactions between the SAM linker system and bioactive molecules.
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3.2 Materials
11-phosphonoundecanoic

acid

(96%

purity),

11-phosphonoundecylacrylate,

12-

mercaptododecylphosphonic acid (95% purity), N-hydroxysuccinimide (NHS) (98%), N-(3dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), vancomycin hydrochloride
(≥80%), and Dulbecco’s phosphate buffered saline were obtained from Sigma Aldrich and used as
received. 3-maleimidopropionic acid N-hydroxysuccinimide ester (99%) was supplied by Alfa
Aesar. Spermine NONOate (≥98%) and the nitrate/nitrite colorimetric assay kit were supplied by
Cayman Chemical. KRSRC (≥98%) was synthesized by GenScript. Tetrahydrofuran, Optima
grade, obtained from Fisher Scientific was distilled over sodium and benzophenone prior to use.
Acetonitrile was also supplied by Fisher Scientific. Methanol was obtained from Duquesne
University and dried over 4A molecular sieves. Ethanol and 18 MΩ water were also obtained from
Duquesne University. Titanium aluminum vanadium (Ti-6Al-4V), 0.52 mm thickness was
purchased from Goodfellow Inc. (Coraopolis, PA US).
3.3 Methods
3.3.1 Preparation of Titanium Aluminum Vanadium
Ti-6Al-4V was prepared by sanding with 150, 320, 400, and 600 grit sand paper. Substrates
were then cut into 1 cm by 1 cm coupons. These coupons were sonicated in acetone for 15 minutes
and then placed in boiling methanol for 15 minutes to remove any residue from the surface. Then,
substrates were removed and placed sanded-side-up on a petri dish in a 120°C oven overnight to
dry. After drying, substrates were stored in a glass vial until use.
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3.3.2 Formation of Single Functionalized Ti-6Al-4V
Ti-6Al-4V substrates modified with one type of SAM were used to immobilize either
vancomycin, spermine NONOate, or KRSR(C) to the surface (Table 3.1).
Table 3.1: SAMs and target moieties for the single functionalization of Ti-6Al-4V.
SAM Tail Group
Acrylate
Carboxylic
Thiol

Bioactive Molecule
KRSR(C)
Spermine NONOate
Vancomycin

Target Moiety
SH
NH2
NH2

3.3.2.1 Immobilization of Vancomycin (R1)
Immobilization of vancomycin to the Ti-6Al-4V surface was accomplished through
crosslinking with 3-maleimidopropionic acid N-hydroxysuccinimide ester to thiol terminated
SAMs (Scheme 3.1). A primary amine present within the vancomycin structure, that was not
responsible for its bioactivity, was used to form an amide bond with the crosslinking agent. Then,
the thiol tail of a SAM formed on Ti-6Al-4V was used to form a C-S bond to the maleimide portion
of the crosslinker, chemically linking vancomycin to the surface.
First, thiol terminated SAMs were formed on Ti-6Al-4V. Ti-6Al-4V substrates were
chilled at 4°C for 30 minutes, while a solution of 1 mM 12-mercaptodocdecylphosphonic acid in
tetrahydrofuran was warmed to 55°C. Substrates were then sprayed with the warm phosphonic
acid solution. This was repeated for three cycles. After the last spray, substrates were dried in a
60°C oven overnight. After a 15-minute rinse in deposition solvent and overnight drying,
substrates were ready for vancomycin immobilization.
A solution of 2 mg/mL vancomycin and 20 mM 3-maleimidopropionic acid Nhydroxysuccinimide ester was prepared in 50/50 (v/v) acetonitrile and water. The reaction
proceeded for one hour protected from light at room temperature. Then, substrates modified with
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the thiol terminated SAM were placed modified-side-up in the vancomycin/linker solution for one
hour, protected from light, under N2, at room temperature. After one hour, substrates were removed
and rinsed in reaction solvent for one minute prior to drying overnight under vacuum.
a)

a)
Vancomycin

Maleimide/NHS linker

Formation of amide
bond

b)
Formation of C-S
bond

b)
Reaction of thiol
with maleimide

Scheme 3.1: Immobilization of vancomycin to thiol terminated SAMs through a) amide bond
formation between vancomycin and the NHS portion of the crosslinker followed by b) C-S
bond formation between a thiol terminated SAM and the maleimide linker.
3.3.2.2 Immobilization of KRSR(C) (R2)
The cell adhesion peptide KRSR was purchased with the addition of a sacrificial cysteine.
This cysteine possessed a free thiol that was used to form a C-S bond with the alkene of an acrylate
terminated SAM via a base catalyzed thiol-ene Michael addition (Scheme 3.2).
Acrylate terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates at 4°C
for 30 minutes, while a solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran was
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. This was
repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After
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a 15-minute rinse in deposition solvent and overnight drying, substrates were ready for KRSR(C)
immobilization.
Ti-6Al-4V modified with acrylate terminated SAMs was placed sanded-side up in a
solution containing 1 mg/mL of KRSR(C) and 5 µL of triethylamine. The reaction was performed
over ice, protected from light, under N2 for four hours. After four hours, substrates were removed,
placed in water for one minute, and then dried overnight under vacuum.

Triethylamine

KRSR(C)

Acrylate
terminated SAM

Formation of C-S bond

Scheme 3.2: Immobilization of KRSR(C) to acrylate terminated SAMs via base catalyzed
thiol-ene Michael addition.
3.3.2.3 Immobilization of Spermine NONOate (R3)
The nitric oxide releasing molecule spermine NONOate was immobilized to Ti-6Al-4V
through amide bond formation with a SAM possessing a carboxylic tail group and EDC/NHS
coupling (Scheme 3.3).
Carboxylic acid terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates
at 4°C for 30 minutes, while a solution of 1 mM 11-phosphonoundecanoic acid in methanol was
warmed at 55°C. Substrates were then sprayed with the warm phosphonic acid solution. Substrates
were dried at room temperature for one minute. This was repeated for three cycles. After the last
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spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent
and overnight drying, substrates were ready for spermine NONOate immobilization.
a)

a)

EDC

Activation with EDC
NHS

b)
Amide bond
formation

b)
spermine NONOate

Scheme 3.3: Immobilization of spermine NONOate to carboxylic terminated SAMs through
a) EDC/NHS activation, followed by b) amide bond formation between a primary amine of
spermine NONOate and the carboxylic tail of a phosphonic acid SAM through displacement
of the NHS group.
Substrates modified with a carboxylic acid terminated SAM were placed sanded-side-up
in a solution that was 20 mM in EDC and 50 mM in NHS in 2-propanol. The solution was allowed
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to react for 30 minutes at room temperature, protected from light, under N2. After 30 minutes,
substrates were removed and allowed to dry under vacuum for one hour. Substrates were then
placed in a 20 mM spermine NONOate solution prepared in a mixture of ethanol and water (4:1,
v/v). Then, substrates were rinsed in ethanol and water (4:1) for one minute, and then allowed to
dry under vacuum overnight.
3.3.3 Formation of Dual Functionalized Ti-6Al-4V
SAMs with two different tail groups at the interface were used to co-immobilize
vancomycin, spermine NONOate, or KRSR(C) (Table 3.2).
Table 3.2: SAMs and target moieties for the dual functionalization of Ti-6Al-4V.
SAM Tail Group
Acrylate & Carboxylic
Acrylate & Thiol
Carboxylic & Thiol

Bioactive Molecule
KRSR & Spermine NONOate
KRSR & Vancomycin
Spermine NONOate & Vancomycin

Target Moiety
SH & NH2
SH & NH2
NH2 & NH2

3.3.3.1 Immobilization of Vancomycin and KRSR(C) (R1 & R2)
Previous work on ceramic materials has shown that immobilization of vancomycin
followed by the immobilization of KRSR(C) maintained the bioactivity of both molecules.70 Coimmobilization of both vancomycin and KRSR(C) to Ti-6Al-4V surfaces was first accomplished
by forming thiol and acrylate terminated SAMs on Ti-6Al-4V. Ti-6Al-4V was pretreated at 4°C
for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran
and a separate solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran were warmed at
55°C. Using a TLC sprayer, SAMs were deposited through aerosol deposition by spraying
substrates with the warm phosphonic acid solutions; first with the thiol solution and then the
acrylate. This was repeated for three cycles. After the last spray, substrates were dried in a 60°C
oven overnight. After a 15-minute rinse in deposition solvent, substrates were dried overnight prior
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to bioactive molecule immobilization. Then, Ti-6Al-4V modified with acrylate and thiol
terminated SAMs were used to immobilize vancomycin (R1) (Scheme 3.4). Substrates were dried
overnight and then functionalized with KRSR(C) (R2) (Scheme 3.5).

Scheme 3.4: Immobilization of vancomycin (R1) to thiol and acrylate terminated SAMs
through amide and C-S bond formation with a maleimide/NHS crosslinker.

Scheme 3.4: Immobilization of vancomycin (R1) to thiol and acrylate terminated SAMs
through amide and C-S bond formation with a maleimide/NHS crosslinker.

Scheme 3.5: Immobilization of KRSR(C) (R2) to thiol and acrylate terminated SAMs through
C-S bond formation between the alkene of an acrylate terminated SAM and a free thiol of
KRSR(C) via a thiol-ene Michael addition after vancomycin (R1) immobilization.
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3.3.3.2 Immobilization of KRSR(C) and Spermine NONOate (R2 & R3)
Co-immobilization of both KRSR(C) and spermine NONOate was accomplished by
forming acrylate and carboxylic terminated SAMs on Ti-6Al-4V. Substrates were pretreated at
4°C for 30 minutes, while a solution of 1 mM 11-phosphonoundecanoic acid in methanol and a
separate solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran were warmed at 55°C.
Substrates were then sprayed with the warm phosphonic acid solutions; first with the acrylate
solution and then the carboxylic solution. Substrates were dried at room temperature for one
minute. This was repeated for three cycles. After the last spray, substrates were dried in a 60°C
oven overnight. After a 15-minute rinse in deposition solvent and overnight drying, substrates were
ready for bioactive molecule immobilization.
Ti-6Al-4V modified with acrylate and carboxylic terminated SAMs were utilized to
immobilize KRSR(C) (R2) (Scheme 3.6). Substrates were dried overnight and used to immobilize
spermine NONOate (R3) (Scheme 3.7). Spermine NONOate was immobilized last to avoid
premature release of NO during the long peptide immobilization.

Scheme 3.6: Immobilization of KRSR(C) (R2) to carboxylic acid and acrylate terminated
SAMs through C-S bond formation between the alkene of an acrylate terminated SAM and a
free thiol of KRSR(C) via a thiol-ene Michael addition.
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Scheme 3.7: Immobilization of spermine NONOate (R3) to acrylate and carboxylic acid
terminated SAMs via EDC/NHS crosslinking and amide bond formation after KRSR(C) (R2)
immobilization.
3.3.3.3 Immobilization of Vancomycin and Spermine NONOate (R1 & R3)
Co-immobilization of both vancomycin and spermine NONOate was accomplished by
forming thiol and carboxylic terminated SAMs on Ti-6Al-4V. Substrates were pretreated at 4°C
for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran
and a separate solution of 1 mM 11-phosphonoundecanoic acid in methanol were warmed at 55°C.
Substrates were then sprayed with the warm phosphonic acid solutions; first with the thiol solution
and then the carboxylic solution. Substrates were dried at room temperature for one minute. This
was repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight.
After a 15-minute rinse in deposition solvent and overnight drying, substrates were ready for
bioactive molecule immobilization.
Immobilization of both vancomycin and spermine NONOate to Ti-6Al-4V surfaces was
accomplished by using Ti-6Al-4V modified with thiol and carboxylic terminated SAMs to first
immobilize vancomycin (R1) (Scheme 3.8). Substrates were dried overnight and then
functionalized with spermine NONOate (R3) (Scheme 3.9). Spermine NONOate was linked last
to prevent premature NO release.
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Scheme 3.8: Immobilization of vancomycin (R1) to thiol and carboxylic acid terminated SAMs
through amide and C-S bond formation with a maleimide/NHS crosslinker.

Scheme 3.9: Immobilization of spermine NONOate (R3) to thiol and carboxylic acid
terminated SAMs via EDC/NHS crosslinking and amide bond formation after vancomycin
(R1) immobilization.
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3.3.4 Formation of Triple Functionalized Ti-6Al-4V
SAMs with three different tail groups at the interface were used to immobilize vancomycin,
KRSR(C), and spermine NONOate (Table 3.3). Immobilizing each bioactive molecule to the
surface required strategic attachment methods to ensure preservation of the molecules’ activity
once covalently linked. Vancomycin was covalently linked to the surface first, followed by
KRSR(C). KRSR(C) was attached second to prevent masking of the peptide due to the large
vancomycin molecule to help maintain its activity70. Finally, spermine NONOate was attached last
to the Ti-6Al-4V to inhibit premature NO release during the immobilization steps of the other
bioactive molecules as spermine release is sensitive to temperature, light, and changes in pH.44
Table 3.3: SAMs and target moieties for the triple functionalization of Ti-6Al-4V.
SAM Tail Group
Thiol, Acrylate, and
Carboxylic

Bioactive Molecule

Target Moiety

Vancomycin, KRSR, and Spermine NONOate

NH2, SH, & NH2

3.3.4.1 Immobilization of Vancomycin, KRSR(C), and Spermine NONOate (R1, R2, &R3)
Thiol, acrylate, and carboxylic terminated SAMs were formed on Ti-6Al-4V to serve as
linkers to immobilize the desired bioactive molecules. Substrates were pretreated at 4°C for 30
minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran, a
solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran, and a solution of 1 mM 11phosphonoundecanoic acid in methanol were warmed to 55°C. Substrates were then sprayed with
the warm phosphonic acid solutions; first with the thiol solution, then the acrylate solution, and
then with the carboxylic solution. Substrates were dried at room temperature for one minute. After
spraying, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition
solvent and overnight drying, substrates were ready for bioactive molecule immobilization.
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Ti-6Al-4V modified with the acrylate, carboxylic, and thiol terminated SAMs was used to
immobilize vancomycin (R1) (Scheme 3.10).

After overnight drying, KRSR(C) (R2) was

covalently linked to the surface (Scheme 3.11). Finally, spermine NONOate (R3) was immobilized
to the Ti-6Al-4V surface (Scheme 3.12).

Scheme 3.10: Immobilization of vancomycin (R1) to thiol, acrylate, and carboxylic acid
terminated SAMs through amide and C-S bond formation with a maleimide/NHS crosslinker.

Scheme 3.11: Immobilization of KRSR(C) (R2) to carboxylic acid, thiol, and acrylate
terminated SAMs through C-S bond formation between the alkene of an acrylate terminated
SAM and a free thiol of KRSR(C) via a thiol-ene Michael addition after vancomycin (R1)
immobilization.

77

Scheme 3.12: Immobilization of spermine NONOate (R3) to thiol, acrylate, and carboxylic
acid terminated SAMs via EDC/NHS crosslinking and amide bond formation after vancomycin
(R1) immobilization and KRSR(C) (R2) immobilization.
3.3.5 Immobilization Characterization
3.3.5.1 Diffuse Reflectance Infrared Spectroscopy
Successful immobilization of the bioactive molecules was confirmed through analysis
using a Thermo Nicolet-Nexus FT-IR with a diffuse reflectance attachment. The spectra were
collected under N2 to suppress stretches associated with CO2 and H2O. A total of 1024 scans were
collected per sample with a resolution of 4 cm-1. Unmodified Ti-6Al-4V substrates were used as
the backgrounds for analysis; they did not possess stretches representative of the SAM molecules.
Differences in the IR spectrum between the SAM linker and the bioactive molecule were used to
confirm attachment.
3.3.5.2 Contact Angle Analysis
The wettability of unmodified and modified Ti-6Al-4V substrates was examined through
the use of static contact angle analysis with a Ramè-hart standard contact angle goniometer (Model
200-U1). This was performed after the substrates were sonicated in solvent for 15 minutes and
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allowed to dry overnight. Millipore water (2 µL) was brought into contact with the coupon surface
using a 10 µL syringe. A total of three drops were placed on each surface, and a total of three
different substrates of each modification type were examined (n=9). The droplets were imaged and
then analyzed using DROPimage standard software to obtain contact angle values. Contact angle
values of the functionalized surfaces were compared to unfunctionalized Ti-6Al-4V and standard
deviations (SD) were calculated.
3.3.5.3 Release of Nitric Oxide (Griess Assay)
NO release from spermine NONOate modified Ti-6Al-4V was assessed through a
nitrate/nitrate colorimetric assay (Griess) supplied by Cayman Chemical (Figure 3.5).73-74 The
total concentration of NO released from the system is first measured through the conversion of
NO3- to NO2- by nitrate reductase.75 This was then followed by the addition of the Griess reagents,
which convert NO2- into a colored azo compound (λmax =540 nm). The concentration of this
compound directly determines the concentration of NO2- as it was converted from NO. NO release
from spermine NONOate modified substrates was assessed over two hours. Functionalized
substrates were placed into individual vials and covered with 0.9 mL of phosphate buffered saline
(PBS). The vials were placed on an incubator/shaker at 37°C, protected from light. Every 15
minutes, all of the PBS was removed from the vial and frozen at -20°C until assay. The 0.9 mL
was then replaced with fresh PBS.
The PBS samples were thawed and added to a 96-well plate as per kit instructions. A
nitrate/nitrite calibration curve was generated using reagents supplied by the kit. Briefly 80 µL of
smaple was incubated with 10 µL of enzyme cofactor mixture and 10 µL of nitrate reductase
mixture. After a one hour incubation, 50 µL of Griess Reagent 1 and 50 µL of Griess Reagent 2
were added to each well. The contents of the well plate were incubated at room temperature for 10
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minutes prior to UV-Vis analysis. The absorbance of the wells was read using an Infinite M1000
microplate reader (Tecan, USA) at an absorbance of 540 nm. The external calibration curve as
well as dilution factors were used to determine the concentration of NO released from the
substrates (n=9).

Nitrate

Nitrate
reductase

Nitrite

N-(1Naphthyl)ethylenediamine
(Griess Reagent 2)

Sulfanilamide (Griess Reagent 1)
Azo product (λmax =540 nm)
Figure 3.5: Nitrite/nitrate colorimetric assay for the determination of NO released from
spermine NONOate functionalized substrates.
3.4 Results
3.4.1 Single Functionalized Ti-6Al-4V
3.4.1.1 Immobilization of Vancomycin (R1)
Covalent attachment of vancomycin to thiol terminated SAMs on Ti-6Al-4V was
accomplished through maleimide/NHS crosslinking (Scheme 3.1). An amide bond was formed
between the crosslinking agent and a primary amine of the vancomycin. Then, the maleimide with
the vancomycin linked was used to form a C-S bond between the thiol tail of the SAM and the
maleimide portion of the crosslinking agent. After immobilization, the thiol terminated SAM was
ordered with the CH2 asym at 2917 cm-1 and the CH2 sym at 2848 cm-1 (Figure 3.6) This indicated
that the reaction did not affect the packing of the alkyl chains as SAMs retained their all trans
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confirmation. The SAM remained bound to Ti-6Al-4V in a bidentate manner, with a P=O stretch
at 1203 cm-1 and a P-O stretch at 1050 cm-1 observed (Figure 3.7).
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Figure 3.6: DRIFT spectra of the methylene stretching region after immobilization of
vancomycin demonstrating that the alkyl chains of the SAMs were oriented in an all trans
confirmation as shown by the CH2 asym at 2917 cm-1 and the CH2 sym at 2848 cm-1.
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Figure 3.7: DRIFT spectra of the immobilization of vancomycin as evidenced by the presence
of the C=C stretching of the phenol ring at 1488 cm-1 and the C-O stretch at 1227 cm-1. The
broad peak at 1620 cm-1 is attributable to both the C-OO- stretch and amide I C=O stretching
within vancomycin. Amide II stretching was observed at 1428 cm-1.
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Attachment of the vancomycin molecule was evidenced by the presence of the C=C
stretching of the phenol ring at 1488 cm-1 and the C-O stretch at 1227 cm-1 (Figure 3.7). The broad
peak at 1620 cm-1 is attributable to both the C-OO- stretch and amide I C=O stretching within
vancomycin. Amide II stretching was observed at 1428 cm-1. A peak attributable to the lactam
portion of the maleimide crosslinker was also observed at 1736 cm-1 (Figure 3.7). While stretches
representative of the vancomycin molecule and linker were observed, the C-S stretch of the bond
formed between the vancomycin and maleimide/NHS crosslinker was not observed; this stretch is
not diagnostic in the IR.76
Covalently attaching vancomycin to thiol terminated SAMs resulted in surfaces that
exhibited a hydrophilic contact angle value (Table 3.4). The presence of several hydrophilic
functional groups such as NH and OH within the molecule’s structure would account for the
hydrophilic contact angle value. This value agrees well with values observed when vancomycin
was immobilized on stainless steel (24 ± 12°).27 The large standard deviation indicates variability
in the presentation of the vancomycin at the surface. This could be due to different orientations of
the molecule or to the presence of the linker at the interface.
Table 3.4: Contact angle analysis before and after immobilization of vancomycin to thiol
terminated SAMs.
Molecule
Thiol terminated SAM
Immobilized vancomycin

Average ± SD (°)
61.5 ± 7.4
47.4 ± 13.6

3.4.1.2 Immobilization of KRSR(C) (R2)
The cell adhesion peptide KRSR(C) was covalently linked to the Ti-6Al-4V surface via
base catalyzed C-S bond formation with the alkene of an acrylate terminated SAM (Scheme 3.2).
After immobilization, the alkyl chains of the SAM linker remained ordered in an all trans
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confirmation, as shown by the CH2 asym at 2915 cm-1 and the CH2 sym at 2847 cm-1 (Figure 3.8).
The phosphonic acid head group of the SAM remained bound to the Ti-6Al-4V surface as P=O
stretching at 1265 cm-1 and P-O stretching at 1144 cm-1 were observed, indicating bidentate
binding to Ti-6Al-4V (Figure 3.9). Carbonyl stretching of the acrylate functional tail of the SAM
was also observed at 1726 cm-1 demonstrating the presence of the linker (Figure 3.9).
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Figure 3.8: DRIFT spectra of the methylene stretching region after immobilization of
KRSR(C) demonstrating that the alkyl chains of the SAMs were oriented in an all trans
confirmation as evidenced by the position of the CH2 asym stretch at 2915 cm-1 and the CH2
sym stretch at 2847 cm-1.
Stretches that were attributed to the peptide sequence were observed after immobilization
(Figure 3.9). Stretches present in the IR spectrum included the C=O amide I stretching at 1671
cm-1, as well as N-H stretching for amide II at 1567 cm-1 of the peptide backbone. These stretches
were unique to the peptide and were not observed in the acrylate SAM linker. As with the
immobilization of vancomycin, stretching due to the C-S bond formed to covalently link the
KRSR(C) to the acrylate SAM was not observed.
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Figure 3.9: DRIFT spectra of the immobilization of the KRSR(C) peptide where stretches at
1671 cm-1 and 1567 cm-1 characteristic of amide I and amide II stretching respectively indicate
covalent attachment.
After attachment of KRSR(C) to Ti-6Al-4V, the surface wettability decreased (Table 3.5).
This was unexpected given the presence of several hydrophilic functional groups within the
peptide, such as NH, OH, and COOH. This may be explained by peptide interactions in which the
hydrophilic groups are shielded from the water droplet, and the carbon containing backbone is
exposed. The large standard deviation also indicates variability in the presentation of the peptide
at the surface. The peptide may be oriented differently on various portions of the surface.
Table 3.5: Contact angle analysis before and after immobilization of KRSR(C) to acrylate
terminated SAMs.
Molecule
Acrylate terminated SAM
Immobilized KRSR(C)
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Average ± SD (°)
55.4 ± 8.8
89.7 ± 14.7

3.4.1.3 Immobilization of Spermine NONOate
Spermine NONOate was attached to the Ti-6Al-4V surface using EDC/NHS coupling via
amide bond formation with a carboxylic terminated SAM (Scheme 3.3). After immobilization, the
alkyl chain became disordered, with cis orientations present within the alkyl chain. The CH2 asym
stretch was observed at 2928 cm-1 and the CH2 sym stretch was observed at 2854 cm-1 (Figure
3.10). Stretches corresponding to the phosphonic acid head group of P-O at 1157 cm-1 and P-OH
at 918 indicated that the SAM was in a mixed binding mode, with hydrogen bonding to the surface
(Figure 3.11).

100.0

Percent Reflectance

87.5

75.0

SpermineNONOate solid

100.0

99.5

99.0

Carboxylic terminated SAM

100
98
96
3500

Immobilized SpermineNONOate
3250

2928 2854

3000

2750

2500

-1

Wavenumbers (cm )

Figure 3.10: DRIFT spectra of the methylene stretching region after spermine NONOate
immobilization indicating the presence of a disordered alkyl chain with cis orientations as
evidenced by the CH2 asym at 2928 cm-1 and the CH2 sym at 2854 cm-1.
After immobilization, stretches representative of the spermine NONOate molecule were
observed within the IR spectrum. These include the stretch at 1656 cm-1 corresponding to the amide
I stretch, as well as the amide II stretch at 1563 cm-1 (Figure 3.11). Importantly, a small stretch
was observed at 1500 cm-1 due to the NO group, which indicates the presence of the nitric oxide
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donating moiety within the linked molecule. The attachment of the spermine NONOate to
carboxylic acid terminated SAMs resulted in surfaces that exhibited a low contact angle value,
indicating a hydrophilic surface (Table 3.6). The nitric oxide donating group and primary amines
within spermine NONOate are likely responsible for the hydrophilicity.
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Figure 3.11: DRIFT spectra of the immobilization of spermine NONOate molecule where
stretches were observed at 1656 cm-1 and 1563 cm-1 corresponding to the amide I and amide II
stretches of the spermine NONOate molecule.
Table 3.6: Contact angle analysis before and after immobilization of spermine NONOate to
carboxylic terminated SAMs.
Molecule
Carboxylic terminated SAM
Immobilized Spermine NONOate

Average ± SD (°)
37.5 ± 11.8
18.5 ± 9

Release of NO from spermine NONOate modified Ti-6Al-4V was quantified using a
nitrate/nitrite colorimetric assay. The degradation of spermine NONOate into NO is a first order
process.77 An initial burst release of 31.6 ± 0.5 nanomoles of NO was observed at 15 minutes,
which was 41 ± 0.22% of total NO release, followed by sustained, linear release for two hours
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(Figure 3.12). This followed a biphasic release pattern, rather than a solely first or second order

Cumulative Nanomoles of NO Released

profile. The total release was 77.0 ± 1.8 nanomoles.
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Figure 3.12: Spermine NONOate functionalized Ti-6Al-4V substrates had a burst release of
31.6 ± 0.5 nanomoles of nitric oxide at 15 minutes with a total release after two hours of 77.0
± 1.8 nanomoles of nitric oxide.
3.4.2 Dual Functionalized Ti-6Al-4V
3.4.2.1 Immobilization of Vancomycin and KRSR(C) (R1 &R2)
Co-immobilization of vancomycin and KRSR(C) to thiol and acrylate terminated SAMs
was accomplished through specifically designed reactions between the SAM tail group and a target
functional group within the bioactive molecule. Covalent attachment of vancomycin to thiol
terminated SAMs on Ti-6Al-4V was accomplished through maleimide/NHS crosslinking (Scheme
3.4). Then, KRSR(C) was covalently linked via a base catalyzed thiol-ene Michael addition
(Scheme 3.5). After co-immobilization, the thiol and acrylate terminated SAMs were ordered with
the CH2 asym at 2914 cm-1 and the CH2 sym at 2847 cm-1 (Figure 3.13). This indicated that the
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reaction did not affect the packing of the alkyl chains. The SAMs remained bound to Ti-6Al-4V
in a tridentate manner, based on the P-O stretch at 1076 cm-1 observed in the IR spectrum (Figure
3.14).
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Figure 3.13: DRIFT spectra of the methylene stretching region after vancomycin and
KRSR(C) co-immobilization indicating the presence of an ordered alkyl chain with all trans
confirmations as evidenced by the CH2 asym stretch at 2914 cm-1 and the CH2 sym stretch at
2847 cm-1.
Stretches attributed to either KRSR(C) or vancomycin were observed after immobilization
(Figure 3.14). This included a broad carbonyl stretch centered around 1737 cm-1. This broad
stretch has two shoulders, which were also observed after the immobilization of vancomycin, but
not within the KRSR(C) solid. In addition, amide I and amide II stretches were observed at 1666
cm-1 and 1568 cm-1, respectively. Stretches of the C-S bonds formed to link the two bioactive
molecules to the Ti-6Al-4V surface were not observed as C-S stretching is weak in the IR.76
Covalently attaching vancomycin and KRSR(C) to thiol and acrylate terminated SAMs
resulted in surfaces that exhibited a hydrophilic contact angle value (Table 3.7). The presence of
several hydrophilic functional groups such as NH and OH within the vancomycin structure would
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contribute to the surface wettability. The presence of similar groups including amines, carboxylic
acid, and hydroxyl groups would also contribute to the surface wettability.
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Figure 3.14: DRIFT spectra after co-immobilization of vancomycin and KRSR(C) with
stretches attributable to either KRSR(C) or vancomycin such as a broad carbonyl stretch
centered around 1737 cm-1 and amide I and amide II stretches at 1666 cm-1 and 1568 cm-1,
respectively were observed.
Table 3.7: Contact angle analysis before and after co-immobilization of vancomycin and
KRSR(C) to thiol and acrylate terminated SAMs.
Molecule(s)
Thiol and acrylate terminated SAM
Co-immobilized vancomycin & KRSR(C)
Acrylate terminated SAM
Immobilized KRSR(C)
Thiol terminated SAM
Immobilized vancomycin

Average ± SD (°)
58.7 ± 7.7
43.8 ± 8.3
55.4 ± 8.8
89.7 ± 14.7
61.5 ± 7.4
47.4 ± 13.6

3.4.2.2 Immobilization of KRSR(C) and Spermine NONOate (R2 & R3)
Co-immobilization of KRSR(C) and spermine NONOate to acrylate and carboxylic acid
terminated SAMs was accomplished through covalent bond formation between the alkene of the
acrylate and a free thiol of the peptide by a thiol-ene Michael addition (Scheme 3.6), followed by
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amide bond formation between the carboxylic SAM and a primary amine within spermine
NONOate via EDC/NHS crosslinking (Scheme 3.7). After co-immobilization, the acrylate and
carboxylic terminated SAMs became partially disordered. The CH2 asym stretch at 2921 cm-1 and
the CH2 sym stretch at 2849 cm-1 indicate the presence of both trans and cis orientations within
the alkyl chain (Figure 3.15). The SAMs remained bound to Ti-6Al-4V in a tridentate manner,
with a P-O stretch at 1076 cm-1 observed in the IR spectrum (Figure 3.16).
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Figure 3.15: DRIFT spectra of the methylene stretching region after KRSR(C) and spermine
NONOate co-immobilization indicating the presence of an alkyl chain with both cis and trans
confirmations as evidenced by the presence of the stretches of CH2 asym at 2921 cm-1 and the
CH2 sym at 2849 cm-1.
Stretches attributable to either KRSR(C) or spermine NONOate were observed after
immobilization (Figure 3.16). This included a carbonyl stretch centered around 1730 cm-1. This
stretch can be attributable to the SAM linkers as well as both bioactive molecules. What is unique
is the presence of the amide I and amide II stretches at 1647 cm-1 and 1554 cm-1, respectively.
These stretches are only found within the bioactive molecules and not within the SAM linkers.
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Furthermore, a small stretch around 1500 cm-1 was observed within the IR spectrum, indicating
the presence of the nitric oxide donating moiety of spermine NONOate.
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Figure 3.16: DRIFT spectrum after co-immobilization of KRSR(C) and spermine NONOate
where stretches attributed to either molecule such as a carbonyl stretch centered around 1730
cm-1 as well as the amide I and amide II stretches at 1647 cm-1 and 1554 cm-1, respectively
were observed.
Covalently attaching KRSR(C) and spermine NONOate to acrylate and carboxylic acid
terminated SAMs resulted in surfaces that exhibited a hydrophilic contact angle value (Table 3.8).
A hydrophilic value was expected, given the hydrophilicity of surfaces only functionalized with
spermine NONOate. The value was higher than that observed for surfaces only modified with
spermine. This increase in contact angle value is likely due to the presence of KRSR(C) at the
interface which possessed a higher contact angle value than spermine NONOate. This is supported
by the large standard deviation that was observed, indicating variability in surface chemistry.
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Table 3.8: Contact angle analysis before and after co-immobilization of KRSR(C) and
spermine NONOate to acrylate and carboxylic acid terminated SAMs.
Molecule(s)
Acrylate & carboxylic acid terminated SAM
Co-immobilized KRSR(C) & spermine NONOate
Acrylate terminated SAM
Immobilized KRSR(C)
Carboxylic acid terminated SAM
Immobilized spermine NONOate

Average ± SD (°)
53.6 ± 10.0
36.4 ± 12.4
55.4 ± 8.8
89.7 ± 14.7
37.5 ± 11.8
18.5 ± 9.0

The amount of NO released from dual functionalized KRSR(C) and spermine NONOate
substrates was examined using a Griess assay (Figure 3.17). A burst release of 65.1 ± 0.3
nanomoles of NO was observed after 15 minutes. This burst release was higher than what was
observed for single modified substrates. Release from the dual functionalized Ti-6Al-4V was
observed over a two hour time period. The total release was 107.6 ± 1.5 nanomoles. This may
indicate physisorption of the spermine NONOate to the surface via electrostatic or other
interactions with the cell adhesion peptide.
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Figure 3.17: KRSR(C) and spermine NONOate functionalized Ti-6Al-4V substrates had a
burst release of 65.1 ± 0.3 nanomoles of nitric oxide at 15 minutes with a total release after two
hours of 107.6 ± 1.5 nanomoles of nitric oxide.
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3.4.2.3 Immobilization of Vancomycin and Spermine NONOate (R1 & R3)
Co-immobilization of vancomycin and spermine NONOate to thiol and carboxylic acid
terminated SAMs was accomplished through covalent bond formation between the thiol SAM and
a primary amine of the vancomycin using a maleimide/NHS crosslinker (Scheme 3.8). Then, an
amide bond was formed between the carboxylic SAM and a primary amine within spermine
NONOate via EDC/NHS crosslinking (Scheme 3.9). After co-immobilization, the thiol and
carboxylic terminated SAMs became disordered; the CH2 asym stretch at 2927 cm-1 and the CH2
sym stretch at 2854 cm-1 indicated the presence of cis orientations within the alkyl chain (Figure
3.18). The SAMs remained bound to Ti-6Al-4V in a tridentate manner, with a P-O stretch at 1149
cm-1 observed (Figure 3.19).

100

Percent Reflectance

99

98

Carboxylic & Thiol SAM

100.0

99.5

99.0

1. Vancomycin Attachment

100
99

2854

98
97
3100

1,2. Spermine Attachment
3000

2927
2900

2800

-1

Wavenumbers(cm )

Figure 3.18: DRIFT spectra of the methylene stretching region after KRSR(C) and spermine
NONOate co-immobilization indicating the presence of an alkyl chain with cis confirmations
as evidenced by the presence of the CH2 asym stretch at 2927 cm-1 and the CH2 sym stretch at
2854 cm-1.
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Stretches attributed to vancomycin and spermine NONOate were observed after
immobilization (Figure 3.19). This included a carbonyl stretch centered at 1725 cm-1. This stretch
can be attributed to the SAM linkers as well vancomycin. As with the vancomycin functionalized
Ti-6Al-4V this C=O stretch contains a shoulder that can be due to the maleimide portion of the
crosslinker. Amide I and amide II stretches at 1643 cm-1 and 1549 cm-1 which are present within
both bioactive molecules were also observed. These stretches are only found within the bioactive
molecules and not within the SAM linkers. Furthermore, a small stretch around 1500 cm -1 was
observed within the IR spectrum, indicating the presence of the nitric oxide donating moiety of
spermine NONOate.
100

Percent Reflectance

99
98

Carboxylic & Thiol SAM

100.0

99.5

99.0

1. Vancomycin Attachment

100

1725
96

1149

1549

1236

1643
1,2. Spermine Attachment

92
1800

1700

1600

1500

1400

1300

1200

1100

1000

900

-1

Wavenumbers(cm )

Figure 3.19: DRIFT spectra of stretches attributable to vancomycin or spermine NONOate
were observed after immobilization; stretches included the C=O stretch centered around 1725
cm-1 as well as the amide I and amide II stretches at 1643 cm-1 and 1549 cm-1, respectively.
Covalently attaching vancomycin and spermine NONOate to thiol and carboxylic acid
terminated SAMs resulted in surfaces that exhibited a hydrophilic contact angle value (Table 3.9).
A hydrophilic value was expected, given the hydrophilicity of surfaces only functionalized with
spermine NONOate. The value was lower than that observed for surfaces only modified with
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spermine. This may be due to interactions between spermine NONOate and vancomycin such as
hydrogen bonding.
Table 3.9: Contact angle analysis before and after co-immobilization of vancomycin and
spermine NONOate to acrylate and carboxylic acid terminated SAMs.
Molecule(s)
Thiol & carboxylic acid terminated SAM
Co-immobilized vancomycin & spermine NONOate
Thiol terminated SAM
Immobilized vancomycin
Carboxylic acid terminated SAM
Immobilized spermine NONOate

Average ± SD (°)
44.4 ± 6.6
6.3 ± 5.8
61.5 ± 7.4
47.4 ± 13.6
37.5 ± 11.8
18.5 ± 9.0

The amount of NO released from dual functionalized vancomycin and spermine NONOate
substrates was examined using a Griess assay (Figure 3.20). A burst release of 84.9 ± 0.4
nanomoles of NO was observed after 15 minutes. This burst release was higher than what was
observed for single modified substrates. Release from the dual functionalized Ti-6Al-4V was
observed over a two hour time period. The total release was 117.6 ± 1.4 nanomoles. This may
indicate physisorption of the spermine NONOate to the surface via electrostatic or other
interactions with the cell adhesion peptide. This is supported by the low contact angle value.
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Figure 3.20: Vancomycin and spermine NONOate functionalized Ti-6Al-4V substrates had a
burst release of 84.9 ± 0.4 nanomoles of nitric oxide at 15 minutes with a total release after two
hours of 117.6 ± 1.4 nanomoles of nitric oxide.
3.4.3 Triple Functionalized Ti-6Al-4V (R1, R2, & R3)
Triple immobilization of vancomycin, KRSR(C), and spermine NONOate to thiol, acrylate
and carboxylic acid terminated SAMs on Ti-6Al-4V was accomplished through the use of
orthogonal chemistry, with unique, specific reactions responsible for covalently linking each
bioactive molecule. The thiol terminated SAM and a primary amine of the vancomycin were used
in conjunction with a maleimide/NHS crosslinker to form a C-S and amide bond (Scheme 3.10).
Next, a C-S bond between the acrylate terminated SAM and a thiol within KRSR(C) was formed
under mildly basic conditions (Scheme 3.11). Then, an amide bond was formed between the
carboxylic SAM and a primary amine within spermine NONOate via EDC/NHS crosslinking
(Scheme 3.12).
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After the immobilization of vancomycin, the SAMs were ordered with the CH2 asym
stretch observed at 2918 cm-1 and the CH2 sym stretch observed at 2849 cm-1 (Figure 3.21). The
SAMs were bound to the surface in a monodentate manner as a P=O stretch at 1209 cm-1, a P-O
cm-1, and a P-OH stretch at 930 cm-1 were observed within the IR spectrum (Figure 3.22).
Additional stretches observed include a C=O stretch at 1736 cm-1, which is attributable to both
vancomycin, the SAMs, as well as the lactam rings of the maleimide linker. Amide II stretching
was present within the IR spectrum at 1586 cm-1 accompanied with a C=C stretch at 1467 cm-1 of
the phenol rings after vancomycin immobilization (Figure 3.22). These stretches were also
observed on substrates functionalized with only vancomycin.
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Figure 3.21: DRIFT spectra of the methylene stretching region after vancomycin
immobilization on triple functionalized Ti-6Al-4V. The alkyl chain was ordered with trans
confirmations as evidenced by the CH2 asym stretch at 2918 cm-1 and the CH2 sym stretch at
2849 cm-1.
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Figure 3.22: DRIFT spectra after the immobilization of vancomycin on triple functionalized
Ti-6Al-4V. Stretches attributed to vancomycin were observed such as a C=O stretch centered
around 1736 cm-1, a C=C stretch of the phenol ring at 1467 cm-1, as well as the amide II stretch
at 1586 cm-1.
Next, KRSR(C) was immobilized to the Ti-6Al-4V surface. SAMs were a mixture of
ordered and disordered with the presence of both cis and trans confirmations within the alkyl
chain. This was evidenced by the CH2 asym stretch observed at 2919 cm-1 and the CH2 sym stretch
observed at 2849 cm-1 (Figure 3.23). Ordered SAMs are preferred as they present their tail groups
in a consistent manner at the interface. SAMs were bound to the surface in a tridentate manner as
P=O stretching at 1027 cm-1 was observed in the IR spectrum (Figure 3.24). A carbonyl stretch
was observed at 1739 cm-1 (Figure 3.24), shifted slightly from what was observed for the
immobilization of vancomycin at 1736 cm-1. The broadness of this stretch indicates multiple
vibrational modes occurring simultaneously. This is expected given the different molecules on the
surface that exhibit carbonyl stretching. In the IR spectrum, amide I and amide II stretching at
1670 cm-1 and 1546 cm-1 were also observed. Amide stretching is found within both vancomycin
and KRSR(C) molecules.
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Figure 3.23: DRIFT spectra of the methylene stretching region after KRSR(C) immobilization
on triple functionalized Ti-6Al-4V. The alkyl chain contained both cis and trans confirmations
as evidenced by the CH2 asym stretch at 2919 cm-1 and the CH2 sym stretch at 2849 cm-1.

100

Percent Reflectance

95

KRSR(C) in water

90
100.0

99.5

1. Vancomycin Attachment

99.0
100.0
99.5

1739 1670

1262

1546

1027
1,2. KRSR(C) attachment

99.0
1800

1600

1400

1200

1000

800

-1

Wavenumbers (cm )

Figure 3.24: DRIFT spectrum with stretches attributed to vancomycin and KRSR(C) on triple
functionalized Ti-6Al-4V were observed after immobilization such as a C=O stretch centered
around 1739 cm-1 as well as the amide I and amide II stretching at 1670 cm-1 and 1586 cm-1,
respectively.
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Finally, spermine NONOate was covalently linked to the Ti-6Al-4V surface. SAMs
remained disordered; the CH2 asym at 2926 cm-1 and the CH2 sym at 2851 cm-1 were observed in
the IR spectrum (Figure 3.25). The shift in the IR stretching could be attributed to destabilization
of the SAM due to repeated solvent exposure. SAMs remained bound to the surface in a mixed
manner, as P-O stretches at 1164 cm-1 and 1089 cm-1 as well as a P-OH stretch at 909 cm-1
indicative of hydrogen bonding to the surface were present within the IR spectrum (Figure 3.26).
Stretches attributed to spermine NONOate, vancomycin, and KRSR(C) on triple functionalized
Ti-6Al-4V were observed including a C=O stretch centered around 1736 cm-1 as well as the amide
I and amide II stretching at 1655 cm-1 and 1564 cm-1, respectively. A small stretch at approximately
1500 cm-1 indicated the presence of the nitric oxide donating moiety.
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Figure 3.25: DRIFT spectra after spermine NONOate immobilization on triple functionalized
Ti-6Al-4V, SAMs were disordered with CH2 asym stretching and CH2 sym stretching observed
at 2926 cm-1 and 2851 cm-1, respectively. This indicates cis confirmations within the alkyl
chain.
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Figure 3.26: DRIFT spectra after spermine NONOate attachment with stretches attributable to
spermine NONOate, vancomycin, and KRSR(C) observed including a C=O stretch centered
around 1736 cm-1 as well as the amide I and amide II stretching at 1655 cm-1 and 1564 cm-1,
respectively.
Covalently attaching vancomycin, KRSR(C), and spermine NONOate to thiol, acrylate,
Figure 3.26: DRIFT spectra after spermine NONOate attachment with stretches attributable to
spermine
NONOate,
vancomycin,
andresulted
KRSR(C)
observedthat
including
a C=O
stretch centered
and
carboxylic
acid terminated
SAMs
in surfaces
exhibited
a hydrophilic
contact
-1
-1
around 1736 cm as well as the amide I and amide II stretching at 1655 cm and 1564 cm-1,
angle
value (Table 3.10). A hydrophilic value was expected, given the hydrophilicity of the dual
respectively.
functionalized surfaces. The amount of NO released from triple functionalized substrates was
examined using a Griess assay (Figure 3.27). A burst release of 51.0 ± 0.4 nanomoles of NO was
observed after 15 minutes. This burst release was similar to what was observed for single
functionalized substrates and lower than dual functionalized substrates. Release from the triple
functionalized Ti-6Al-4V was observed over a two-hour time period. The total release was 74.7 ±
1.6 nanomoles. As this is similar to what was observed for Ti-6Al-4V only functionalized with
spermine NONOate, the loading of the spermine NONOate was comparable.
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Table 3.10: Contact angle analysis before and after co-immobilization of vancomycin,
KRSR(C), and spermine NONOate to acrylate, thiol, and carboxylic acid terminated SAMs.
Molecule(s)
Thiol, acrylate, & carboxylic acid terminated SAM
Molecule(s)
Vancomycin, KRSR(C),
and spermine NONOate immobilized
Thiol, acrylate, & carboxylic
acid terminated
SAM
Thiol terminated
SAM
Vancomycin, KRSR(C),
and spermine
NONOate immobilized
Immobilized
Vancomycin
Thiol terminated
SAM
Carboxylic
acid terminated
SAM
Immobilized
Vancomycin
Immobilized spermine NONOate
Carboxylic
acid terminated
Acrylate
terminatedSAM
SAM
Immobilized
spermine
NONOate
Immobilized KRSR(C)
Acrylate terminated SAM
Immobilized KRSR(C)

Average ± SD (°)
23.9 ± 16.6
Average13.6
± SD(°)
± 11.2
23.9 ±61.5
16.6± 7.4
13.6 47.4
± 11.2
± 13.6
61.537.5
± 7.4± 11.8
47.4 ±18.5
13.6± 9.0
37.5 ±55.4
11.8± 8.8
18.589.7
± 9.0± 14.7
55.4 ± 8.8
89.7 ± 14.7

Table 3.10: Contact angle analysis before and after co-immobilization of vancomycin and
spermine NONOate to acrylate and carboxylic acid terminated SAMs.
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Figure 3.27: Triple functionalized Ti-6Al-4V substrates had a burst release of 51.0 ± 0.4
nanomoles of nitric oxide at 15 minutes with a total release after two hours of 74.7 ± 1.6
nanomoles of nitric oxide.
3.5 Discussion
Figure 3.27: Triple functionalized Ti-6Al-4V substrates had a burst release of 51.0 ± 0.4
nanomoles
of nitric
oxide at optimized
15 minutestowith
total release
after twosubstrates
hours of were
74.7 ±
1.6 to
Attachment
conditions
forma single
functionalized
used
nanomoles of nitric oxide.
synthesize dual and triple functionalized substrates through chemical reactions with the SAM tail
and a target functional group within the bioactive molecule. Successful covalent attachment was
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confirmed using IR spectroscopy by comparing stretches present within the bioactive molecule
and the immobilized molecule.
Unfortunately, the bioactive molecules and SAM linkers share several functional groups
including amides, amines, and carboxylic acids. Therefore, stretches that were unique to the
individual bioactive molecules indicated successful covalent attachment. In vancomycin, these
stretches corresponded to the phenol ring as well as the lactam rings of the maleimide/NHS
crosslinking agent (Figure 3.7). Stretches of this linker were expected in the IR as this structure
remains after immobilization of vancomycin.
Covalent attachment of the cell adhesion peptide KRSR(C) on dual and triple
functionalized substrates was difficult to assess given shared functional groups with vancomycin
and spermine NONOate. Here, attachment was confirmed via the subtle differences in peak
position. When co-immobilized with vancomycin, the positions of the amide I and amide II
stretches were used to verify attachment (Figure 3.14). This was similar with spermine NONOate,
since it shares stretches with KRSR(C) and vancomycin. In the case of spermine NONOate, the
stretch corresponding to the nitric oxide donating group was diagnostic, therefore attachment was
confirmed with the presence of this stretch (Figure 3.16).
The presence of hydrophilic groups within the bioactive molecules at the interface
contributed to the low contact angle values observed for several of the functionalized surfaces.
However, KRSR(C) functionalized substrates exhibited a more hydrophobic contact angle value.
This was not anticipated, as this molecule possesses several hydrophilic portions. Large,
physiosorbed amounts of KRSR(C) to the surface may explain this. The peptide may have oriented
itself in a manner in which the hydrophilic portions were shielded. When multiple molecules were
linked to Ti-6Al-4V, these surfaces illustrated contact angle values that were representative of each
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bioactive molecule. Variability in the surface wettability, as evidenced by the standard deviation,
was observed in several of the combinations. Therefore, it is likely that these molecules were
unevenly distributed across the surface. This would need to be confirmed with other techniques
such as mapping mass spectrometry or atomic force microscopy (AFM) which would help
characterize SAM uniformity as well as the distribution of these molecules on the surface.
Uneven distribution or physisorption of spermine NONOate may also explain results for
substrates functionalized with this bioactive molecule. These substrates exhibited very hydrophilic
contact angle values, which were difficult to measure, given the droplet’s preference to interact
with the surface. When nitric oxide release was assessed from the different functionalizations, dual
functionalized substrates released more nitric oxide than single functionalized substrates.
Theoretically, single functionalized spermine NONOate would release more nitric oxide than dual
functionalized substrates, since there would be more sites available for spermine NONOate
attachment on substrates only possessing carboxylic acid SAMs. The large release from dual
functionalized indicates physisorption of the spermine NONOate to surfaces possessing
vancomycin or KRSR(C). It is possible for hydrogen bonding and electrostatic interactions to
occur between these bioactive molecules. When immobilized with both KRSR(C) and
vancomycin, nitric oxide release was more comparable to that observed for spermine NONOate
single functionalized substrates. The presence of both of these other molecules may interfere with
the spermine’s ability to adsorb to the surface. The quantity of nitric oxide released from single
and triple functionalized substrates was within values observed for a nitric oxide molecule
immobilized on Ti-6Al-4V (89 ± 4.8 nanomoles).44
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3.6 Conclusions
Using orthogonal chemical reactions, substrates functionalized with vancomycin,
KRSR(C), and spermine NONOate were formed. Covalent attachment of these bioactive
molecules was confirmed with IR spectroscopy through distinct differences in the IR spectra
before and after functionalization. Contact angle analysis and nitric oxide release indicated
potential physisorption of KRSR(C) and spermine NONOate to Ti-6Al-4V.
The covalent attachment of these molecules to Ti-6Al-4V should not affect their bioactivity
as this would diminish their effectiveness at preventing bacterial adhesion and encouraging
osteoblast adhesion. Therefore, these substrates were next subjected to bacterial challenges to
examine their antimicrobial properties. Then, human bone cells were grown on functionalized Ti6Al-4V to characterize cytotoxicity of bioactive molecule immobilization.
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Chapter 4: Bacterial Adhesion and Viability on Functionalized Titanium Aluminum
Vanadium
4.1 Introduction
Bacteria adhesion to the Ti-6Al-4V surface leads to biofilm formation and subsequent
infection which contribute to implant failure.1-7 There are several species of bacteria that colonize
Ti-6Al-4V which include Gram positive Staphylococcus bacteria, such as Staphylococcus aureus
and Staphylococcus epidermidis and Gram negative species including Pseudomonas aeruginosa.2,
8

These bacteria can form a biofilm on the implant surface, rendering them difficult to treat with

traditional antibiotics as antibiotics have difficulty diffusing through the polymer matrix of the
biofilm.8-9 Compounding this issue, is the development of antibiotic resistant bacteria within this
biofilm due to the sublethal doses of antibiotics (Figure 4.1).6, 10

A few bacteria
are resistant

Resistant bacteria

Antibiotics kill
the diseasecausing bacteria

Resistant bacteria
have preferred
conditions to
proliferate

Resistant bacteria
can transfer their
resistance

Susceptible bacteria

Figure 4.1: Development of antibiotic resistant bacteria within a biofilm.
In this work, Ti-6Al-4V was functionalized with vancomycin and spermine NONOate.
Vancomycin is an antibiotic that is effective against Gram positive bacteria and is frequently used
to treat orthopedic implant infections.10-23 Spermine NONOate is a nitric oxide releasing molecule.
Nitric oxide exhibits antimicrobial effects whose efficacy is specific to the bacterial species.24-25
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Nitric oxide has also been indicated to cause a dispersal event in biofilms, allowing the bacteria to
be targeted by traditional antibiotics.26-34 The co-immobilization of both antimicrobial agents to
the surface would allow for a synergistic effect.26, 35-37
Here, functionality of the biomolecules was characterized through bacterial challenges with
either Staphylococcus epidermidis (S. epidermidis), or Escherichia coli (E. coli). S. epidermidis
was chosen given its prevalence in orthopedic implant infections. E. coli was used as a
representative Gram negative species.38 The adhesion of these bacteria to and viability on bioactive
molecule functionalized Ti-6Al-4V was assessed using fluorescence microscopy.
4.2 Materials
Lennox Luria-Bertani (LB) media was obtained from MP Biomedicals, Inc, and two
capsules were dissolved per 50 mL of double deionized water (ddH2O) and autoclaved prior to
use. E. coli (ATCC® 25922) and S. epidermidis (ATCC 14990) were obtained from American
Type Culture Collection (ATCC). The LIVE/DEAD

TM

BacLightTM Bacterial Viability Kit was

obtained from Thermo Fisher Scientific. 11-phosphonoundecanoic acid (96% purity), 11phosphonoundecylacrylate,
hydroxysuccinimide

12-mercaptododecylphosphonic

(NHS)

(98%),

acid

(95%

purity),

N-

N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide

hydrochloride (EDC), vancomycin hydrochloride (≥80%), and Dulbecco’s phosphate buffered
saline (PBS) were obtained from Sigma Aldrich and used as received. 3-maleimidopropionic acid
N-hydroxysuccinimide ester (99%) was supplied by Alfa Aesar. Spermine NONOate (≥98%) was
supplied by Cayman Chemical. KRSRC (≥98%) was synthesized by GenScript. Tetrahydrofuran,
Optima grade, obtained from Fisher Scientific was distilled over sodium and benzophenone prior
to use. Acetonitrile was also supplied by Fisher Scientific. Methanol was obtained from Duquesne
University and dried over 4A molecular sieves. Ethanol and 18 MΩ water were also obtained from
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Duquesne University. Titanium aluminum vanadium (Ti-6Al-4V), 0.52 mm thickness was
purchased from Goodfellow Inc. (Coraopolis, PA US).
4.3 Methods
4.3.1 Preparation of Titanium Aluminum Vanadium
Ti-6Al-4V was prepared by sanding with 150, 320, 400, and 600 grit sand paper. Substrates
were then cut into 1 cm by 1 cm coupons. These coupons were sonicated in acetone for 15 minutes
and then placed in boiling methanol for 15 minutes to remove any residue from the surface. Then,
substrates were removed and placed sanded-side-up on a petri dish in a 120°C oven overnight to
dry. After drying, substrates were stored in a glass vial until use.
4.3.2 Formation of Single Functionalized Ti-6Al-4V
4.3.2.1 Immobilization of Vancomycin (R1)
Ti-6Al-4V substrates were chilled at 4°C for 30 minutes, while a solution of 1 mM 12mercaptodocdecylphosphonic acid in tetrahydrofuran was warmed to 55°C. Substrates were then
sprayed with the warm phosphonic acid solution. This was repeated for three cycles. After the last
spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent
and overnight drying, substrates were ready for vancomycin immobilization.
A solution of 2 mg/mL vancomycin and 20 mM 3-maleimidopropionic acid Nhydroxysuccinimide ester was prepared in 50/50 (v/v) acetonitrile and water. The reaction
proceeded for one hour protected from light at room temperature. Then, substrates modified with
the thiol terminated SAM were placed modified-side-up in the vancomycin/linker solution for one
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hour, protected from light, under N2, at room temperature. After one hour, substrates were removed
and rinsed in reaction solvent for one minute prior to drying overnight under vacuum.
4.3.2.2 Immobilization of KRSR(C) (R2)
Acrylate terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates at 4°C
for 30 minutes, while a solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran was
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. This was
repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After
a 15-minute rinse in deposition solvent and overnight drying, substrates were ready for KRSR(C)
immobilization.
Ti-6Al-4V modified with acrylate terminated SAMs was placed sanded-side up in a
solution containing 1 mg/mL of KRSR(C) and 5 µL of triethylamine. The reaction was performed
over ice, protected from light, under N2 for four hours. After four hours, substrates were removed,
placed in water for one minute, and then dried overnight under vacuum.
4.3.2.3 Immobilization of Spermine NONOate (R3)
Carboxylic acid terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates
at 4°C for 30 minutes, while a solution of 1 mM 11-phosphonoundecanoic acid in methanol was
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. Substrates
were dried at room temperature for one minute. This was repeated for three cycles. After the last
spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent
and overnight drying, substrates were ready for spermine NONOate immobilization.
Substrates modified with a carboxylic terminated SAM were placed sanded-side-up in a
solution that was 20 mM in EDC and 50 mM in NHS in 2-propanol. The solution was allowed to
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react for 30 minutes at room temperature, protected from light, under N2. After 30 minutes,
substrates were removed and allowed to dry under vacuum for one hour. Substrates were then
placed in a 20 mM spermine NONOate solution prepared in a mixture of ethanol and water (4:1,
v/v). Then, substrates were rinsed in ethanol and water (4:1) for one minute, and then allowed to
dry under vacuum overnight.
4.3.3 Formation of Dual Functionalized Ti-6Al-4V
4.3.3.1 Immobilization of Vancomycin and KRSR(C) (R1 & R2)
Co-immobilization of both vancomycin and KRSR(C) to Ti-6Al-4V surfaces was first
accomplished by forming thiol and acrylate terminated SAMs on Ti-6Al-4V. Ti-6Al-4V was
pretreated at 4°C for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid
in tetrahydrofuran and a separate solution of 2 mM 11-phosphonoundecylacrylate in
tetrahydrofuran were warmed to 55°C. Substrates were then sprayed via aerosol deposition with
the warm phosphonic acid solutions; first with the thiol solution and then the acrylate. This was
repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After
a 15-minute rinse in deposition solvent, substrates were dried overnight prior to bioactive molecule
immobilization. Then, Ti-6Al-4V modified with acrylate and thiol terminated SAMs was used to
immobilize vancomycin (R1). Substrates were dried overnight and then KRSR(C) was
immobilized (R2).
4.3.3.2 Immobilization of KRSR(C) and Spermine NONOate (R2 & R3)
Ti-6Al-4V substrates were pretreated at 4°C for 30 minutes, while a solution of 1 mM 11phosphonoundecanoic

acid

in

methanol

and

a

separate

solution

of

2

mM

11-

phosphonoundecylacrylate in tetrahydrofuran were warmed to 55°C. Substrates were then sprayed
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with the warm phosphonic acid solutions; first with the acrylate solution and then the carboxylic
acid solution. Substrates were dried at room temperature for one minute. This was repeated for
three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After a 15-minute
rinse in deposition solvent and overnight drying, substrates were ready for bioactive molecule
immobilization.
Ti-6Al-4V modified with acrylate and carboxylic acid terminated SAMs were utilized to
immobilize KRSR(C) (R2). Substrates were dried overnight and spermine NONOate was
immobilized (R3). Spermine NONOate was immobilized last to avoid premature release of NO
during the long peptide immobilization.
4.3.3.3 Immobilization of Vancomycin and Spermine NONOate (R1 & R3)
Co-immobilization of both vancomycin and spermine NONOate was accomplished by
forming thiol and carboxylic terminated SAMs on Ti-6Al-4V. Substrates were pretreated at 4°C
for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran
and a separate solution of 1 mM 11-phosphonoundecanoic acid in methanol were warmed to 55°C.
Substrates were then sprayed with the warm phosphonic acid solutions; first with the thiol solution
and then the carboxylic acid solution. Substrates were dried at room temperature for one minute.
This was repeated for three cycles. After the last spray, substrates were dried in a 60°C oven
overnight. After a 15-minute rinse in deposition solvent and overnight drying, substrates were
ready for bioactive molecule immobilization.
Immobilization of both vancomycin and spermine NONOate to Ti-6Al-4V surfaces was
accomplished by using Ti-6Al-4V modified with thiol and carboxylic acid terminated SAMs to
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immobilize vancomycin (R1). Substrates were dried overnight and then spermine NONOate was
immobilized (R3). Spermine NONOate was linked last to prevent premature NO release.
4.3.4 Formation of Triple Functionalized Ti-6Al-4V
4.3.4.1 Immobilization of Vancomycin, KRSR(C), and Spermine NONOate (R1, R2, & R3)
Thiol, acrylate, and carboxylic acid terminated SAMs were formed on Ti-6Al-4V to serve
as linkers to immobilize the desired bioactive molecules. Substrates were pretreated at 4°C for 30
minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran, a
solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran, and a solution of 1 mM 11phosphonoundecanoic acid in methanol were warmed to 55°C. Substrates were then sprayed with
the warm phosphonic acid solutions; first with the thiol solution, then the acrylate solution, and
then with the carboxylic acid solution. Substrates were dried at room temperature for one minute.
After the spraying, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in
deposition solvent and overnight drying, substrates were ready for bioactive molecule
immobilization.
Ti-6Al-4V modified with the acrylate, carboxylic acid, and thiol terminated SAMs was
used to immobilize vancomycin (R1). After overnight drying, substrates were used to chemically
link KRSR(C) to the surface (R2). Finally, spermine NONOate was attached to the surface (R3).
4.3.5 Escherichia coli and Staphylococcus epidermidis Culture
4.3.5.1 Escherichia coli Culture
E. coli (ATCC® 25922) was frozen in vials of glycerol and stored at -80°C until use. A
culture was started by the addition of one inoculation loop of E. coli to 10 mL of LB media in a T-
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25 cm2 culture flask. The E. coli flask was incubated overnight under shaking conditions at 37°C
and diluted to an optical density at 600 nm (OD600) of 0.0125 through a twofold dilution before
beginning bacterial assays.
4.3.5.2 Staphylococcus epidermidis Culture
S. epidermidis (ATCC® 14990) was frozen in vials of glycerol and stored at -80°C until
use. A culture was started by the addition of one inoculation loop of S. epidermidis to 10 mL of
LB media in a T-25 cm2 culture flask. The S. epidermidis flask was incubated overnight under
shaking conditions at 37°C and diluted to an optical density at 600 nm (OD600) of 0.0125 through
a twofold dilution before beginning bacterial assays.
4.3.6 Bacterial Viability Determination using Fluorescence Microscopy
4.3.6.1 Bacterial Viability Assay
The viability of bacteria grown on functionalization Ti-6Al-4V surfaces was assessed by
diluting the resulting overnight bacterial culture of either E. coli or S. epidermidis to an OD600 of
0.0125 in 50/50 LB Media and PBS. PBS was incorporated to encourage release of the NO from
spermine NONOate functionalized substrates as it contains molecules capable of donating a proton
to spermine NONOate, triggering release.36 In each well of a 24-well plate, 800 µL of the
planktonic 0.0125 OD600 bacteria were added. Three wells each contained (i) bacteria +
unmodified Ti-6Al-4V, (ii) bacteria + SAM modified Ti-6Al-4V, or (iii) bacteria + bioactive
molecule functionalized Ti-6Al-4V. The well plate was placed on an incubator/shaker at 37°C for
1.5 hours while protected from light.
After this time, the well plate was removed and then bacteria were stained using the
LIVE/DEAD

TM

BacLightTM Bacterial Viability Kit. First, growth media was aspirated off, and
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then the substrates were washed twice with 0.5 mL of PBS to remove any traces of growth media.
The dye components were thawed and vortexed briefly. Then, 7.5 µL of component 1 and 7.5 µL
of component 2 of the stain kit were added to a centrifuge tube, followed by 5 mL of PBS. Then,
300 µL of the prepared stain were added to each well. The well plate was incubated, protected
from light, at 37°C for 15 minutes. The wells were then rinsed with 0.5 mL of PBS. Bacteria were
fixed by adding 0.5 mL of 50/50 glycerin/PBS (v/v). The kit utilizes mixtures of the SYTO®9
green-fluorescent nucleic acid stain and the red-fluorescent nucleic acid stain, propidium iodide.39
When used alone, the SYTO®9 stain generally labels all bacteria in a population, those with an
intact membrane and those with damaged membranes. In contrast, propidium iodide penetrates
only bacteria with damaged membranes, causing a reduction in the SYTO®9 stain fluorescence
when both dyes are present. With an appropriate mixture of the SYTO®9 and propidium iodide
stains, bacteria with an intact cell membrane stain fluorescent green, whereas bacteria with
damaged membranes stain fluorescent red (Figure 4.2).

SYTO®9

Propidium Iodide
Dead Cell

Viable Cell

SYTO®9

SYTO®9
Nucleus

Nucleus

SYTO®9

Figure 4.2: Staining of bacterial cells with the LIVE/DEAD TM BacLightTM Bacterial
Viability Kit where SYTO®9 generally labels all bacterial cells and propidium iodide
selectively stains dead cells, causing a reduction in fluorescence of SYTO®9.
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4.3.6.2 Bacteria Counting using Fluorescence Microscopy
A Zeiss Axioskop2 MAT materials microscope for imaging was used to image and count
fluorescently stained bacteria. Bacteria were imaged using 50x magnification and fluorescence
filters. Three areas on each substrate were imaged. The number of live and dead cells were counted
on nine images for each sample and control. The number of live adhered bacteria as well as the
percent viability were calculated. Both values were normalized to bacteria grown on unmodified
Ti-6Al-4V.
4.3.6.3 Statistics
Statistical analysis was performed using Origin 2019 software. Normality of obtained data
was determined using the Shapiro-Wilk test. Nonparametric methods including the Kruskal-Wallis
one-way analysis of variance were used to determine the averages and statistical significance of
collected data at the p<0.05 level of significance where applicable as data was not normally
distributed. Statistically analyzed data is presented as mean ± standard error (SE) or as standard
deviation (SD) where noted.
4.4 Results
4.4.1 S. epidermidis Adhesion and Viability
4.4.1.1 Single Functionalized Ti-6Al-4V
4.4.1.1.1 Vancomycin Functionalized Ti-6Al-4V
Adhesion and viability of S. epidermidis on vancomycin functionalized substrates was
assessed through fluorescence imaging of the bacteria (Figure 4.3). Vancomycin functionalized
substrates had statistically less live bacteria cells adhered when compared to the thiol terminated

122

SAM which was used as the linker, but the number of cells was not statistically different than
unmodified Ti-6Al-4V (Figure 4.4, Table 4.1). While the vancomycin and thiol linker did not
affect the bacterial adhesion, immobilized vancomycin was able to reduce bacterial viability by 64
± 27% (SD) (Figure 4.5, Table 4.2). While dead cells were observed on substrates modified with
thiol terminated SAMs, the thiol SAM was not statistically different than the unmodified Ti-6Al4V.

a)

b)

c)

Figure 4.3: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) thiol terminated
SAM modified Ti-6Al-4V c) vancomycin functionalized Ti-6Al-4V.
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Figure 4.4: S. epidermidis adhesion to vancomycin functionalized substrates and controls;
vancomycin did not affect bacteria adhesion. # = statistically different, * = statistically different
than control.
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Table 4.1: S. epidermidis adhesion to vancomycin functionalized substrates and controls.
Normalized Number of Live Cells ± SE
100 ± 16
181 ± 43
67 ±10

Substrate
Unmodified Ti-6Al-4V
Thiol terminated SAM on Ti-6Al-4V
Vancomycin functionalized Ti-6Al-4V
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Figure 4.5: S. epidermidis viability on vancomycin functionalized substrates and controls;
vancomycin exhibited a 64 ± 27% (SD) reduction in viability. # = statistically different, * =
statistically different than control.

Table 4.2: S. epidermidis viability on vancomycin functionalized substrates and controls.
Normalized Viability of Cells ± SE
100 ± 8
71 ± 7
36 ± 4

Substrate
Unmodified Ti-6Al-4V
Thiol terminated SAM on Ti-6Al-4V
Vancomycin functionalized Ti-6Al-4V
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4.4.1.1.2 Spermine NONOate Functionalized
Bacteria adhesion and viability were also examined on spermine NONOate functionalized
substrates (Figure 4.6). Spermine NONOate functionalized substrates exhibited statistically lower
adhesion compared to unmodified Ti-6Al-4V (Figure 4.7, Table 4.3). While lower adhesion was
observed, immobilized spermine NONOate did not affect the bacterial viability (Figure 4.8, Table
4.4).

a)

b)

c)

Figure 4.6: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) carboxylic acid
terminated SAM modified Ti-6Al-4V c) spermine NONOate functionalized Ti-6Al-4V.
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Figure 4.7: S. epidermidis adhesion to spermine NONOate functionalized substrates and
controls; spermine NONOate decreased bacteria adhesion. # = statistically different, * =
statistically different than control.
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Table 4.3: S. epidermidis adhesion to spermine NONOate functionalized substrates and
controls.
Substrate
Unmodified Ti-6Al-4V
Carboxylic acid terminated SAM on Ti-6Al-4V
Spermine NONOate functionalized Ti-6Al-4V

Normalized Number of Live Cells ± SE
100 ± 24
36 ± 7
23 ± 4

Normalized Percent Viability
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Figure 4.8: S. epidermidis viability on spermine NONOate functionalized substrates and
controls; spermine NONOate exhibited no reduction in viability. # = statistically different, * =
statistically different than control.

Table 4.4: S. epidermidis viability on spermine NONOate functionalized substrates and
controls.
Substrate
Unmodified Ti-6Al-4V
Carboxylic acid terminated SAM on Ti-6Al-4V
Spermine NONOate functionalized Ti-6Al-4V
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Normalized Viability of Cells ± SE
100 ± 1
96 ± 1
94 ± 2

4.4.1.2 Dual Functionalized Ti-6Al-4V
4.4.1.2.1 Vancomycin and KRSR(C) Dual Functionalized
S. epidermidis adhesion to and viability on dual functionalized substrates was also
examined by imaging the bacteria (Figure 4.9). When vancomycin was co-immobilized with the
cell adhesion peptide KRSR(C), there was no statistical difference between the number of live
bacteria cells adhered when compared to the thiol and acrylate SAMs or the control (Figure 4.10,
Table 4.5) as assayed by fluorescence microscopy. Vancomycin and KRSR(C) substrates were
able to decrease S. epidermidis viability by 36 ± 28% (SD) compared to viability on unmodified
Ti-6Al-4V (Figure 4.11, Table 4.6). The reduction in viability was less than that observed for
vancomycin immobilized alone (64 ±27% (SD)). Substrates functionalized with the bioactive
molecules also exhibited statistically lower bacterial viability than that observed on thiol and
acrylate terminated SAMs.
a)

c)

b)

Figure 4.9: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) thiol terminated
and acrylate terminated SAM modified Ti-6Al-4V c) vancomycin and KRSR(C) functionalized
Ti-6Al-4V.

Table 4.5: S. epidermidis adhesion to vancomycin and KRSR(C) dual functionalized substrates
and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol & acrylate terminated SAMs on Ti-6Al-4V
Vancomycin & KRSR(C) functionalized Ti-6Al-4V
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Normalized Number of Live Cells ± SE
100 ± 19
103 ± 14
74 ± 29

Normalized Number of Live Cells
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Figure 4.10: S. epidermidis adhesion to vancomycin and KRSR(C) dual functionalized
substrates and controls; vancomycin co-immobilized with KRSR(C) did not affect bacteria
adhesion. # = statistically different, * = statistically different than control.
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Figure 4.11: S. epidermidis viability on vancomycin and KRSR(C) dual functionalized
substrates and controls; vancomycin and KRSR(C) co-immobilized decreased bacteria viability
by 36 ± 28% (SD). # = statistically different, * = statistically different than controls.
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Table 4.6: S. epidermidis viability on vancomycin and KRSR(C) dual functionalized substrates
and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol & acrylate terminated SAMs on Ti-6Al-4V
Vancomycin & KRSR(C) functionalized Ti-6Al-4V

Normalized Viability of Cells ± SE
100 ± 1
93 ± 6
64 ± 9

4.4.1.2.2 Vancomycin and Spermine NONOate Dual Functionalized
S. epidermidis was imaged on vancomycin and spermine functionalized substrates using
fluorescence microscopy (Figure 4.12). Substrates with co-immobilized vancomycin and
spermine NONOate did not have a statistically different number of live bacterial cells adhered
compared to unmodified Ti-6Al-4V (Figure 4.13, Table 4.7). The viability of S. epidermidis
grown on vancomycin and spermine NONOate substrates was not statistically different than the
control, but it was statistically different than viability for cells grown on thiol and carboxylic acid
SAM modified Ti-6Al-4V (Figure 4.14, Table 4.8).
a)

b)

c)

Figure 4.12: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) thiol terminated
and carboxylic acid terminated SAM modified Ti-6Al-4V c) vancomycin and spermine
NONOate functionalized Ti-6Al-4V.
Table 4.7: S. epidermidis adhesion to vancomycin and spermine NONOate dual functionalized
substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol & carboxylic acid terminated SAMs on Ti-6Al-4V
Vancomycin & spermine NONOate functionalized Ti-6Al-4V

129

Normalized Number of Live Cells ± SE
100 ± 18
143 ± 22
105 ± 35
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Figure 4.13: S. epidermidis adhesion to vancomycin and spermine NONOate dual
functionalized substrates and controls; vancomycin co-immobilized with spermine NONOate
did not affect bacteria adhesion. # = statistically different, * = statistically different than control.
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Figure 4.14: S. epidermidis viability on vancomycin and spermine NONOate dual
functionalized substrates and controls; vancomycin co-immobilized with spermine NONOate
did not affect bacteria viability. # = statistically different, * = statistically different than control.
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Table 4.8: S. epidermidis viability on vancomycin and spermine NONOate dual functionalized
substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol & carboxylic acid terminated SAMs on Ti-6Al-4V
Vancomycin & spermine NONOate functionalized Ti-6Al-4V

Normalized Viability of Cells ± SE
100 ± 9
112 ± 5
77 ± 8

4.4.1.3 Triple Functionalized Ti-6Al-4V
S. epidermidis adhesion to and viability on triple functionalized surfaces was examined
through fluorescence microscopy (Figure 4.15). Here, the thiol, carboxylic, and acrylate
terminated SAMs on the surface were able to prevent bacteria adhesion, when compared to
unmodified and functionalized Ti-6Al-4V (Table 4.9, Figure 4.16). These SAMs in combination
were able to prevent the adhesion of S. epidermidis. Bacteria that were adhered on these surfaces
exhibited statistically comparable viability to unmodified Ti-6Al-4V and Ti-6Al-4V
functionalized with all three bioactive molecules (Figure 4.17, Table 4.10).
a)

b)

c)

Figure 4.15: Fluorescent images of S. epidermidis on a) Ti-6Al-4V control b) thiol terminated,
acrylate terminated, and carboxylic acid terminated SAM modified Ti-6Al-4V c) vancomycin,
KRSR(C), and spermine NONOate triple functionalized Ti-6Al-4V.
Table 4.9: S. epidermidis adhesion to vancomycin, KRSR(C), and spermine NONOate triple
functionalized substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol, acrylate, & carboxylic acid terminated SAMs on Ti-6Al-4V
Vancomycin, KRSR(C), & spermine NONOate functionalized Ti-6Al-4V
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Normalized Number of Live Cells ±
SE
100 ± 9
60 ± 13
72 ± 11

Normalized Number of Live Cells

140
120
100

*

80
60
40
20
0
Unmodified

Triple SAM

Triple Functionalized

Substrate

Figure 4.16: S. epidermidis adhesion to vancomycin, KRSR(C), and spermine NONOate triple
functionalized substrates and controls; functionalization did not affect bacteria adhesion. # =
statistically different, * = statistically different than control.
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Figure 4.17: S. epidermidis viability on vancomycin, KRSR(C), and spermine NONOate triple
functionalized substrates and controls; functionalization did not affect bacteria viability. # =
statistically different, * = statistically different than control.
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Table 4.10: S. epidermidis viability on vancomycin, KRSR(C), and spermine NONOate triple
functionalized substrates and controls.
Normalized Viability of Cells ± SE
100 ± 2
96 ± 3
93 ± 4

Substrate
Unmodified Ti-6Al-4V
Thiol, acrylate, & carboxylic acid terminated SAMs on Ti-6Al-4V
Vancomycin, KRSR(C), & spermine NONOate functionalized Ti-6Al-4V

4.4.2 E. coli Adhesion and Viability
4.4.2.1 Single Functionalized Ti-6Al-4V
4.4.2.1.1 Vancomycin Functionalized
Adhesion and viability of E. coli on single functionalized substrates was assessed through
fluorescence imaging of the bacteria after 1.5 hours (Figure 4.18). Vancomycin functionalized
substrates had statistically less live bacteria cells adhered when compared to the thiol terminated
SAM as well as unmodified Ti-6Al-4V (Table 4.11, Figure 4.19). Immobilized vancomycin also
did not affect E. coli viability (Figure 4.20, Table 4.12).
a)

b)

c)

Figure 4.18: Fluorescent images of E. coli on a) Ti-6Al-4V control b) thiol terminated SAM
modified Ti-6Al-4V c) vancomycin functionalized Ti-6Al-4V.

Table 4.11: E. coli adhesion to vancomycin functionalized substrates and controls.
Normalized Number of Live Cells ± SE
100 ± 23
54 ± 7
41 ±9

Substrate
Unmodified Ti-6Al-4V
Thiol terminated SAM on Ti-6Al-4V
Vancomycin functionalized Ti-6Al-4V
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Figure 4.19: E. coli adhesion to vancomycin functionalized substrates and controls;
vancomycin reduced bacteria adhesion. # = statistically different, * = statistically different than
control.
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Figure 4.20: E. coli viability on vancomycin functionalized substrates and controls;
vancomycin exhibited no reduction in bacteria viability. # = statistically different, * =
statistically different than control.
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Table 4.12: E. coli viability on vancomycin functionalized substrates and controls.
Normalized Viability of Cells ± SE
100 ± 0
100 ± 0
100 ± 0

Substrate
Unmodified Ti-6Al-4V
Thiol terminated SAM on Ti-6Al-4V
Vancomycin functionalized Ti-6Al-4V

4.4.2.1.2 Spermine NONOate Functionalized
E. coli bacteria were imaged on spermine NONOate functionalized substrates (Figure
4.21). Spermine NONOate functionalized substrates had statistically lower E. coli adhesion when
compared to unmodified Ti-6Al-4V and carboxylic acid SAM modified Ti-6Al-4V (Table 4.13,
Figure 4.22). Immobilized spermine NONOate decreased E. coli viability by 27 ± 20% (SD) when
compared to unmodified Ti-6Al-4V control (Figure 4.23, Table 4.14). Also, there was statistically
less bacteria adhered to the functionalized Ti-6Al-4V in comparison to the carboxylic terminated
SAM.
a)

b)

c)

Figure 4.21: Fluorescent images of E. coli on a) Ti-6Al-4V control b) carboxylic acid
terminated SAM modified Ti-6Al-4V c) spermine NONOate functionalized Ti-6Al-4V.

Table 4.13: E. coli adhesion to spermine NONOate functionalized substrates and controls.

Substrate
Unmodified Ti-6Al-4V
Carboxylic acid terminated SAM on Ti-6Al-4V
Spermine NONOate functionalized Ti-6Al-4V
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Normalized Number of Live Cells ± SE
100 ± 9
118 ± 39
29 ± 21
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Figure 4.22: E. coli adhesion to spermine NONOate functionalized substrates and controls;
spermine NONOate decreased bacteria adhesion. # = statistically different, * = statistically
different than control.
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Figure 4.23: E. coli viability on spermine NONOate functionalized substrates and controls;
spermine NONOate exhibited a 27 ± 20% (SD) reduction in viability. # = statistically different,
* = statistically different than control.
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Table 4.14: E. coli viability on spermine NONOate functionalized substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Carboxylic acid terminated SAM on Ti-6Al-4V
Spermine NONOate functionalized Ti-6Al-4V

Normalized Viability of Cells ± SE
100 ± 0
100 ± 0
73 ± 7

4.4.2.2 Dual Functionalized Ti-6Al-4V
4.4.2.2.1 Vancomycin and Spermine NONOate Dual Functionalized
E. coli were imaged on the functionalized Ti-6Al-4V surface after a 1.5 hour incubation
(Figure 4.24). Co-immobilization of vancomycin and spermine NONOate on Ti-6-Al-4V
generated surfaces that were able to resist E. coli attachment (Table 4.15, Figure 4.25). These
surfaces also showed statistically less bacterial adhesion than the thiol and carboxylic acid
terminated SAMs used as linkers. While preventing bacterial adhesion, these surfaces showed no
antimicrobial properties against E. coli (Figure 4.26, Table 4.16).

a)

b)

c)

Figure 4.24: Fluorescent images of E. coli on a) Ti-6Al-4V control b) thiol terminated and
carboxylic acid terminated SAM modified Ti-6Al-4V c) vancomycin and spermine NONOate
functionalized Ti-6Al-4V.

Table 4.15: E. coli adhesion to vancomycin and spermine NONOate dual functionalized
substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol & carboxylic acid terminated SAMs on Ti-6Al-4V
Vancomycin & spermine NONOate functionalized Ti-6Al-4V
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Normalized Number of Live Cells ± SE
100 ± 14
114 ± 12
39 ± 5
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Figure 4.25: E. coli adhesion to vancomycin and spermine NONOate dual functionalized
substrates and controls; vancomycin co-immobilized with spermine NONOate reduced bacteria
adhesion. # = statistically different, * = statistically different than control.
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Figure 4.26: E. coli viability on vancomycin and spermine NONOate dual functionalized
substrates and controls; vancomycin co-immobilized with spermine NONOate did not affect
bacteria viability. # = statistically different, * = statistically different than control.
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Table 4.16: E. coli viability on vancomycin and spermine NONOate dual functionalized
substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol & carboxylic acid terminated SAMs on Ti-6Al-4V
Vancomycin & spermine NONOate functionalized Ti-6Al-4V

Normalized Viability of Cells ± SE
100 ± 0
97 ± 1
99 ± 1

4.4.2.2.2 Spermine NONOate and KRSR(C) Dual Functionalized
The viability and adhesion of E. coli on spermine NONOate and KRSR(C) dual
functionalized substrates was determined by imaging the bacteria (Figure 4.27). Substrates that
were functionalized with KRSR(C) and spermine NONOate were unable to affect bacterial
adhesion (Table 4.17, Figure 4.28). The carboxylic acid and acrylate terminated SAM linkers
were able to retard adhesion of E. coli. Neither the SAM linkers or the KRSR(C) and spermine
NONOate dual functionalized substrates affected E. coli viability (Figure 4.29, Table 4.18).
a)

b)

c)

Figure 4.27: Fluorescent images of E. coli on a) Ti-6Al-4V control b) acrylate terminated and
carboxylic acid terminated SAM modified Ti-6Al-4V c) KRSR(C) and spermine NONOate
functionalized Ti-6Al-4V.
Table 4.17: E. coli adhesion to KRSR(C) and spermine NONOate dual functionalized
substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Acrylate & carboxylic acid terminated SAMs on Ti-6Al-4V
KRSR(C) & spermine NONOate functionalized Ti-6Al-4V
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Normalized Number of Live Cells ± SE
100 ± 6
70 ± 6
87 ± 11
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Figure 4.28: E. coli adhesion to KRSR(C) and spermine NONOate dual functionalized
substrates and controls; spermine NONOate co-immobilized with KRSR(c) did not reduced
bacteria adhesion. # = statistically different, * = statistically different than control.
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Figure 4.29: E. coli viability on KRSR(C) and spermine NONOate dual functionalized
substrates and controls; spermine NONOate co-immobilized with KRSR(C) did not affect
bacteria viability. # = statistically different, * = statistically different than control.
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Table 4.18: E. coli viability on KRSR(C) and spermine NONOate dual functionalized
substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Acrylate & carboxylic acid terminated SAMs on Ti-6Al-4V
KRSR(C) & spermine NONOate functionalized Ti-6Al-4V

Normalized Viability of Cells ± SE
100 ± 0
100 ± 0
100 ± 0

4.4.2.3 Triple Functionalized Ti-6Al-4V
The adhesion and viability of E. coli to and on substrates functionalized with vancomycin,
KRSR(C), and spermine NONOate were examined (Figure 4.30). The SAM linkers used for the
attachments of the bioactive molecules showed less bacterial adhesion when compared to controls
(Table 4.19, Figure 4.31). The presentation of the different SAMs at the interface is interfering
with the bacteria’s ability to adhere. The anti-adhesive properties of spermine NONOate
previously observed in the single functionalization are absent here as functionalized Ti-6Al-4V
had statistically comparable bacteria adhesion to Ti-6Al-4V controls.
a)

b)

c)

Figure 4.30: Fluorescent images of E. coli on a) Ti-6Al-4V control b) thiol terminated, acrylate
terminated, and carboxylic acid terminated SAM modified Ti-6Al-4V c) vancomycin,
KRSR(C), and spermine NONOate triple functionalized Ti-6Al-4V.
Table 4.19: E. coli adhesion to vancomycin, KRSR(C), and spermine NONOate triple
functionalized substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol, acrylate, & carboxylic acid terminated SAMs on Ti-6Al-4V
Vancomycin, KRSR(C), & spermine NONOate functionalized Ti-6Al-4V
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Normalized Number of Live Cells ±
SE
100 ± 4
61 ± 5
80 ± 6
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Figure 4.31: E. coli adhesion to vancomycin, KRSR(C), and spermine NONOate triple
functionalized substrates and controls; functionalization did not affect bacteria adhesion. # =
statistically different, * = statistically different than control.
The SAM linker was able to prevent bacterial adhesion, but its presence on the surface did
not negatively affect the bacteria viability, since viability was statistically comparable to bacteria
grown on unmodified Ti-6Al-4V (Table 4.20, Figure 4.32). While vancomycin previously did not
show activity against E. coli, spermine NONOate demonstrated limited antimicrobial effects.
When immobilized with vancomycin and KRSR(C), spermine NONOate did not affect bacteria
viability.
Table 4.20: E. coli viability on vancomycin, KRSR(C), and spermine NONOate triple
functionalized substrates and controls.
Substrate
Unmodified Ti-6Al-4V
Thiol, acrylate, & carboxylic acid terminated SAMs on Ti-6Al-4V
Vancomycin, KRSR(C), & spermine NONOate functionalized Ti-6Al-4V
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Normalized Viability of Cells ± SE
100 ± 6
113 ± 1
109 ± 1
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Figure 4.32: E. coli viability on vancomycin, KRSR(C), and spermine NONOate triple
functionalized substrates and controls; functionalization did not affect bacteria viability. # =
statistically different, * = statistically different than control.
4.5 Discussion
The antimicrobial properties of single, dual, and triple functionalized surfaces were
examined. These surfaces were challenged with either E. coli or S. epidermidis. Initially, the
adhesion and viability of bacteria on single functionalized substrates was examined. This was
undertaken to characterize what effect the attached molecules vancomycin or spermine NONOate,
as well as the SAMs used to covalently link them, had on these properties.
Vancomycin is an antibiotic with primary activity against Gram positive species.11, 14, 17 It
was therefore expected that substrates functionalized with this antibiotic would show efficacy
against S. epidermidis.14-15,

17-19, 40

Vancomycin functionalization of Ti-6Al-4V decreased the

viability of S. epidermidis by 64 ± 27% (SD) (Figure 4.5). This illustrates that covalently
immobilizing vancomycin did not render it ineffective against the bacteria. This result is consistent
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with a previous study where stainless steel was functionalized with vancomycin.10 In this work,
vancomycin was able to reduce the biomass of Gram positive bacteria biofilms for extended
periods of time.10
Substrates functionalized with vancomycin had no appreciable effect on the viability of E.
coli (Figure 4.20). Vancomycin has very selective effectiveness against Gram negative species,
of which E. coli is not included.13, 15, 19, 22, 41 Immobilized vancomycin did inhibit bacterial adhesion
to the functionalized surface. Nonspecific adhesion occurs through molecular chemistry processes
such as van der Waals, Lewis acid/base, electrostatic, and hydrophobic forces.42-43 Very generally,
hydrophilic surfaces can inhibit bacterial adhesion, although this is specific to bacterial species
and surface.44-46 The hydrophilic nature of the vancomycin functionalized Ti-6Al-4V is one
explanation for the reduction in E. coli adhesion. One specific method of adhesion for E. coli
involves their pili.47 Coatings targeting this mechanism utilize sugar-based inhibitors to prevent
bacterial attachment. Vancomycin is a glycopeptide, with a sugar moiety. Therefore, this, in
conjunction with the hydrophilic nature of the surface, may be the cause of the observed reduction
in bacterial adhesion.
The other molecule of interest was the spermine NONOate, a nitric oxide releasing
molecule. Nitric oxide has been indicated as an antimicrobial capable of dispersing bacterial
biofilms.29, 48-53 Substrates functionalized with spermine NONOate did not affect S. epidermidis
viability (Figure 4.8). However, immobilized spermine NONOate was able to decrease the
viability of E. coli on functionalized Ti-6Al-4V by 27 ± 20% (SD) (Figure 4.23). The preferential
susceptibility of Gram negative species over Gram positive species to nitric oxide has been
observed in other studies.29, 36 Species of Gram positive bacteria are capable of producing their
own nanomolar (nM) amounts of nitric oxide through bacterial nitric oxide synthase as a defense
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mechanism to oxidative stress, antimicrobial treatments, and other bacterial species.

54-55

The

concentrations of nitric oxide released from spermine NONOate functionalized substrates are in
the nanomolar range. This concentration is comparable to that released by the bacteria naturally.
Therefore, these organisms are capable of tolerating the amount of nitric oxide released without
any ill effects to viability.
While selectivity was observed in spermine NONOate’s ability to affect bacterial viability,
the nitric oxide releasing molecule prevented the adhesion of both S. epidermidis and E. coli to
functionalized Ti-6Al-4V (Figure 4.7, Figure 4.22). Bacterial adhesion reduction on nitric oxide
functionalized surfaces has been reported in the literature for several species, including
Pseudomonas aeruginosa and Staphylococcus aureus.

48, 52

While each bacterial species has

unique methods of adhesion, it is thought that NO prevents bacterial adhesion through reactive
intermediates such as N2O3 and N2O4, which are able to destroy bacterial adhesin proteins which
mediate surface adhesion.51
Next, substrates in which two bioactive molecules were co-immobilized were subjected to
challenges with either S. epidermidis or E. coli. Substrates were challenged with the bacterial
species that the immobilized molecules had showed efficacy against when immobilized solely.
This was undertaken to determine if co-immobilization altered previously observed adhesive and
viability properties.
When vancomycin was co-immobilized with an osteoblast cell adhesion peptide,
KRSR(C), the viability of S. epidermidis was reduced by 36 ± 28% (SD) (Figure 4.11). This
reduction was lower than that observed for substrates solely functionalized with vancomycin,
which showed a 64 ± 27% (SD) reduction in viability. This decrease in effectiveness may be due
to lower loading of vancomycin on the surface due to the presence of KRSR(C). Interactions
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between vancomycin and KRSR(C) also can affect vancomycin’s functionality.23 Hydrogen
bonding interactions between KRSR(C) and vancomycin would negatively affect vancomycin’s
functionality, as hydrogen bonding is necessary for its mechanism of action against Gram positive
bacteria.11, 21, 56-57
A reduction in efficacy was also observed for spermine NONOate when it was coimmobilized with KRSR(C). These substrates were not able to resist E. coli attachment or impact
bacterial viability (Figure 4.28, Figure 4.29). Nitric oxide studies on these substrates illustrated
that the amount of nitric oxide released from this dual functionalized surface was higher than that
for surfaces only functionalized with spermine NONOate. Therefore, the presence of the KRSR(C)
is affecting bacterial adhesion. Bacteria often recognize peptide sequences expressed by
mammalian cells, it is possible that the bacteria is attracted to the KRSR(C) sequence.58 In this
work, bacteria adhesion to KRSR(C) immobilized alone was not examined, but this should be
explored further to determine if bacteria preferentially adhere to these surfaces.
The combination of vancomycin and spermine NONOate on dual functionalized substrates
was able to resist E. coli adhesion (Figure 4.25) but not S. epidermidis adhesion (Figure 4.13).
Surfaces single functionalized with either vancomycin or spermine NONOate were also able to
resist E. coli attachment. Their co-immobilization does not affect the method of action for either
in preventing the Gram negative’s species adhesion. Vancomycin was unable to significantly affect
the adhesion of S. epidermidis on single functionalized substrates. Adhesion of S. epidermidis onto
the dual functionalized substrates possessed a large standard error. The discrepancy in Gram
positive bacterial adhesion between the single and dual functionalized substrates with spermine
NONOate may be attributable to variabilities with surface coverage of the bioactive molecules.
Vancomycin and spermine NONOate dual functionalized substrates did not significantly affect
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bacterial viability for either species. While vancomycin co-immobilized with KRSR(C) was able
to affect S. epidermidis viability, in combination with spermine, no such effect was observed.
Gram positive species of bacteria can produce their own nitric oxide and will do so to combat
stress to antibiotics. The nanomolar concentrations at the interface are comparable to those
naturally produced by the bacteria.54-55 Therefore, the presence of the nitric oxide may be inducing
a change within the bacteria which renders them less susceptible to the vancomycin. This
hypothesis would need to be examined further however. It is also possible that the vancomycin
concentration on the surface is not sufficient to decrease viability. Additionally, interactions
between the spermine NONOate molecule and vancomycin, such as hydrogen bonding, would
impact vancomycin’s ability to interact with the D-alanine residues within the peptidoglycan wall.
Interactions with these residues are critical for vancomycin’s mode of action.11
Finally, the adhesion and viability of bacteria species was examined on triple
functionalized surfaces that contained vancomycin, KRSR(C), and spermine NONOate. The
presence of these three molecules at the interface did not affect bacterial adhesion or viability.
Surface coverage of the antimicrobial agents may not have been sufficient to prevent attachment
or reduce viability. Interactions discussed previously between the bioactive molecules may also
contributed to these observations.
The SAM linkers that were used to covalently attach the three molecules did exhibit an
effect on the bacteria adhesion but not viability (Figure 4.16, Figure 4.31). Coatings designed
specifically to resist bacterial adhesion by altering the physicochemical properties of the substrate
so that conditioning films do not form and/or bacteria-substrate interactions are not favored are an
area of interest to prevent bacteria colonization.45,

59

These “passive” coatings include

poly(ethylene glycol), poly(ethylene oxide) brushes, hydrophilic polyurethanes, and others.10, 45-46,
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60-61

The effectiveness of passive coatings for reducing bacteria adhesion is limited and varies

drastically depending on bacterial species.9 Within these coatings, surface charging is an important
factor for controlling bacterial adhesion.43 Alteration of surface charging, with an overall neutral
charge has been shown to be effective.

43

The presentation of the charged groups of carboxylic

acid and thiol of the SAM linkers at the interface may be responsible for the reduction in adhesion.
The distribution of these molecules at the surface was not assessed, therefore this cannot be
concluded conclusively.
4.6 Conclusions
The ability of functionalized Ti-6Al-4V to prevent bacterial adhesion and reduce bacterial
viability was examined. Immobilized vancomycin and co-immobilized vancomycin with
KRSR(C) were able to reduce S. epidermidis viability, with a decrease in effectiveness noted in
when vancomycin was co-immobilized with KRSR(C). Spermine NONOate was able to reduce
bacterial adhesion for both species while also inhibiting E. coli viability on single functionalized
substrates. When vancomycin was co-immobilized with spermine NONOate, no antimicrobial
properties were observed. Ti-6Al-4V functionalized with vancomycin, KRSR(C), and spermine
NONOate were also unable to inhibit bacteria viability. The SAM linkers utilized to immobilize
vancomycin, KRSR(C), and spermine NONOate in combination decreased adhesion of both
species examined.
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Chapter 5: Osteoblast Adhesion and Viability on Functionalized Titanium Aluminum
Vanadium
5.1 Introduction
Successful osseointegration is critical for orthopedic implant stability and longevity.1-7
Osseointegration is achieved through boney in-growth via the deposition of new bone by
osteoblasts.8-9 Unfortunately, Ti-6Al-4V is not osteoinductive or osteoconductive.10 This leads to
loosening of these implants, which contributes to implant failure. In order to combat this, the Ti6Al-4V surface can be functionalized with bioactive molecules to encourage osteoblast adhesion.1,
11-14

In this work, Ti-6Al-4V was functionalized with a cell adhesion peptide, KRSR to facilitate
osteoblast adhesion to the surface. KRSR was synthesized with a sacrificial cysteine whose free
thiol was used to form a C-S bond between an acrylate terminated SAM and the peptide. This
peptide was immobilized in conjunction with antimicrobial agents, spermine NONOate and
vancomycin using SAMs as chemical linkers. Covalent attachment of these molecules should not
negatively affect osteoblast adhesion or viability on the Ti-6Al-4V surface. Here, osteoblast
adhesion and viability on bioactive molecule functionalized and SAM modified substrates were
assessed using fluorescence microscopy.
5.2 Materials
Normal human osteoblasts (NHOsts) and osteoblast subculturing reagents (HEPES
buffered saline, Trypsin/EDTA, and Trypsin neutralizing solution) were purchased from LONZA.
Osteoblast basal medium and growth supplements were purchased from Cell Applications. The
LIVE/DEADTM Viability/Cytoxicity Kit for mammalian cells was purchase from Thermo Fisher
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Scientific. 11-phosphonoundecanoic acid (96% purity), 11-phosphonoundecylacrylate, 12mercaptododecylphosphonic acid (95% purity), N-hydroxysuccinimide (NHS) (98%), N-(3dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), vancomycin hydrochloride
(≥80%), trypan blue 0.4%, and Dulbecco’s phosphate buffered saline (PBS) were obtained from
Sigma Aldrich and used as received. 3-maleimidopropionic acid N-hydroxysuccinimide ester
(99%) was supplied by Alfa Aesar. Spermine NONOate (≥98%) was supplied by Cayman
Chemical. KRSRC (≥98%) was synthesized by GenScript. Tetrahydrofuran, Optima grade,
obtained from Fisher Scientific was distilled over sodium and benzophenone prior to use.
Acetonitrile was also supplied by Fisher Scientific. Methanol was obtained from Duquesne
University and dried over 4A molecular sieves. Ethanol and 18 MΩ water were also obtained from
Duquesne University. Titanium aluminum vanadium (Ti-6Al-4V), 0.52 mm thickness was
purchased from Goodfellow Inc. (Coraopolis, PA US).
5.3 Methods
5.3.1 Preparation of Titanium Aluminum Vanadium
Ti-6Al-4V was prepared by sanding with 150, 320, 400, and 600 grit sand paper. Substrates
were then cut into 1 cm by 1 cm coupons. These coupons were sonicated in acetone for 15 minutes
and then placed in boiling methanol for 15 minutes to remove any residue from the surface. Then,
substrates were removed and placed sanded-side-up on a petri dish in a 120°C oven overnight to
dry. After drying, substrates were stored in a glass vial until use.
5.3.2 Formation of Single Functionalized Ti-6Al-4V
5.3.2.1 Immobilization of Vancomycin (R1)
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Ti-6Al-4V substrates were chilled at 4°C for 30 minutes, while a solution of 1 mM 12mercaptodocdecylphosphonic acid in tetrahydrofuran was warmed to 55°C. Substrates were then
sprayed with the warm phosphonic acid solution. This was repeated for three cycles. After the last
spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent
and overnight drying, substrates were ready for vancomycin immobilization.
A solution of 2 mg/mL vancomycin and 20 mM 3-maleimidopropionic acid Nhydroxysuccinimide ester was prepared in 50/50 (v/v) acetonitrile and water. The reaction
proceeded for one hour protected from light at room temperature. Then, substrates modified with
the thiol terminated SAM were placed modified-side-up in the vancomycin/linker solution for one
hour, protected from light, under N2, at room temperature. After one hour, substrates were removed
and rinsed in reaction solvent for one minute prior to drying overnight under vacuum.
5.3.2.2 Immobilization of KRSR(C) (R2)
Acrylate terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates at 4°C
for 30 minutes, while a solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran was
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. This was
repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After
a 15-minute rinse in deposition solvent and overnight drying, substrates were ready for KRSR(C)
immobilization.
Ti-6Al-4V modified with acrylate terminated SAMs was placed sanded-side up in a
solution containing 1 mg/mL of KRSR(C) and 5 µL of triethylamine. The reaction was performed
over ice, protected from light, under N2 for four hours. After four hours, substrates were removed,
placed in water for one minute, and then dried overnight under vacuum.
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5.3.2.3 Immobilization of Spermine NONOate (R3)
Carboxylic acid terminated SAMs were formed on Ti-6Al-4V by pretreating the substrates
at 4°C for 30 minutes, while a solution of 1 mM 11-phosphonoundecanoic acid in methanol was
warmed to 55°C. Substrates were then sprayed with the warm phosphonic acid solution. Substrates
were dried at room temperature for one minute. This was repeated for three cycles. After the last
spray, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in deposition solvent
and overnight drying, substrates were ready for spermine NONOate immobilization.
Substrates modified with a carboxylic terminated SAM were placed sanded-side-up in a
solution that was 20 mM in EDC and 50 mM in NHS in 2-propanol. The solution was allowed to
react for 30 minutes at room temperature, protected from light, under N2. After 30 minutes,
substrates were removed and allowed to dry under vacuum for one hour. Substrates were then
placed in a 20 mM spermine NONOate solution prepared in a mixture of ethanol and water (4:1,
v/v). Then, substrates were rinsed in ethanol and water (4:1) for one minute, and then allowed to
dry under vacuum overnight.
5.3.3 Formation of Dual Functionalized Ti-6Al-4V
5.3.3.1 Immobilization of Vancomycin and KRSR(C) (R1 & R2)
Co-immobilization of both vancomycin and KRSR(C) to Ti-6Al-4V surfaces was first
accomplished by forming thiol and acrylate terminated SAMs on Ti-6Al-4V. Ti-6Al-4V was
pretreated at 4°C for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid
in tetrahydrofuran and a separate solution of 2 mM 11-phosphonoundecylacrylate in
tetrahydrofuran were warmed to 55°C. Substrates were then sprayed via aerosol deposition with
the warm phosphonic acid solutions; first with the thiol solution and then the acrylate. This was
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repeated for three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After
a 15-minute rinse in deposition solvent, substrates were dried overnight prior to bioactive molecule
immobilization. Then, Ti-6Al-4V modified with acrylate and thiol terminated SAMs was used to
immobilize vancomycin (R1). Substrates were dried overnight and then KRSR(C) was
immobilized (R2).
5.3.3.2 Immobilization of KRSR(C) and Spermine NONOate (R2 & R3)
Ti-6Al-4V substrates were pretreated at 4°C for 30 minutes, while a solution of 1 mM 11phosphonoundecanoic

acid
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and
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solution

of

2

mM

11-

phosphonoundecylacrylate in tetrahydrofuran were warmed to 55°C. Substrates were then sprayed
with the warm phosphonic acid solutions; first with the acrylate solution and then the carboxylic
acid solution. Substrates were dried at room temperature for one minute. This was repeated for
three cycles. After the last spray, substrates were dried in a 60°C oven overnight. After a 15-minute
rinse in deposition solvent and overnight drying, substrates were ready for bioactive molecule
immobilization.
Ti-6Al-4V modified with acrylate and carboxylic acid terminated SAMs were utilized to
immobilize KRSR(C) (R2). Substrates were dried overnight and spermine NONOate was
immobilized (R3). Spermine NONOate was immobilized last to avoid premature release of NO
during the long peptide immobilization.
5.3.3.3 Immobilization of Vancomycin and Spermine NONOate (R1 & R3)
Co-immobilization of both vancomycin and spermine NONOate was accomplished by
forming thiol and carboxylic terminated SAMs on Ti-6Al-4V. Substrates were pretreated at 4°C
for 30 minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran
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and a separate solution of 1 mM 11-phosphonoundecanoic acid in methanol were warmed to 55°C.
Substrates were then sprayed with the warm phosphonic acid solutions; first with the thiol solution
and then the carboxylic acid solution. Substrates were dried at room temperature for one minute.
This was repeated for three cycles. After the last spray, substrates were dried in a 60°C oven
overnight. After a 15-minute rinse in deposition solvent and overnight drying, substrates were
ready for bioactive molecule immobilization.
Immobilization of both vancomycin and spermine NONOate to Ti-6Al-4V surfaces was
accomplished by using Ti-6Al-4V modified with thiol and carboxylic acid terminated SAMs to
immobilize vancomycin (R1). Substrates were dried overnight and then spermine NONOate was
immobilized (R3). Spermine NONOate was linked last to prevent premature NO release.
5.3.4 Formation of Triple Functionalized Ti-6Al-4V
5.3.4.1 Immobilization of Vancomycin, KRSR(C), and Spermine NONOate (R1, R2, & R3)
Thiol, acrylate, and carboxylic acid terminated SAMs were formed on Ti-6Al-4V to serve
as linkers to immobilize the desired bioactive molecules. Substrates were pretreated at 4°C for 30
minutes, while a solution of 1 mM 12-mercaptododecylphosphonic acid in tetrahydrofuran, a
solution of 2 mM 11-phosphonoundecylacrylate in tetrahydrofuran, and a solution of 1 mM 11phosphonoundecanoic acid in methanol were warmed to 55°C. Substrates were then sprayed with
the warm phosphonic acid solutions; first with the thiol solution, then the acrylate solution, and
then with the carboxylic acid solution. Substrates were dried at room temperature for one minute.
After the spraying, substrates were dried in a 60°C oven overnight. After a 15-minute rinse in
deposition solvent and overnight drying, substrates were ready for bioactive molecule
immobilization.
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Ti-6Al-4V modified with the acrylate, carboxylic acid, and thiol terminated SAMs was
used to immobilize vancomycin (R1). After overnight drying, substrates were used to chemically
link KRSR(C) to the surface (R2). Finally, spermine NONOate was attached to the surface (R3).
5.3.5 Osteoblast Cell Culture
Normal human osteoblasts (NHOsts) isolated from a 5-year-old female (LONZA) were
thawed from a -200˚C liquid N2 dewar and plated into T-75 cm2 tissue culture flasks at a seeding
density of 5,000 cells per 5 cm2 of flask surface area. Then, 15 mL of osteoblast basal medium
(OBM) were added. Tissue culture flasks were then placed into an incubator at 37˚ and 5% CO 2
for 24 hours, to allow live osteoblasts to adhere to the flask interior. After 24 hours, the OBM
media was replaced to remove any residual cryoprotectant. Then, cell attachment and division
were monitored daily until attached cells achieved approximately 80% confluence. OBM was
changed every other day after initial seeding during the days until desired confluence was reached.
Once cells reached 80% confluence they were subcultured.
Osteoblasts were subcultured according to the protocol provided by LONZA. Briefly, 15
mL of HEPES was used to rinse the T-75 cm2 flask. This rinse was discarded. Then, 6 mL of
trypsin EDTA was introduced into the flask to detach cells. After several minutes and confirmation
that cells were detached, 12 mL of trypsin neutralizing solution were added. The cell suspension
was then centrifuged at 21,000 RPM for 5 minutes. The supernatant was aspirated off and cells
were resuspended in 2 mL of fresh media. In three microcentrifuge vials, 100 µL of trypan blue
was added with 100 µL of cell suspension. A hemocytometer was then used to count the number
of cells. Counting was performed in triplicate. Cells were then seeded into new T-75 cm2 flasks at
a density of 5,000 cells per 5 cm2 of surface area or used for the cell trial.
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5.3.5.1 Osteoblast Cell Trial
NHOsts isolated from a 5-year-old female were cultured to 80% confluence. Cells were
then detached from the flasks, as described above, and then diluted to 10,000 cells per mL of OBM.
Then, 1 mL of cell/media suspension was added to each well containing either (i) unmodified Ti6Al-4V, (ii) SAM modified Ti-6Al-4V, or (iii) functionalized Ti-6Al-4V. Samples and controls
were performed in triplicate. Substrates were rinsed in ethanol and allowed to dry in a sterile hood
prior to placement in the well plate. The well plate was then incubated at 37˚C with 5% CO2.
Media in the wells was replaced each day. Adhesion and viability on substrates were examined on
Days 1, 4, and 7.
5.3.5.2 Osteoblast Imaging
After 1, 4, and 7 days the number of attached live and dead cells were determined using
the LIVE/DEADTM Viability/Cytotoxicity assay kit (Figure 5.1). With this kit, live cells are
distinguished by the presence of intracellular esterase activity, determined by the enzymatic
conversion of calcein AM into the fluorescent calcein, which is retained in living cells.15 Ethidium
homodimer enters cells with damaged membranes and undergoes an enhancement of fluorescence
upon binding to nucleic acids. Ethidium homodimer is not able to pass through the membrane of
intact cells. Briefly, the well plate was removed from the incubator and media was aspirated off.
Substrates were rinsed with PBS prior to staining with the two dye components of the kit.
Cells were then imaged with a Zeiss Axioskop2 microscope with AxioVision software and
fluorescence filters. Three spots on each sample with an area of 0.6 mm were imaged under 10x
magnification. The number of live cell and dead cells were then counted for each substrate and
control. The number of live cells was divided by the total number of cells to determine the percent
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viability. The number of live adhered osteoblasts as well as osteoblast viability was normalized to
osteoblasts grown on unmodified Ti-6Al-4V.

Ethidium Homodimer

Calcein AM
Esterase

DNA Binding

Calcein
Nucleus

Dead Cell

Viable Cell

Figure 5.1: Fluorescent staining of osteoblasts for microscopic imaging where live cells
fluoresce green due to the conversion of calcein AM to calcein and dead cells fluoresce red
upon the binding of ethidium homodimer to DNA.
5.3.6 Statistical Analysis
Statistical analysis was performed using Origin 2019 software. Normality of obtained data
was determined using the Shapiro-Wilk test. Nonparametric methods including the Kruskal-Wallis
one-way analysis of variance were used to determine the averages and statistical significance of
collected data at the p<0.05 level of significance where applicable as data was not normally
distributed. Statistically analyzed data is presented as mean ± standard error (SE).
5.4 Results
5.4.1 Single Functionalized Ti-6Al-4V
Covalently linked bioactive molecules and the SAMs used to chemically immobilize them
should not negatively affect the viability of osteoblast cells. It was expected that substrates
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functionalized with the cell adhesion peptide KRSR would show an increased number of live
adhered cells with improved viability over controls as KRSR(C) encourages osteoblast attachment.
Osteoblast adhesion and viability to substrates functionalized with one bioactive molecule was
examined by culturing NHOsts and seeding them onto functionalized substrates. Adhesion and
viability were then assessed on Days 1,4, and 7 through a LIVE/DEADTM Viability/Cytotoxicity
assay kit and fluorescence microscopy (Figure 5.2).
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Day 4

Day 1
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Figure 5.2: Representative Live/DeadTM fluorescent images of osteoblasts attached to control
unmodified and bioactive molecule functionalized Ti-6Al-4V on Days 1, 4, and 7. A=
unmodified Ti-6Al-4V, B= acrylate terminated SAM, C=carboxylic terminated SAM, D= thiol
terminated SAM, E= KRSR(C) functionalized, F= spermine NONOate functionalized, G=
vancomycin functionalized.
Functionalization of the Ti-6Al-4V surfaces did not affect the initial attachment of
osteoblast cells on Day 1 (Table 5.1, Figure 5.3). On Days 4 and 7, functionalized surfaces did
not affect the number of live cells present on the surfaces when compared to the controls for those
time points. The number of live cells on each day sampled was statistically comparable to the
number of live cells adhered to the unmodified Ti-6Al-4V control.
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Table 5.1: Osteoblast adhesion to functionalized Ti-6Al-4V on Days 1, 4, and 7.
Normalized Number of Live Osteoblasts ± SE
Day 1
Day 4
Day 7
100 ± 19
100 ± 18
100 ± 18
111 ± 40
104 ± 26
174 ± 20
74 ± 17
68 ± 16
67 ± 13
92 ± 32
92 ± 27
161 ± 43
80 ± 24
71 ± 25
67 ± 24
72 ± 18
101 ± 33
111 ± 33
57 ± 12
91 ± 30
156 ± 40

Substrate

Normalized Number of Live Osteoblasts

Unmodified Ti-6Al-4V
KRSR(C) functionalized
Spermine NONOate functionalized
Vancomycin functionalized
Acrylate terminated SAM
Carboxylic terminated SAM
Thiol terminated SAM

200

Unmodified

KRSR(C)
150

Spermine
Vancomycin

100

Acrylate
50

Carboxylic
Thiol

0

Day 1

Day 4

Day 7

Figure 5.3: Osteoblast adhesion to unmodified and single functionalized Ti-6Al-4V on Days
1, 4, and 7. Surface modification with SAMs and functionalization with bioactive molecules
did not affect osteoblast adhesion.
The viability of osteoblasts present on functionalized Ti-6Al-4V was characterized (Table
5.2, Figure 5.4). After 24 hours, osteoblast viability on functionalized substrates was statistically
similar to unmodified Ti-6Al-4V. This was also observed on Days 4 and 7. The immobilized
bioactive molecules did not negatively or positively affect osteoblast viability on any of the days
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observed. The SAM linkers used to chemically link the molecules did not affect the osteoblast
viability.
Table 5.2: Osteoblast viability on unmodified and functionalized Ti-6Al-4V on Days 1, 4,
and 7.
Substrate
Unmodified Ti-6Al-4V
KRSR(C) functionalized
Spermine NONOate functionalized
Vancomycin functionalized
Acrylate terminated SAM
Carboxylic terminated SAM
Thiol terminated SAM

Normalized Osteoblast Viability + SE
Day 1
Day 4
Day 7
100 ± 12
100 ± 8
100 ± 8
111 ± 13
102 ±11
118 ± 5
114 ± 10
74 ± 10
90 ± 9
94 ± 11
80 ± 8
110 ± 5
111 ± 8
94 ± 9
107 ± 12
88 ± 9
81 ± 6
96 ± 9
85 ± 12
57 ± 12
97 ± 10

Normalized Osteoblast Viability

200

Unmodified
KRSR(C)

150

Spermine
Vancomycin

100

Acrylate
Carboxylic

50

Thiol
0

Day 1

Day 4

Day 7

Figure 5.4: Osteoblast viability on unmodified and functionalized Ti-6Al-4V on Days 1, 4,
and 7. Surface modification with SAMs and functionalization with bioactive molecules did
not affect osteoblast viability.
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5.4.2 Dual Functionalized Ti-6Al-4V
Osteoblast adhesion and viability to surfaces functionalized with two molecules was
assessed through fluorescence microscopy (Figure 5.5). Adhesion was determined by counting
the number of live osteoblast cells present on the Ti-6Al-4V surfaces (Table 5.3, Figure 5.6). At
the initial timepoint, the number of live cells on each sample was comparable to the control. On
Day 4 however, substrates modified with vancomycin and spermine NONOate showed statistically
less live osteoblast cells on the surface compared to controls. This was also observed on the same
day for substrates where spermine NONOate and KRSR(C) were co-immobilized. On Day 7
however, no difference was noted between samples and controls.
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Day 7

Day 4

Day 1

A

Figure 5.5: Representative Live/DeadTM fluorescent images of osteoblasts attached to control
unmodified and bioactive molecule dual functionalized Ti-6Al-4V on Days 1, 4, and 7. A=
unmodified Ti-6al-4V, B= acrylate & carboxylic terminated SAMs, C= acrylate & thiol
terminated SAMs, D= carboxylic & thiol terminated SAMs, E= KRSR(C) & spermine
NONOate dual functionalized, F= KRSR(C) & vancomycin dual functionalized, G=
vancomycin & spermine NONOate dual functionalized.
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Table 5.3: Osteoblast adhesion to functionalized Ti-6Al-4V on Days 1, 4, and 7.
Substrate
Unmodified Ti-6Al-4V
Acrylate & thiol terminated SAMs
Acrylate & carboxylic terminated SAMs
Carboxylic & thiol terminated SAMs
KRSR(C) & vancomycin dual functionalized
KRSR(C) & spermine NONOate dual functionalized
Spermine NONOate & KRSR(C) dual functionalized

Normalized Number of Live Osteoblasts + SE
Day 1
Day 4
Day 7
100 ± 17
100 ± 9
100 ± 10
108 ±12
78 ± 5
53 ±11
85 ± 12
77 ± 5
75 ± 9
70 ± 14
85 ±3
69 ± 13
82 ± 9
64 ± 8
76 ± 12
61 ± 13
52 ± 4
84 ± 7
57 ± 8
46 ± 6
55 ± 8

Normalized Number of Live Osteoblasts

150

#

Unmodified

Thiol & Acrylate

#

100

Thiol & Carboxylic
Acrylate & Carboxylic
**
*
*

50

Vancomcyin & KRSR(C)
Vancomycin & Spermine NONOate
Spermine NONOate & KRSR(C)

0
Day 1

Day 4

Day 7

Figure 5.6: Osteoblast adhesion to unmodified and dual functionalized Ti-6Al-4V on Days
1, 4, and 7. Vancomycin co-immobilized with spermine NONOate decreased osteoblast
adhesion on Day 4 when compared to controls. Spermine NONOate co-immobilized with
KRSR(C) decreased osteoblast adhesion compared to controls on Day 4. # = statistically
different, * = statistically different than controls.
Viability of cells present on functionalized surfaces was also examined (Table 5.4, Figure
5.7). On Day 1, there was no statistical difference in viability between functionalized Ti-6Al-4V
and controls. Differences were observed between SAM linkers and spermine NONOate and
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KRSR(C); viability was lower on the functionalized substrates. On Day 4 no differences were
observed between samples and controls. On Day 7, the viability of osteoblasts grown on substrates
with vancomycin and spermine NONOate co-immobilized was statistically lower than controls.
Table 5.4: Osteoblast viability on unmodified and dual functionalized Ti-6Al-4V on Days 1,
4, and 7.
Normalized Osteoblast Viability + SE
Day 1
Day 4
Day 7
100 ± 5
100 ± 7
100 ± 4
110 ±2
103 ± 5
90 ± 6
110 ± 3
91 ± 4
76 ± 6
110 ± 4
99 ± 5
79 ± 11
113 ± 4
96 ± 7
92 ± 5
78 ± 6
79 ± 4
88 ± 5
85 ± 4
72 ± 4
60 ± 4

Substrate
Unmodified Ti-6Al-4V
Acrylate & thiol terminated SAMs
Acrylate & carboxylic terminated SAMs
Carboxylic & thiol terminated SAMs
KRSR(C) & vancomycin dual functionalized
KRSR(C) & spermine NONOate dual functionalized
Spermine NONOate & KRSR(C) dual functionalized

Normalzied Osteoblast Viability

150

#
#

Unmodified
#
#

Thiol & Acrylate
#

Thiol & Carboxylic

100

Acrylate & Carboxylic
*
*

50

Vancomcyin & KRSR(C)
Vancomycin & Spermine NONOate
Spermine NONOate & KRSR(C)

0
Day 1

Day 4

Day 7

Figure 5.7: Osteoblast viability on unmodified and dual functionalized Ti-6Al-4V on Days
1, 4, and 7. On Day 7, vancomycin co-immobilized with spermine NONOate reduced
osteoblast viability compared to controls. # = statistically different, * = statistically different
than controls.
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5.4.3 Triple Functionalized Ti-6Al-4V
Osteoblast adhesion and viability on surfaces functionalized with all three bioactive
molecules was characterized (Figure 5.8). The number of live osteoblasts on Day 1 for each
sample was statistically the same as the control (Table 5.5, Figure 5.9). Changes in the number
of live osteoblast cells were observed on Day 4. On Day 4, substrates modified with thiol, acrylate,
and carboxylic acid terminated SAMs, which were used as chemical linkers, showed statistically
less live osteoblast cells on the surface when compared to controls. This was also observed for
substrates where spermine NONOate and KRSR(C) were co-immobilized. On Day 7 however, no
difference was noted between samples and controls.
B

C

Day 7

Day 4

Day 1

A

Figure 5.8: Representative Live/DeadTM fluorescent images of osteoblasts attached to control
unmodified and bioactive molecule triple functionalized Ti-6Al-4V on Days 1, 4, and 7. A=
unmodified Ti-6al-4V, B= thiol, acrylate, and carboxylic terminated SAMs, C= vancomycin,
KRSR(C), and spermine NONOate triple functionalized Ti-6Al-4V.
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Table 5.5: Osteoblast adhesion to triple functionalized Ti-6Al-4V on Days 1, 4, and 7.

Substrate
Unmodified Ti-6Al-4V
Thiol, acrylate, & carboxylic SAM
Vancomycin, KRSR(C), & spermine NONOate triple functionalized

Normalized Number of Live
Osteoblasts + SE
Day 1
Day 4
Day 7
100 ± 17
100 ± 9
100 ± 10
60 ± 5
57 ± 8
67 ± 7
68 ± 15
66 ±11
100 ± 12

Normalized Number of Live Osteoblasts

150

Unmodified
Thiol, Acrylate & Carboxylic
100

Vancomycin, KRSR(C), & Spermine NONOate

*
*
50

0
Day 1

Day 4

Day 7

Figure 5.9: Osteoblast adhesion to unmodified and triple functionalized Ti-6Al-4V on Days
1, 4, and 7. On Day 4, thiol, acrylate, and carboxylic acid terminated SAMs reduced osteoblast
adhesion compared to controls. # = statistically different, * = statistically different than
controls.

The viability of cells present on functionalized surfaces was also examined. On Day 1,
there was no statistical difference in viability between functionalized Ti-6Al-4V and controls
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(Table 5.6, Figure 5.10). This was noted on Day 4 as well. On Day 7, the viability of osteoblasts
cultured on thiol, acrylate, and carboxylic SAMs was statistically lower than controls, but triple
functionalized Ti-6Al-4V did not negatively affect osteoblast viability.
Table 5.6: Osteoblast viability on triple functionalized Ti-6Al-4V on Days 1, 4, and 7.
Substrate
Unmodified Ti-6Al-4V
Thiol, acrylate, & carboxylic SAM
Vancomycin, KRSR(C), & spermine NONOate triple functionalized

Normalized Osteoblast Viability + SE
Day 1
Day 4
Day 7
100 ± 5
100 ± 5
100 ± 4
110 ± 4
72 ± 6
71 ± 6
73 ± 9
87 ± 10
86 ± 6

Normalzied Osteoblast Viability

150

#

100

*

50

Unmodified
Thiol, Acrylate & Carboxylic
Vancomycin, KRSR(C), & Spermine NONOate
0
Day 1

Day 4

Day 7

Figure 5.10: Osteoblast viability on unmodified and triple functionalized Ti-6Al-4V on Days
1, 4, and 7. Thiol, acrylate, and carboxylic acid terminated SAMs reduced osteoblast viability
on Day 7. # = statistically different, * = statistically different than controls.
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5.5 Discussion
Successful integration between orthopedic implants and the host bone is crucial for implant
longevity and stability. Integration occurs when osteoblasts, which are cells responsible for the
formation of new bone, are able to adhere to the surface and proliferate. However, osteoblast
adhesion and proliferation on Ti-6Al-4V is limited. Here, Ti-6Al-4V was functionalized with
several bioactive molecules aimed at preventing bacterial colonization and encouraging osteoblast
adhesion. A cell adhesion peptide, KRSR(C) was chemically immobilized to the Ti-6Al-4V
surface solely and in combination with vancomycin and spermine NONOate. Vancomycin and
spermine NONOate were included to address bacterial colonization.
The adhesion to and viability of osteoblasts on functionalized Ti-6Al-4V as well as Ti-6Al4V modified with the SAM linkers used to immobilize the molecules was examined. The
molecules and their SAM linkers should not be cytotoxic to osteoblasts since osteoblast
recruitment to and proliferation on Ti-6Al-4V is essential for implant integration. The presence of
the cell adhesion peptide KRSR alone and in combination with the other molecules should
encourage osteoblast adhesion and viability as this peptide specifically targets osteoblasts.12, 16-19
Cellular response on single functionalized substrates was characterized using fluorescence
microscopy. Osteoblasts were able to adhere to Ti-6Al-4V regardless of bioactive molecule
functionalization or SAM modification (Figure 5.3). Furthermore, these alterations to the Ti-6Al4V surface did not exhibit any cytotoxic effects on cells (Figure 5.4). Covalent attachment of the
cell adhesion peptide, KRSR(C) at the interface did not support osteoblast adhesion or viability
beyond what was observed for unmodified Ti-6Al-4V. This result was unexpected, given
precedence in the literature for the selectivity and increased adhesion of osteoblasts to KRSR.12,
17-18, 20-21 16, 19, 22-23

This discrepancy may be attributed to a few different causes. The surface density
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of the cell adhesion peptide has been shown to affect its ability to encourage osteoblast adhesion.23
It is possible that while the KRSR(C) was present at the interface, the surface coverage was not
substantial enough to cause an observable effect. Another is the orientation of KRSR(C) at the
interface. If KRSR(C) was not oriented on the surface in a way in which it could be recognized by
the osteoblast cell its functionality could be reduced. Studies have demonstrated the specificity of
this sequence for desirable adhesion, therefore masking of the sequence could inhibit its adhesion
properties.19, 23-24 In previous work, the addition of the sacrificial cysteine did not affect KRSR
activity.18, 20
Co-immobilization of multiple bioactive molecules to the surface may alter cellular
response. When this was examined, co-immobilized vancomycin and KRSR(C) did not negatively
or positively affect osteoblast adhesion or viability (Figure 5.6, Figure 5.7). These results were
consistent with those observed in single functionalized substrates (Figure 5.3, Figure 5.4).
Substrates with spermine NONOate co-immobilized with either KRSR(C) or vancomycin
negatively affected osteoblast adhesion and viability on specific days (Figure 5.6, Figure 5.7).
Single functionalized vancomycin and KRSR(C) did not show similar effects. Osteoblast tolerance
and compatibility of/with KRSR and vancomycin are well documented within literature.12, 16-17, 1920, 22, 25-26

The undesirable cell response may be attributed to the presence of spermine NONOate

in the dual functionalization. While single functionalized spermine NONOate did not affect
adhesion or viability (Figure 5.3, Figure 5.4), its presence in combination with vancomycin and
KRSR(C) was not tolerated by the cells.
Spermine NONOate is a nitric oxide releasing molecule and nitric oxide generates reactive
species.27-38 While this was tolerated with single functionalized substrates, negative effects were
observed with dual functionalized substrates (Figure 5.6, Figure 5.7). This may be due to the local
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concentration and release rate of the nitric oxide. Results from the nitrate/nitrite colorimetry assay
performed previously indicated a larger amount of nitric oxide released from co-immobilized
spermine NONOate (Figure 3.20, Figure 3.17) compared to single immobilized spermine
NONOate (Figure 3.12). This difference in concentration could explain the differences observed
in cellular response. Additionally, evidence in the literature suggests that lower concentrations of
nitric oxide (picomolar) are not cytotoxic to osteoblasts but higher concentrations can negatively
affect cells.39-42 The rate at which the nitric oxide is released greatly affects its local
concentration.43 As the nitric oxide concentration has a profound effect on cellular activity, the
release kinetics form the NO donor must be considered when understanding the observed cytotoxic
effects.43-47 Spermine NONOate has a half-life of approximately 40 minutes, therefore there would
be a large initial influx of nitric oxide.48 This high, localized concentration may explain the
decreased adhesion and viability of osteoblasts when spermine NONOate was co-immobilized.
The cytotoxic effects observed on dual functionalized Ti-6Al-4V possessing spermine
NONOate were not observed on triple functionalized surfaces (Figure 5.9, Figure 5.10). Again,
this can be connected to the amount of nitric oxide released from these surfaces. Nitric oxide
release from single functionalized Ti-6Al-4V (Figure 3.12) was comparable to release determined
for the triple functionalized Ti-6Al-4V (Figure 3.21). This concentration was tolerated by the
osteoblasts with both the single (Figure 5.3, Figure 5.4) and triple (Figure 5.9, Figure 5.10)
functionalized Ti-6Al-4V.
While Ti-6Al-4V functionalized with the three different bioactive molecules did not affect
osteoblast adhesion or viability, the SAMs used to chemical immobilize these molecules to the
surface did (Figure 5.9, Figure 5.10). In the single (Figure 5.3, Figure 5.4) and dual (Figure 5.6,
Figure 5.7) SAM modified substrates, these results were not observed. Therefore, it is the unique
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surface chemistry and distribution of the triple SAM which is the cause of this effect. Interactions
between osteoblasts and materials depend on several aspects including topography, chemistry, or
surface energy.8

49-50

The surface charging has also been shown to play a role in osteoblast

adhesion.12 The changes to any number of these characteristics due to the presence of the triple
SAM may be responsible for the decrease in osteoblast adhesion and viability observed.
5.6 Conclusions
Immobilization of the cell adhesion peptide, KRSR(C) alone and in combination with
vancomycin and/or spermine NONOate did not improve osteoblast adhesion or viability on Ti-6Al-4V. The combination of spermine NONOate with either vancomycin or KRSR(C) negatively
affected adhesion and viability. This was due to high, local concentrates of nitric oxide. Inclusion
of all three bioactive molecules on the surface showed no effect on osteoblast cells. The SAM
linkers used to immobilize these molecules altered the surface chemistry, inhibiting osteoblast
attachment and viability.
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Chapter 6: Summary
6.1 Conclusions
Orthopedic implant surgery occurrences are expected to rise in the coming decades due to
the aging population and prevalence of degenerative diseases.1-2 These implants are comprised of
several materials including polymers, ceramics, and metals.3 A metal frequently used in orthopedic
implant applications is the titanium alloy, titanium aluminum vanadium (Ti-6Al-4V). This alloy
is chosen due to its corrosion resistance and mechanical properties.4-7 Unfortunately, Ti-6Al-4V is
not osteoinductive or osteoconductive, therefore new bone deposition by osteoblasts onto Ti-6Al4V is limited.8 Additionally, Ti-6Al-4V is susceptible to bacterial colonization by several species
including Gram positive Staphylococcus bacteria, such as Staphylococcus aureus and
Staphylococcus epidermidis and Gram negative species including Pseudomonas aeruginosa.9-14
This lack of new bone deposition and bacterial proliferation contribute to implant failure, which
necessitates implant removal.9, 14-15
Osseointegration and bacterial adhesion are addressed via several strategies. Methods
focus on modifying the surface of Ti-6Al-4V with coatings to encourage osteoblast attachment
and prevent bacterial adhesion.12, 16-19 These coatings tend not to be multifunctional and there are
concerns associated with stability and release of toxic agents through degradation.20 In this work,
an alternative strategy using self-assembled monolayers (SAMs) was employed to functionalize
the surface of Ti-6Al-4V. SAMs were chosen due to their non-toxic nature and stability.16, 21-25
The tail group of the SAM allows for chemical reactions at the interface, which can be used to
covalently immobilize bioactive molecules.
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In order to generate a multifunctional surface, SAMs possessing different tail groups were
formed on Ti-6Al-4V in single, dual, and triple SAM modified surfaces. Modification of reaction
conditions including spray cycles and substrate pretreatment resulted in the formation of stable
and ordered SAMs. Of the phosphonic acid SAMs formed on Ti-6Al-4V, molecules terminated
with a thiol, acrylate, or carboxylic acid were chosen as linkers for the attachment of bioactive
molecules (Figure 6.1). These specific tail groups formed SAMs in a consistent, facile manner on
the Ti-6Al-4V surface with ordered alkyl chains whether or alone or in combination with one
another. Furthermore, these tail groups allowed for orthogonal chemical reactions to immobilize
desired bioactive molecules.

Vancomycin
Spermine NONOate
KRSR(C) peptide

Figure 6.1: Functionalization of Ti-6Al-4V using SAMs as linkers for the immobilization of
bioactive molecules.
The bioactive molecules selected for immobilization addressed both osteoblast adhesion
and bacterial colonization. Spermine NONOate, a nitric oxide releasing molecule, and
vancomycin, an antibiotic, were chosen to prevent bacterial colonization. KRSR(C), a cell
adhesion peptide was selected to encourage osteoblast adhesion to Ti-6Al-4V. Vancomycin was
immobilized to Ti-6Al-4V through the use of a maleimide crosslinker. Spermine NONOate was
covalently linked through amide bond formation with a carboxylic acid terminated SAM. The
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peptide KRSR(C) was chemically attached through a thiol-ene Michael addition with an acrylate
terminated SAM. Ti-6Al-4V substrates were functionalized with one, two, or all three of the
bioactive molecules. This was undertaken so that their activity in each could be assessed and
compared.
The single, dual, and triple immobilization of these molecules was confirmed through
diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy. The covalent attachment of
these molecules resulted in hydrophilic surfaces with contact angle values less than 90°. Nitric
oxide release from functionalized Ti-6Al-4V was assessed through the Griess assay, with single
and triple functionalized surfaces releasing comparable amounts of nitric oxide, 77.0 ± 1.8 and
74.7 ± 1.6 nanomoles respectively. Dual functionalized substrates with co-immobilized spermine
NONOate exhibited higher nitric oxide release of 107.6 ± 1.5 nanomoles for spermine NONOate
with KRSR(C) and 117.6 ±1.4 nanomoles for spermine NONOate with vancomycin.
The activity of the antimicrobial molecules immobilized alone and in conjunction with the
other bioactive molecules was determined via challenges with Staphylococcus epidermidis (S.
epidermidis), a Gram positive species and Escherichia coli (E. coli), a Gram negative species
through fluorescence staining and imaging of the bacteria. Vancomycin immobilized alone was
able to reduce the viability of S. epidermidis by 64 ± 27% (SD). Spermine NONOate was able to
reduce viability of E. coli by 27 ± 20% but not that of S. epidermidis. The selectivity observed was
attributed to Gram positive species’ ability to generate their own nitric oxide, leading to tolerance
of nitric oxide’s effects.26 Spermine NONOate was able to prevent the adhesion of both species to
single functionalized surfaces which has previously been observed in the literature on other
substrates.27-29
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Antimicrobial effectiveness was only maintained for one of the dual functionalizations,
when KRSR(C) was co-immobilized with vancomycin. This dual functionalized surface showed
a reduction in S. epidermidis viability of 36 ± 28% (SD). This was approximately half the reduction
in viability observed for vancomycin immobilized alone. The loss in effectiveness may be due to
interactions between vancomycin and KRSR(C) or lower surface loading. Surfaces possessing all
three bioactive molecules were not able to limit viability of either bacterial species. Local
concentrations were either not sufficient or interactions between molecules negatively impacted
their effectiveness.
Finally, osteoblast adhesion and viability on functionalized Ti-6Al-4V was characterized
through fluorescence staining and microscopy. Covalent attachment of these bioactive molecules
should not elicit cytotoxic effects within osteoblast cells. Furthermore, attachment of the KRSR(C)
cell adhesion peptide to Ti-6Al-4V was expected to encourage osteoblast adhesion to Ti-6Al-4V
and improve cell viability. While individual immobilization of bioactive molecules did not
negatively affect adhesion or viability, KRSR(C) functionalized substrates showed no statistically
significant increase in live osteoblast adhesion or viability. Surface loading and distribution of the
cell adhesion peptide dictate its effectiveness at recruiting osteoblast adhesion.30 These factors may
contribute to the lack of a positive, observed effect.
Co-immobilization of spermine NONOate with either vancomycin or KRSR(C) negatively
impacted osteoblast viability. Dual functionalized substrates exhibited higher concentrations of
nitric oxide release than single or triple functionalized. The larger, local concentrations are thought
to be the source of observed cytotoxicity. The lack of observed cytotoxicity on triple functionalized
substrates supports this, as these substrates showed nitric oxide release consistent with single
functionalized Ti-6Al-4V.
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In this work, SAMs were used to covalently link the bioactive molecules vancomycin,
spermine NONOate, and KRSR(C) to Ti-6Al-4V through specific organic reactions with the SAM
tails and target functional groups within the bioactive molecules. These molecules were
immobilized on their own and in combination. While desirable antimicrobial properties were noted
for single functionalized substrates these effects were lost in triple functionalized substrates.
Surface loading and coverage were likely not sufficient. Furthermore, co-immobilization of
spermine NONOate with the other bioactive molecules showed cytotoxic effects to osteoblasts,
due to large surface concentration. This work highlights the importance of concentration,
molecular interactions, and release rates of molecules on cellular response.
6.2 Future Work
Bacteria and osteoblast behavior on functionalized Ti-6Al-4V was distinctly influenced by
the unique surface properties of each functionalization. While the surfaces were characterized
using DRIFT and contact angle analysis, other complimentary techniques could be used to provide
a more complete understanding of the surface chemistry.
The distribution of the functionalized molecules on the surface affects their activity. The
distribution

of

bioactive

molecules

could

be

assessed

using

matrix-assisted

laser

desorption/ionization time-of-flight mass spectrometry imaging. With this technique, mapping of
the immobilized molecules would be possible with a spatial resolution of approximately 100
microns.31-32 Differences in distribution and surface coverage between single, dual, and triple
functionalized substrates could be assessed. This information would help explain if surface
coverage was the cause of decreased bioactivity within triple functionalized substrates.
Additionally, the accuracy of mass spectrometry would allow for the specific determination of the
covalent bonds formed in each immobilization. If undesirable reactions between bioactive
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molecules occurred, this would be elucidated with mass spectrometry analysis. Side reactions with
portions of the molecules responsible for their mechanism of action would impact their efficacy.
Furthermore, bioactive molecule selection could be adjusted to improve osteoblast
adhesion while preventing bacterial colonization. For instance, spermine NONOate could be
replaced with an antibiotic that targets Gram negative species. In this work the inclusion of
spermine NONOate demonstrated limited antimicrobial efficacy combined with osteoblast
cytotoxicity. While KRSR(C) was chosen in this application due to its enhanced osteoblast
binding, its immobilization showed no effect on osteoblast adhesion and viability for any of the
functionalizations examined. If this observation was a consequence of surface coverage or
molecular interactions is unclear. A peptide with the RGD sequence with a cysteine modification
could be easily substituted in this platform for the KRSR(C). This alteration may improve
osteoblast adhesion and viability.33-35
6.3 Project Impact
Surfaces of metallic orthopedic implants strongly influence their chemical and biological
properties as they serve as the interface between the bulk metal and host environment. Alteration
of these surfaces is necessary to facilitate successful host-implant integration. In this work, SAMs
were utilized as a platform to chemically immobilize bioactive molecules to the Ti-6Al-4V surface
aimed at addressing osteoblast adhesion and bacterial colonization.
This flexible platform allows for the immobilization of a variety of molecules including
antibiotics, peptides, and nitric oxide releasing compounds. Although in this work immobilized
molecules did not retain their bioactivity, alternative immobilization strategies can be employed.
The functional groups within these molecules used in the formation of covalent bonds are prevalent
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in other classes of bioactive molecules. This permits control of the interfacial properties of Ti-6Al4V with bioactive molecules specific to the metal’s application. Furthermore, as SAMs form on
other metal oxide surfaces, this transferable platform can be used to alter their interfacial properties
as well.
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